|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/16 ¤W¤È 06:14:44²Ä 2520 ½g¦^À³
|
¹ï¤£°_ ¡A¦A«×§ó¥¿ ¤H·Rµt¡A´N©ö³sµf¥X¿ù ¡]61/124¡^/¡]81/224¡^=1 .360¡A¡]35//124¡^/¡]50/224¡^= 1.265 ¤~¹ï «e¤å¤¤¬ÛÀ³¦ì¤lªº¨Æ¥ó²v¤ñ»~´Ó¡A½Ð½Ì ÁÂÁ¤j®a¡I Faith ¤j¤j ¼ç¤ô¤Ó¤[¡A®ð¥inåx«Ü¤[§r ¸g±`¤W¨Ó³z³z®ð¡A¤~¤£P¤Ó´e¡A¤j¹Ù¤]¦³ºë¯«¹Â³¥i¦Y «¤j¸`¤é¤~¤W¨Ó¡A§Ú̦h¾j±o«Ü §Æ±æ±z¸g±`´£携¥´®ð ÁÂÁ±z ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/15 ¤U¤È 11:22:01²Ä 2519 ½g¦^À³
|
¸É¥R¤@¤U ¡]¨Æ¥ó²v¤ñ¡^¤ñ1.36¤j¡A¥B¸ÕÅç²Õ¨Æ¥ó¼Æ¤j©ó81¡A...... ÁÂÁ¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/15 ¤U¤È 11:14:18²Ä 2518 ½g¦^À³
|
«ù¤[ªº¯E§J¤j¤j ·PÁ±zªº´£ÂI¡AÅý¤p§Ì«ä¦ÒµÛ ¼ÒÀÀµÛ822¥¼¨Ó¦¨¥\ªº¾÷·|¦³¦h¤Ö ¤]¥Ñ©ó¥xÁÞ¤jªº¯«©_²Õ¦X¡] 81¡A61¡^¡A«ê»P±zªº HR=0.7 «Ü±µªñ ¤p§Ì¦b¼ÒÀÀ¹Lµ{¤¤¡A¤@¦¸´N¤¤ªº¡A¨S¦A°µ²Ä¤G¦¸ªº½Õ¾ã Åý§Ú·Pı¨ì³o²Õ°t¹ï®e©ö¦¨¥\ ¦A¥J²Ó·Q¤@¤U¡A³o²Õ°t¹ïªº¨Æ¥ó²v¤ñ¡]81/224¡^/¡]61/124¡^=1.360¡A¤]¥u¬O¥Ñ²{ª¾ªº²v¤ñ¡]50/224¡^/¡]35/124¡^=1.265¡A¼W¥[ 7.5% ¨Ì·Ó±zªº±À´ú......¸ÕÅç²Õªº¨Æ¥ó¤H¼ÆÁͽw¡A¹ï·Ó²Õªº¨Æ¥ó¤H¼Æ¥Ã¼W¥[ ¡]81¡A61¡^À³¤£Ãø¹F¨ì¡A¦A¥[¤W¹ï·Ó²Õ¤£n¦³¶W¤Zªºªí²{¡]§Y¹ï·Ó²Õªº¨Æ¥ó¤£n¦b¤¤¡B«á¬q¤~µo¥Í¡^ ¦]¦¹¡]81¡A61¡^¦b¹ê»Úµo¥Íªº¾÷·|¡A©ÎªÌ±Æ¦C¸Õºâ¦¨¥\ªº¾÷²v³£«Ü¤j ©Ò¥H¤p§Ì»{¬°³o²Õ°t¹ï©Î¥i§@¬°¤@ӼЬñ¡]·íµM¥i¯àÁÙ¦³§ó¦nªº²v¤ñ¡A¦ýÀ³¤]®t¶Z¤£¤j¡^ ¡]¨Æ¥ó²v¤ñ¡^¤ñ1.36¤j¡A¥un¹ï·Ó²Õ¤£¶W¤Z¡A´N®e©ö¹F°}¡AY¤ñ1.36¤p¡A´Nn¬Ý±Æ¦C¡A²v¤ñ¶V¤p¶V¤£®e©ö Ã㤣¹F·N ¶È´£¨Ñ¤j®a°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡GAming10141623 µoªí®É¶¡:2016/9/15 ¤U¤È 04:29:31²Ä 2517 ½g¦^À³
|
T¤j: ¸g¸ò¤TÁ`Âå¥Í°Q½×ÅJ223ªº°ÝÃD Âå¥Í»¡:¥Lı±oÀ³¸Ó¨S®Ä,¤£n®ö¶O¿ú. ÃöÁä¦b©ó:[Ra223¥i¥H§@¥Î¦b¡u¦¨°©²ÓM¡v´N¬O°©ÀY¥Í¦¨§@¥Î¼@¯Pªº¦a¤è¡F ¦pªG¬O¡u»k°©²ÓM¡v¨ºªí¥Ü°©ÀY¥¿¦b³Q«I»k¡ARa223´N¬Û¹ï¨S¥Î¤F] Âå¥Í§P©w¬O»k°©²ÓM ©Ò¥HÅJ223¬OµLªk§@¥Î¦b¨ÅÀùÂà°©ªºÂåÀø¤W ³p»»¤j,¥i§_À°§Ú°Ý¤@¤U³o¼Ë¹ï¶Ü? ¨º¤@¦ý¥X²{»k°©²ÓM´N¤£·|¦A¥X²{¦¨°©²ÓM¶Ü? Á{§É¤W©ÎªvÀø¤W¦p¦ó§P©w? ·íÂå¥Í»¡¨S¥Î®É ·í¤Uªº¤ß±¡¸ò¸Ñª¼¥¢±Ñ¤@¼Ë ®Ú¥»¤£¨ì¦ó¥h¦ó±q ®Ú¥»¤£ª¾¹D¸Ó¦p¦ó¨«¤U¤@¨B §Ú¥À¿ËÅ¥¤F¤]Ãø±»¥¢±æ¤§±¡ ¥O¤H¤ß»Ä! Âå¥ÍÁÙ¬O»¡ ÃĦ³¨S¦³¥ÎnºCºC¸Õ,«æ¨S¦³¥Î ©Ò¥H¤@¤ÁÁÙ¬O¦^¨ììÂI«ö³¡´N¯Z §Ú¥u¯à¦A¦¸¤W¨Ó½Ð±Ð§A ³Â·Ð§AÀ°§Ú¦A°Ý°Ý¬Ý ·P¿E¤£ºÉ,ÁÂÁÂ! T¤j: ·íªìÅJ223¬O§A¥ý´£¥X¨Óªº ÁÂÁ§AªºÀ°¦£»P«ü¤Þ ¥i±¤²{¦b¨«¤J¦ºJ¦P. ¤p§Ìª¾¹D§A¹ï³o¨ÇÂåÀøªº¬ÛÃö¸ê°T«D±`¦³¬ã¨s ¥i§_¦A«üÂI©ú¸ô §Ú¬Û«H§AÄ@·NÀ°¦£ªº¸Ü ¤p§ÌÀ³¸Ó·|¤Ö¨«ÞªP¸ô ¯àª§¨ú§ó¦hªº®É¶¡»P¾÷·| ¦b¦¹¥ýÁÂÁ§A. Âàpo³\¤jªº´M¨D¨ó§U |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/14 ¤U¤È 09:01:05²Ä 2516 ½g¦^À³
|
«e±´£¨ìOBI vaccine©M¤ÆÀø¤Î¼Ð¹v¨Ö¥Î¦ü¥G¨S¦³¦X²z©Ê¡A¦ý¬O©Manti-PD1 sequential¨Ö¥Î«o¥i¯à¦³¥[¦¨®ÄªG¡C¦ý¥Ø«eanti-PD1(PDL1)´X¤jÃļt¦hµÛ¾¥¦b¨Ö¥ÎmTKI¡A«Ü¦h¬O°Ó·~¦Ò¶q¤£¦b¸Ü¤U! ¨ä¹êOBIÀ³¸Ó¿n·¥´M¨D©M°ê»Ú¦X§@¡A¦ý¹L¥h¨â¦~(anti-PD1¥¿Éq)¨S¬Ý¨ì¤½¥q¦³¥ô¦ó°Ê§@(§Ú¥u¬O¤p§ë¸ê¤H¡A·íµM¤£ª¾¹DÂi±¤U¦³¨S¦³¡A¦ýµ²ªG¬O¥Ø«e´N¬O¨S¦³)¡A¥HOBIªº²{ª÷³W¼Ò¡A¦pªG¤jÃļt¦³§xÃø¡A¨ä¹ê¥i¥H´M¨D©M¤@¨Ç¤pÃļt¦X§@¡A¨Ò¦pMRUS¡APIRS ¤]¦³«Ü·sªºbi-valent mAb¡A°µ¨ÇP1/2 study¤£¥²ªá«Ü¦h¿ú¤S´X¥G¥iµn¤W°ê»Ú¤j·|ij¡A¤µ¦~ESMO¤£¥²¸¨¨ìªá¤j¿ú¿ìSatellite-S¡A§ó¤£¸Ó¶R®wÂêÑ! ¦^À³¦Ñ¥v: «Ü©êºp¹ïNMDA¤£À´¡AÁʶR¤ß®®©M¤¤¸Î³æ¯Â´N¬O¸ê²£°t¸m¡A¤£¹L³o¨â®a¤½¥qªº°Ê§@&µo¨¥¦³°ê»Ú¤ô·Ç¡C¦³®É¥´¦r¤@°ï¡A¨Sµn¤J«ö°e¥X«á¾ãÓ¥Õ¥´¡A¤£¨£±o¦³ªÅ¦A¥´¦r¤@¦¸! OBI¥Ø«e¦û§Ú°ê¤º¥~ªÑ²¼ªº¸êª÷°t¸m¤£¨ì5%¡A©Ò¥H¥±`µÛ¾¥¤£¦h¡A¤j¦h¬O¦³·s»D(©Î¬O·|ij¡A¨Ò¦pASCO¡BESMO)·|¦^¥»ª©¬Ý¤@¤U¡A·|ÁʤJ¯Âºé´N¬O¾÷Â঳¼ç¤O¡Arisk/reward¥i´Á«Ý¡Aµo¨¥«e³»¦h´N¬O¬Ý¬Ý´XÓªñ´Á°Q½×¡AÁö¨Sªø´Á°lÂܤ½¥qÂIºw¯ßµ¸¡A¦ý¹ï·í¤UijÃD°Q½×¦Û»{µL°¾»á¡A¦pªG³o¼Ë¤£²Å¦Xª©³W¡A¨º´N¦¹¹Dºp!·íµM¹ï°ê¤º¤½¥qÁÙ¬O¦³´Á³\ªº¡A¥u¬OOBI©Ò¥Çªº´XÓ¦pcliffÂI¦Wªº¿ù»~¡A¦pªG¬O¦bUS/EU¡A»@¿ú¨Æ¤p¡A·|¦³«Ü¦h¶Ý¦å«ß®v¶µÛª±ªº! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/14 ¤U¤È 08:38:02²Ä 2515 ½g¦^À³
|
«ä¦Ò¦Ñ¥v¤jªº«ä¦Ò ¦Ñ¥v¤j¤§«e¾ã²z³\¦h§K¬ÌÃĪ«ªºªvÀøÀù¯g®ÄªG¡A³o¤w¸g¬O«á³]¤ÀªRªº¸ê®Æ¦¬¶°¶¥¬q¡C «á³]¤ÀªR¡]Meta-analysis¡^¡A¥i¥H²ºÙ¬°¤ÀªRªº¤ÀªR¡C ¥H¤U¬°ºô¸ô¸ê®Æ¡]¨Ó·½599002220tech1.blogspot.tw/p/blog-page.html¡^¡C Meta analysis ¬°¹ï¨ã¦³¬Û¦P¥Øªº¬Û¤¬¿W¥ßªº¦hÓ¬ã¨sµ²ªG¶i¦æ©w¶q¡]²Îp¡^ºî¦X¤ÀªR¡A¥iºÙ¤§¬°¡u¤ÀªRªº¤ÀªR¡v¡CMeta Analysis ©Ò¥Îªº¥Dn¬O¦X¨Ö¬ã¨sµ²ªG©M¹ï¬ã¨sµ²ªG¶i¦æ»ô©ÊÀËÅ窺²Îp¤èªk¡CMeta Analysis ¥Dn¦bÀ±¸É¶Ç²ÎªºReview Articles¡]¤åÄmºîz¡^ªº¤£¨¬¡C «á³]¤ÀªR¡]Meta-analysis¡^«ü¹B¥Î¶q¤Æªº²Îp§Þ³N¡A°w¹ï¬Y¤@°ÝÃD¡Aºî¦X¥H«e¿W¥ß¬ã¨sµ²ªGªº¤@ºØµûzµ{§Ç¡AµJÂI¸m©ó±N¬Û¦Pªº¬ã¨s°ÝÃD¥B¨Ï¥ÎÅܶµÃþ¦üªº¬ã¨s»`¶°¦^ÅU¡B±N¦U¬ã¨sµ²ªGªº¶q¤Æ¸ê®Æ¦b¦Ò¼{®ÄªGÈ¡]Effect Size¡^¤U°µ¨t²Î©Êªºµ²¦X¡A³Ì«á¹ï¦¹¤@°ÝÃD±o¨ì²Î¾ã©Êªºµ²½×¡C «á³]¤ÀªR¤ÀªRªº¸ê®Æ¤£¬O¦UÓ¬ã¨sªºì©l°O¿ý¡A¦Ó¬O¦UÓ¬ã¨s³ø§i¤w¦³ªº²Îpµ²ªG¡A³oÓµ²ªG¥Dn¦³¨âÃþ¡GúŦUÓ¬ã¨sªº°²³]ÀËÅçµ²ªG¡A¦pt È¡Bp È¡B¥d¤èÈ¡CúƦUÓ¬ã¨s³ø§iªº²Îp¶q¡A¦p¨â§¡¼Æªº®tÈ¡B¬ÛÃö«Y¼Æ¡BÀu¶Õ¤ñµ¥¡C ©Ò¥H¡A¦Ñ¥v¤j¾ã²z¥X§K¬ÌÃĪ«ªºªvÀøÀù¯g¹êÅ礧¨â²ÕMOS¤ë ¡AMOS¼W¥[¤ñ¨Ò HR¡A PÈ ¡A¨â²Õ¦º¤`¤H¼Æ ¡A¨â²ÕÁ{§É¤H¼Æ¡A¤w¸g¬O¥i¥H¤j®a«ä¦Ò§K¬ÌÃĪ«¹ïÀù¯gªºÀø®Äµ{«×¡A¦³¦h¦nªº½d³ò¡C¦Ó822¨ì©³·|¦ì©ó¨ä¤¤þ¤@ºØ±¡§Î¡A¨¬¨Ñ¤j®a°Ñ°u¡C ¾ÇªÌ¸â§Ó¬ê¦b¤å³¹-«á³]¤ÀªR¡G¶q¤Æªº¤åÄm±´°Qªk¡A¡]«ä»P¨¥ ²Ä26¨÷²Ä4´Á 1988¦~11¤ë www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjnj8z1_43PAhUFjJQKHdq4BEgQFggfMAA&url=http%3A%2F%2Fnccuir.lib.nccu.edu.tw%2Fbitstream%2F140.119%2F37865%2F1%2F%25E5%25BE%258C%25E8%25A8%25AD%25E5%2588%2586%25E6%259E%2590%25EF%25BC%259A%25E9%2587%258F%25E5%258C%2596%25E7%259A%2584%25E6%2596%2587%25E7%258D%25BB%25E6%258E%25A2%25E8%25A8%258E%25E6%25B3%2595(%25E6%25A0%25A1%25E6%25AD%25A3%25E7%2589%2588).doc&usg=AFQjCNGPw3FQnf3OGqM1Z6H_IHfsZuJMIw&sig2=lFWyVO-gBmJw33_enNX01Q¡^ ´£¨ì¡G ¨CÓ¬ã¨s¦h¥Î¤£¦Pªº¤è¦¡©Î¤u¨ã¨Ó´ú¶q¨ä¹êÅç®ÄªG¡A¥H¦Ü©ó®ÄªGªº¤j¤p«ÜÃø°µ¸ó¬ã¨sªº¤ñ¸û©Î²Î¦X¡A³Ì¨Îªº¸Ñ¨M¤è¦¡´N¬O±N³o¨Ç®ÄªGªº¤j¤p¥[¥H¼Ð·Ç¤Æ¡A¤]´N¬O»¡¥Î¤@ӲΤ@ªº³æ¦ì±N¨CÓ¹êÅ窺¤j¤p«·s¤Ø«×¤Æ(rescaling)¡C³oÓ§@ªkªº°ò¥»«H©À¬O¡G¨CÓ¹êÅç©Î¬ã¨s¨Æ¹ê¤W³£¬O¦b¦ôp¦P¤@Ó¥À¸s®ÄªG¶q¡A¥u¬O¥Ñ©ó»~®t¡A¦Ó³y¦¨¤F¥¦Ìªº¦ôp¼Æ¦r¦³¥X¤J¡C ºî¦X¤Wz¡A¥HHR¨Ó·í®ÄªGÈ¡AÀ³·í¦X²z¡C Y822ªºOS´Á¤¤¤ÀªR¡AÀHµÛ¹êÅç²Õ¦º¤`¤H¼ÆÁͽw¡A¦Ó¦w¼¢¾¯²Õ¦º¤`¤H¼Æ¥Ã¼W¥[¡A«hHR±q0.79«ùÄò¤U°¡AÀ³¸Ó´N¥i¥H¹w¦ôHR¸¨¦b¦Ñ¥v¤j¾ã²z³\¦h§K¬ÌÀøªkÀù¯g¹êÅ礧¦³®Ä½d³ò¡A¦ÓPȤ]®e©ö¹F¨ìÅãµÛ¤ô·Ç¡C ¨ä¤¤PȪºpºâ¬O¥He¬°©³ªº«ü¼Æ¨ç¼Æ¡A§Y°ª´µ¤À§G©Î±`»¡ªº±`ºA¤À§G¾÷²v¨ç¼Æ¡A¨ç¼Æ¹Ï§Î¬OÄÁ§Î¦±½u¡A©Ò¥HPȧïÅܫܧ֡AHR±q0.79Åܦ¨0.7 ¡A²q´úPÈ¥i¥H«Ü§Ö±q.289 °¬°.05¡C ¥H¤W²q´ú ´£½Ð°Q½×¡C ·q¯¬ ¤¤¬î´r§Ö¡C |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2016/9/14 ¤W¤È 10:14:34²Ä 2514 ½g¦^À³
|
¦Ñ¥v¤j¡A ±zªº½Ñ¦hPO¤å»PµêÃhY¨¦¡A¥O¤H·P¨Ø¬Æ¦Ü·P°Ê¡I Ä@¯à¦V±z¦h¾Ç²ß¡C ·PÁ¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/13 ¤U¤È 11:08:47²Ä 2513 ½g¦^À³
|
·x¤j ¤p¶§¤j ÁÂÁ°Õ,½×¾Ô¦n¹³¤£¬O§Úªº±Mªø,ºâ¤F ´N¦¹¥´¦í,¤£¦b¦^À³¬ÛÃö°ÝÃD,¥H§K¦Ã¬Vª©± §Úª¾¹D·x¤j«Ü¦³Àô«O²z©À,¯uªº«Ü´Î! §Ú±N¦b¥t¤@ª©»P§A¤À¨É |
|
|
·|û¡Gªü¤å10138375 µoªí®É¶¡:2016/9/13 ¤U¤È 10:59:03²Ä 2512 ½g¦^À³
|
·PÁÂT^T,¯E¹©ª©»Ýn§Aªº¨£¸Ñ¨Ó¥¿Å°Q½×ªº¤è¦V. ¥ß½×¦hªÅÂù¦V¨Ã³¯,¤~¬O°·±dªº°Q½×. §_«h,ÁöµM¥X¦Ûµ½·N©M¦Û«H,«o¤]¥i¯à¶Ë¤ÎµL¶d |
|
|
·|û¡GÂyªÌ°ß±©10142617 µoªí®É¶¡:2016/9/13 ¤U¤È 10:27:48²Ä 2511 ½g¦^À³
|
µL½×¬OT^T¤j¡A¥xÁÞ¤j¡A¦Ñ¥v¤j¡Aµ¥µ¥µ¥¡A§Ú³£¸U¤À·P¿E¡C¥ô¦ó¦³«Ø³]©Êªºµo¨¥¡A¤£½×¤f®ð¦nÃa¡A§Ú»{爲³£À³´L«¤Î¹ªÀy¡C³o¹ï²³¯E¤ÍÌ¡A¤~¬O¦n¨Æ¡C³o¬O£¸Ó¶}©ñ©Êªº¥¥x¡A¦p¯à¯Ç¤J§ó¦h¯à¤Hµo¨¥¡A¦¬Àò¬O¤j®aªº¡C ¤pªº¦~¬öµyªø¡A¦ý¬Ý¤H©Î¨¤«×¤§³B«o©Ç¡A¥H¤U¯Â¬°Ó¤H°¾¨£¡C´NT^T¥ý¥Íªñ¤é¤§¤À¨É¡Aµ§Ä²¶¡§Ú¬Ý¨ìªº¬O¯E¹©ªø´Áµo®i¤§¼ç¤O¤Î¾÷·|¡C§ÚÓ¤H»{¬°T^T¥ý¥Íªº¤À¨É¹ï¯E¹©³oÓ°Q½×°Ï¬O«Ü«n£¸¶ô«÷¹Ï¡C¬ß²³¤j¯àÅU¥þ¤j§½¡A¼Ä¤H¤£¦b¦¹¡C ¸Ñª¼¤§«e¨®¤§Å²¡A£¸¨¥°ó¤§§Q¹ú±o¥¢¡Aȱo§Ú̲`«ä¡C |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2016/9/13 ¤U¤È 09:15:10²Ä 2510 ½g¦^À³
|
¥xÁÞ¤j·x·x¤j ¦n´Î´Î...........¥[ªo! ¤ä«ù§AÌ |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/9/13 ¤U¤È 08:00:54²Ä 2509 ½g¦^À³
|
T¤j§A¦n:¤µ¤Ñªº³Ót,§Ú¤£¬O·QÃÒ©ú¯E¹©ªºOBI,¤ñIbrance§ó¥[Àu³Ó,§Ú¥u¬O·Q»¡: ¤Hªº¾Ç°ÝÁöµM¦³°ª§C¤§¤À!¦ý¬O¤ÀªR¡A¤£À³¸Ó±a¦³¿Ø¨ë©Ù¶Â! §Ú«Ü§Æ±æ,±q³o¤@¨è¶}©l,§Ṳ́j®a¥i¥H¾Ç·|À´±o«ç¼Ë¥h¤¬¬Û´L«¡AÁÂÁ¡C ******************************************************** ÃÒ¥æ©Ò«¤j°T®§¤½§i (4174)¯E¹©¥»¤½¥q¼á²M´CÅé³ø¾É 1.¨Æ¹êµo¥Í¤é:105/06/06 (3)»PÄvª§¹ï¤â¬Û®t10Ӥ뤧³ø¾É¡G¸Ó¸ÕÅ礤§¹¦¨¤E¦¸OBI-822ª`®gªº104¦W±wªÌ¤¤¡A¨äµL´c¤Æ¦s¬¡´Á(PFS)¤¤¦ì¼Æ¬°22.5Ó¤ë¡A»P¹ï·Ó²Õ(64¤H)18.1Ó¤ë¡A¬Û®t4.4Ó¤ë¡C ¦³³ø¾É±N¦¹¤@µ²ªG»P¥t¤@¤p¤À¤l¨ÅÀù¼Ð¹vÃĪ«IbranceªvÀø»P¹ï·Ó²Õ¬Û®t10Ӥ뵲ªG¬Û¤ñ¡A»{¬°OBI-822»P¤§¤´¦³¤@¬q®t¶Z¡A¥¼¨Ó¦b²üº¸»X¨üÅ鶧©Ê±Ú¸sªº¨ÅÀùªvÀø¥«³õ¤W±N¨ü¨ì¬D¾Ô¡C¨Æ¹ê¤W¡AIbrance»POBI-822ÃĪ«Äݩʤ£¦P¡AªvÀø¹ï¶H¡B¾÷Âà¤]~²§¡A¥BOBI-822´XµL°Æ§@¥Î¡A»PIbrance·|¤Þ°_¥Õ¦å²y´î¤Ö¤Î·P¬Vµ¥ÄY«°Æ§@¥Î¬Û¤ñ¡A¤GªÌ®t²§¬Æ¤j¡C¥BOBI-822¥¼¨Ó¬Æ¦Ü¥i¯à»PIbrance¨Ö¥Î¡A©¼¦¹¦bÀø¤W¬Û»²¬Û¦¨¡A¦Ó«D¦b¥«³õ¤¬¥¸©ÎÄvª§¡C ³Ì«á¹ïcliff¤j¸U¯ë©êºp,¤p§Ì´N¦¹¥´¦í!ÁÙ½Ðcliff¤j®ü²[! ¥xÁÞ¤j:§A©l²×±aµ¹¤j®a¥¿±ªº¤O¶q,ÁÂÁ§A!¤p§ÌµªÀ³§A·|«ùÄò¹ïÀô¹Ò«OÅ@ºÉ¤@¤v¤§¤O,¥]¬A±q¥Í¬¡,§ë¸ê,¤p«Äªº±Ð¨|¾i¦¨¹ê½î! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/13 ¤U¤È 07:12:20²Ä 2508 ½g¦^À³
|
¼o¸Ü¤Ö»¡ ¤£n°jÁקڪº´£°Ý!!! ( °£¤F²Ä¥|ÃD¥~ ) 1¯E¹©¸ê®Æ¿òº|ªº½T¤£¸Ó,¹ï¤@ӫܪ`«¬ì¾Ç¬ã¨sªº¤H¨Ó»¡«ç»ò·|¥h´£¿ô²³¤j: ¤G´ÁÁ{§É¬ã¨s¦b¦h°ê¦h¤¤¤ß¶i¦æ¡A¥Øªº¦bµû¦ô¦w¥þ©Ê¡F³o©M§Ú©Ò»{ÃѪºP2¬O¤£¦Pªº¥Øªº¡A·|¤£·|ªº¬O¦b¥Ø«e¨S¦³efficacy¤U¤@ºØ©e°ûªº»¡ªk?´NÀRÆ[¨äÅÜ¡C (¬JµM»P©Ò»{ÃѪºP2ªº¥Øªº¤£¦P,¤@Ó·R±¤¤½¥qªºªÑªFÀ³µ½·Nªº´£¿ô¤½¥q©Î¯E¤Í,¦³·NµL·Nªº»~¾É«Ü®e©ö¤Þ°_¯E¤Í¤Ï·P) 2ª©¤Íµ½·N´£¿ô¥h¬Ý^¤åª©¬O»¡©ú¯E¹©ªº¤G´ÁÁ{§É¥Øªº¦b·§©À©ÊÅçÃÒ¡]proof of concept¡^¡A¥ç§YnÃÒ©úÃĪ«¬O§_¥i¥H¦³®ÄªvÀø¦¹¯e¯f 3 OBI 821/822 ªº P2 proof of concept ¥Ø«e´N¬OÁÙ¨S(¦¨¥\)½T»{!(OBI 822/821 ¤~¹ï ³o»ò¦nªºÃĤ]¼g¿ù ) ( 2016 ASCO P13 ¦¨¥\¹F¼Ð«á proof of concept ´N§ó½T»{¤F) ( Rugo : ³o¶µ¬ã¨sÅã¥Ü¹ï¦³§K¬Ì¤ÏÀ³ªí²{ªÌ¤w¹F¨ì¥DnÀø®Ä«ü¼Ð¡A¦P®Éµý¹ê¥H§K¬ÌÀøªkªvÀø¨ÅÀù±wªÌªº¦³®Ä©Ê «ü¯e¯fµL´c¤Æ¦s¬¡´Á PFS ) 4 Âಾ©Ê¨ÅÀùÃįà¥Îªº¦³,¥»ª©¯E¹©²£«~½u»PÄvª§¹ï¤â,·íµM·|°Q½×¨ìIbrance, Perjeta, ¯f±wnªº¬O¦w¥þ¦³®Ä, ¯àÅýÁ`¦s¬¡´Á©µªøªºÃÄ,nªº¬Oµ²ªG,¤£¬O¹Lµ{ (¦¬®×±ø¥ó¬Û¦P) ( n¤£n¹êÅç³]p¤]n¬Û¦P,§ÜÀù¾÷¨î¤]n¬Û¦P,¥´°w¦¸¼Æ¾¯¶q¤]n¬Û¦P ¤~¯à¤ñ¸û ) 5 ²×©óµo²{¤@¦ì¤ñ¯Î±Ò´f°|ªø ¤ñ¯E¹©¥Í§Þ¤½¥q¬ãµo¹Î¶¤ÁÙÁA¸ÑÁÞ¤À¤l¬Ì]ªºÃm¥@X¤~ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/9/13 ¤U¤È 06:29:16²Ä 2507 ½g¦^À³
|
To T^T & ¦Ñ¥v¤j: ÁÂÁ¨â¦ìªº°Q½× ¨ü¯q¤£¤Ö. è¤~¥¿¦nÂsÄý¨ì¤U±³o½g¤å, ¨â¦ì¥i¬Ý¬Ý¦³¨S¦³ °Ñ¦Ò»ùÈ. ¤°¤\¡I¡H¤Æ疗©~µM¤]¯à¿E¬¡§K¬Ì¨t统¡H news.bioon.com/article/6689790.html |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/9/13 ¤U¤È 06:15:58²Ä 2506 ½g¦^À³
|
1¡B©Ò¥HT¤j§A¨S¬Ý^¤åª©¸òRugo½Í¸Üªº¼v¤ù´N¦k¥[§åµû¤F¡H³o´N¬O§A©Ò¿×ªº±M·~¡H 2¡B¥¤ßÀR®ðªº°Q½×¦hªÅ«Ü¦n¡A¦ýT¤j¦ü¥G¨Sµoı§Aªº¥Îµü¥Rº¡Ù^Ùg¿Ø¨ë!¥Î°ê¤ýªº·s¦ç»P¤½¥q¸Û«H¦³°ÝÃD¨Ó©Ù¯E¹©¡AµM«á«o¤S·Q¦b¯E¹©ÁÈ¿ú¡H¡H¡H 3¡B´N¦pT¤j©Ò»¡¡AÃÄÃҳ̫á¬OFDA¨M©w¡A¤]¤£¬O§AT¤j¨M©w!T¤jµo¤å®É¬O§_»{¬°¦Û¤v±M·~Á{¾rFDA¤§¤W¡H |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/9/13 ¤U¤È 05:38:43²Ä 2505 ½g¦^À³
|
To T^T ÁÂÁ§A¸Ñ¨M¤F§ÚªººÃ´b §Ú¤]«Ü¦P·N§A»¡ªº³o¬O¤@¶¡¥«È2B usdªº¤W¥«¤½¥q ¦³¨Ç²¨¥¢¯uªº«Ü¤£¸Ó¥X²{...... °£¤F§Æ±æ¯à¦b¦¹Ä~Äò¬Ý¨ì§Aªº·Qªk ¤]´Á«Ý¦b¤ß®®ª©¯à¬Ý¨ì§Aªº°ª¨£ ÁÂÁÂÅo |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/13 ¤U¤È 04:19:37²Ä 2504 ½g¦^À³
|
¦^À³¦Ñ¥v: ¥Ø«eanti-PD1ªºORR¤£°ª¡A¦ý¬O¥[¤WTKI©Î¬O¤ÆÀø¡A¦³¨Ç¤p«¬¬ã¨sµo²{¥i¥H¼W¥[¤ÏÀ³²v¡Aabstract 3502 ªº·N¸q¦banti-PD1´X¥GµL®Äªº¯f¤H(ORR 4% in past study)¡A¥[¤Wcobi«áORR´£°ª¨ì17%¡M meetinglibrary.asco.org/content/171295-176 §Ú»{¬°Globo-Hªº²z½×¾÷Â঳¼ç¤O¡A¦]¬°¹L¥h¾÷Âण©úªºBCGªvÀø»H¯ÖÀù¡Aªñ¦~µo²{¬O©MBCG¤WªºÁÞ¤À¤l¦³Ãö¡A¦ý¬OOBI 821/822 ªºP2 proof of concept ¥Ø«e¡A¦A±j½Õ¤@¦¸¬O¥Ø«e¡A´N¬OÁÙ¨S(¦¨¥\)½T»{! ¦pªG¤ÆÀø©M¼Ð¹v(TKI)¥i¥H§âÀù²ÓM±þ¦ºÄÀ©ñ¥X§Üì(¥i¯à´N¬Oglobo-H)¡A¨º¨Ö¥Îanti-PD1¥[±jhost immune¥h¬r±þÀù²ÓM´N·|§ïµ½¥Ø«ePD1ªvÀøRR¹L§Cªº°ÝÃD¡C¦ý¬O±q821/822ªº¾÷Âà(¥»¨´N¬O§Üì¤F)¡A¦ü¥G¨S¦³¨Ö¥Îªº¹D²z! Ãö©ó©Ò¿×®Éµ{¡A²{¦b¬O§K¬ÌªvÀøªì©l¡A¦pªG¯àOBI vaccine¯àÃÒ©ú¦³Àø®Ä(vs placebo)¡A·íµM¬O·¥¤jªº¾÷·|¡A¦ý¬O¦pªG¤£¯à¡A¤§«á¥i¯à¤£¬On³æÃÒ©ú¦³Àø®Ä³o»ò²³æ! ¼o¸Ü¦^À³ Án¤j¤£¥Nªí¦³²z¡A ¤åªø¤£¥Nªí¦³®Æ¡A ¥[¤W¤j¤£¥Nªí´L«! ¦Ü¤Ö§Ú¤£Ä±±o¦³³Q´L«¡A¦^À³ªÌn«ü¾É§Ú¸Ó«ç»ò°µ(¹Dºp°Õ!½æªÑ²¼°Õ!)ªº¤£¤Ö¡A§Æ±æ¬O¯à«ü¥¿§Úµû½×ªº¨Æ!¤@¶¡¥«È2B usdªº¤W¥«¤½¥q¡A¸ê®Æ¿ù»~ÁÙn§Ú¥h§ä^¤åª©¡A¹ï§Ú¦³·N¨£ªº¡A§Ú¥u·Q»¡ only God can judge (people)¡A·Q§êºt¤W«Òªº¤H¡A§Ú¥i¯à¨S¯à¤O©M±z·¾³q¡C ¨Ó¦¹µo¨¥¯Âºé¬O¤À¨É·N¨£¡A©Î³\¦³¤H¬Ý¤£ºD³oºØ§å§P¦¡µo¨¥¡A¦ý¦b°ê»ÚÂå¾Ç·|¬O«Ü¥¿±`ªº!§Ú§â¦^À³ªÌ·íªB¤Í¡A§Ú©MªB¤Í¶¡¤£·|¥[¤Wx¤j¡A¦Û»{¦^¨¥¦³¤º®e¡A¤~¬O¹ï¥»ª©¤Î¨ä¥L¤Hªº´L«¡A³oºØ©x¹±¦¡ªº¥[¤W¤j¡A§Ú·QÁÙ¬O§K¤F ¾Ç³N¤W¡A§Y«K¦¬®×±ø¥ó¬Û¦P¡A¤£¦P¬ã¨sªºµ²ªG®³¨Ó¤ñ¸û¡A³£n«Ü¤p¤ß¸ÑŪ¡A§ó¦óªp¨âÓ§¹¥þ¤£¦P¦¬®×±ø¥óªº¬ã¨s¡AºÙOBI822¤ñ Ibrance¦n¡A¬Û«H¤£¬O¥u¦³§Ú¬Ý¨ì°ê¤ýªº·s¦ç¡A¥u¬O¨S¤H´±»¡¥X¯u¬Û! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/12 ¤U¤È 09:48:18²Ä 2503 ½g¦^À³
|
Àù¯g§K¬ÌÀøªk¬O¥þ·sªº»â°ì,¤½¥q»PªÑªF¤]¦bºN¯Á¾Ç²ß¤¤, ¯E¤Í¯u¸Ûªº¤À¨É, ¨C¤H±q¤£¦P¨¤«×¤Á¤J´Á¬ß«÷´ê§ó¼e¼sªºµø³¥, ¨C¤H¤À¨É¤]¶È¬O´£¨Ñ°Ñ¦Ò, ¥»ª©¯E¤Í¤j³£¯àªÃ«ù¿W¥ß«ä¦Ò, ·ÅÄɤ¬°Ê,¬Û¤¬¹ªÀy, ¥un¬OÅÞ¿è«e«á¤@P,¨¥¤§¦³ª« , ¦³®Ä·¾³q¤O»P¦³Â§»ªªº¦æ¬°, ¤£½×¦hªÅ³£¥i´£¥X¬Ýªk ·Q½Ð±Ð T^T ¤j 1 2016 ASCO P13 ´Á¤¤Á`¦s¬¡´Á ¨º¤@±i§ë¼v¤ù¦³¨º¸Ì¤£¬O¹ê¨Æ¨D¬O? ¨º¸Ì¤£¬ì¾Ç? ¬°¤°»ò¨º»ò©È¨ÅÀùOBI822ªº¤¤¦ì¼ÆÁ`¦s¬¡´Á¶W¶VIbrance ? 3 Ibrance ÁöµM¦b¤¤¦ì¼Æ¯e¯fµL´c©Ê¦s¬¡´ÁMPFS 20.2Ó¤ë,¦ý¬O¤¤¦ì¼ÆÁ`¦s¬¡´ÁMOS¥u¦³37.5Ó¤ë,¹w¦ô±N»·§C©ó¨ÅÀùÃÄOBI822 (°Ñ¦Ò2016 ASCO P13) ªº½×z¨º¸Ì¬OµL½]ªº¨¥½×? ´Á¤¤OS¤£¬O¨ã§ïµ½ÁͶÕ?ª©¤W¦³«Ü¦h°Ñ¥[ªÑªF·|ªº¯E¤Í¤]¤À¨Éª½½u¹ºªk, ª½½u¹ºªk¥u¬O§Ö³t¬ã§P¤èªk¤§¤@, ¥t¥~¨Ì¾Ú§K¬ÌÀøªk«p§Àªº¯S©Ê¹êÅç²ÕÁ`¦s¬¡´Áªí²{·|¤ñª½½u¹ºªk¨Óªº¦nªº±À½×¤]¬O¦X²zªº, Ó¤H»P ¤p©_¤j, ¯E§J¤j³£¦³¦P¼Ëªº¬Ýªk 4 ½Ð°ÝºÙ©Iª©¤W«e½ú ²q·Q Cliff ¦Ñ¥v ¾A·í¶Ü ? ¥[Ó¤j¦³¨º»òÃø¶Ü ? 5 S26 ¬O¤°»ò? ¬OÀ¦¨à¥¤¯»¶Ü? ¬Ý¨ì¤½¥q§ë¼v¤ùº|¶ñ´XÓ¦r´Nªgªg¦Û³ß, ¦Û¥H¬°¶e¨ì¾÷·|¥i¥Hײz¯E¹© ? ¤G´ÁÁ{§É¬ã¨s¦b¦h°ê¦h¤¤¤ß¶i¦æ¡A¥Øªº¦bµû¦ô¦w¥þ©Ê¡F¦³®Ä©Ê (§ë¼v¤ùº|¶ñ ¦³®Ä©Ê ) ²Ä¤G´ÁÁ{§É¸ÕÅç¬ã¨sªº¥Dn¥Øªº¬OÅçÃÒÃĪ«Àø®Ä¤Î¶i¤@¨Bªº¦w¥þ©Êµû¦ô¡C³o¤@´Á±N«Ø¥ß·§©À©ÊÅçÃÒ¡]proof of concept¡^¡A¥ç§YÃÒ©úÃĪ«½T¹ê¥i¥H¦³®ÄªvÀø¦¹¯e¯f¡C¦¹´Á¤]·|Ä~Äòµû¦ôÃĪ«ªº¦w¥þ©Ê¡B©Ò²£¥Í¤§°Æ§@¥Î¡A¦P®É·|¨M©w¥X³Ì¨Î¾¯¶q¡B¥Îªk©Mµ¹ÃĶ¡¹j scimonth.blogspot.tw/2013/03/blog-post_8043.html 6§K¬ÌÀøªk¦³Àø®Ä¬Oºî¦X¤F¨ä¥LÃĪ«¡A¨Ã¤£¬O»¡ÃÒ¹ê¤F(¥D°Ê)§K¬ÌÀøªkªºÀø®Ä! Hope Rugo : ³o¶µ¬ã¨sÅã¥Ü¡A¹ï¦³§K¬Ì¤ÏÀ³ªí²{ªÌ¤w¹F¨ì¥DnÀø®Ä«ü¼Ð¡A¦P®Éµý¹ê¥H§K¬ÌÀøªkªvÀø¨ÅÀù±wªÌªº¦³®Ä©Ê ¤£¬Û«HHope Rugo ©Ò¨¥ ¤S¾Ö¦³¯E¹©ªÑ²¼·|¤£·| ÁÍÁ׽Ĭð ? ¥H¤W´N±Ð ¦p¦³±o¸o ·q½Ð¨£½Ì |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/9/12 ¤U¤È 07:57:58²Ä 2502 ½g¦^À³
|
¦Û¤vªº¿ù¤£©ö¦Û¤v¬dı¡A©êºp¤F¡C §ó¥¿¡G »~¡G¡u¡K¤]´N¬O¿à³Õ¤h¦b¸Ñª¼«á¥l¶}ªº»¡©ú·|¤Wªº¦P¤@ª©¥»¡K¡v ¥¿¡G¡u¡K¤]´N¬O¿à³Õ¤h¦bASCO«á¥l¶}ªº»¡©ú·|¤Wªº¦P¤@ª©¥»¡K¡v |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/9/12 ¤U¤È 01:36:21²Ä 2501 ½g¦^À³
|
½Ñ¦ì¤j¤j: ³oÓª©±¬OÄÝ©ó¤j®aªº¡A¤p§Ì¥u¬O¶}Ó¤Þ¨¥¦Ó¤w¡A¥un¨¥¤§¦³ª«¥²µM¨ü¨ìªÖ©w¡C S26©Ò¨¥¡AFDA¤G´Á¸ÕÅç¬O¥Î¨Ó「µû¦ô¦w¥þ©Ê」¡A³oÂI§Ú¤]ı±o«Ü¬ð¤a¡C¤£¹L¦^·¹§ä¥X¤µ¦~6/5¤½¥qª©ªºASCO²³øÀÉ(¨C±i¤U¤èªþ¦³¤¤¤åĶ¤åªºª©¥»¡A¤]´N¬O¿à³Õ¤h¦b¸Ñª¼«á¥l¶}ªº»¡©ú·|¤Wªº¦P¤@ª©¥»)¡ANo.10ªºì¤å¤@¬Ý«K¥i¤@¥ØÁAµM¡Aì¨Ó¤S¬O¤¤¤å½Ķªº°ÝÃD¡C ASCO Slide No.10ì¤å「¡KProof of concept Phase II study at global level for safety and efficacy assessment and Phase III in Taiwan by agreement between Taiwan FDA and OBI Pharma.¡K」¡A²M·¡±Ôz³oÓFDA¤G´ÁÄÝproof of concept¡A¦Ó¥B¬O¬°¤F¦w¥þ©Ê»PÀø®Äªºµû¦ô¡F¦ý°¾°¾¤U¤èªº¤¤¤å³ºÂ²¤Æ¦¨「¡K¥Øªº¬Oµû¦ô¦w¥þ©Ê¡F¤G/¤T´ÁÁ{§É«h¬O¨Ì¯E¹©»P¥xÆW¹Ãĸpªº¨óij¶i¦æ」¡A²{¦bªºS26³o¤@¬q¨S¦³^¤å¥u¦³¤¤¤å¡A¥i¯à¬O±q¤W±ªº¤¤¤å²¾´Ó¹L¨Óªº¡H©Ò¥H¦Ñ°ÝÃD¡A¤¤^¤åĶ¤å¤£¹ïºÙ¡A³o¬O¤£¸Ó¥Çªº¿ù¡A¦]¬°¤j¦h¼Æªº°ê¤º§ë¸ê¤H³£¥uŪ¤¤¤åªº³¡¤À¡C S34ªº³¡¤À¤]¬O¦P¼Ëªº±¡§Î¡A§Ú¤w¸g´£¹L¦h¦¸¤£¦A«ÂСC ³Ìªñªº¤@¥óµo¥Í¦b¤W¶gµo¥¬ªº¤¤¤å·s»D½Z´£¨ì±N©óESMO´Á¶¡¿ìsatellite symposium¡A³Ì«áªº¤@¬q¤º®e»á¬°¤£¶¶¡A¡]µL¥©¤£¥©¦a»PGoogle½Ķ¤º®e¹p¦P¡K¡K¡^¡AÁö¸g¥ß§Y¤ÏÀ³«á¤w·í¤éקï©xºô¤º®e¡A¦ý¤£¶¶ªº¤º®e¤w³Q¦h®a¤¤¤å´CÅé·Óµn¡C ¤¤¤å·s»D½Z¡G「¡KOBl³Ìªñ§¹¦¨¤F349¨ÒÂಾ©Ê¨Å¸¢Àù¤G´Á°ê»ÚÀø®Ä©M¦w¥þ©Ê¬ã¨s¡CAdagloxad Simolenin³Q¿W®a±ÂÅv±q¬ö©À´µ¶© - ³Í¯SµYÀù¯g¤¤¤ßOBI»sÃÄ¡]MSKCC¡^」¡]www.chinatimes.com/realtimenews/20160907003203-260405¡^ ^¤å·s»D½Z¡G「¡KOBI Pharma recently completed a Phase 2 International efficacy and safety study in 349 patients with Metastatic Breast Cancer. Adagloxad Simolenin is exclusively licensed to OBI Pharma from Memorial Sloan-Kettering Cancer Center (MSKCC). 」 ×¥¿«á©xºô¡G「¡K¯E¹©¤w§¹¦¨349¨ÒÂಾ©Ê¨ÅÀù¦h°ê¦h¤¤¤ß¤G´ÁÁ{§É¸ÕÅ窺Àø®Ä©M¦w¥þ©Ê¬ã¨s¡CAdagloxad Simolenin«Y¥Ñ¬ü°ê¥v¶©-³Í¯SµYÀù¯g¤¤¤ß¡]MSKCC¡^¿W®a±ÂÅv¤©¯E¹©¡C」 ¾Ú»¡³Ìªñ¤½¥q¤h®ð§C°g¡K¡A±N¤ß¤ñ¤ß¡A¤£Ãø·Q¹³¡A©Ò¥H6606¤j¯S§O´£¥X·í¦~¤E¦º¤@¥Íªº©¹¨Æ¡A²{¦bŪ¨Óºç¤¤´þ¨ý¦Ê¨ýÂø³¯¡K¡CESMO¥¼¯àª½±µµn¥x³ø§i¡A¤´§V¤O¦Û¿ì¬ã°Q·|¡A¥i¬Ý¥X¤½¥qªº§V¤O¡A¥[ªo¡I T^T¤jÀ³¦³¶KªñÁ{§É·ÓÅ@ªº¸gÅç¡AÄ@¯à¤À¨É±zªº¤ß±o¡C |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2016/9/12 ¤U¤È 12:29:13²Ä 2500 ½g¦^À³
|
S26 §Ú»{¬°¬O¤¤¤å½Ķªº¿ù»~. proof of concept À³¸Ó¤£¬O½Ķ¦¨µû¦ô¦w¥þ©Ê. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/12 ¤W¤È 11:34:51²Ä 2499 ½g¦^À³
|
T¤j ÁÂÁ±zªº«ü¾É ÁÂÁÂ! |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/12 ¤W¤È 11:19:53²Ä 2498 ½g¦^À³
|
to those don¡¦t known well what clinical trials means: www.ntuh.gov.tw/RECO/subject-info/DocLib/%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%E7%9A%84%E5%88%86%E6%9C%9F.aspx qoute: ³oÓ¶¥¬qªº¥Dn¥Øªº¬O¨M©w¤@ºØÃĹï¯S©w¯e¯f¬O§_¨ã¦³Àø®Ä¨Ã¦P®ÉºÊ´ú¨ä¥i¯à¤Þµo¤§¤£¨}¤ÏÀ³¡C reclaim: ¬O§_¨ã¦³Àø®Ä , ¬O§_¨ã¦³Àø®Ä to ²q·Q: In fact, I think you know the answers. some can, some not, mostly depends on which antigen presented. in OBI-821/822 case, should be the later. to ¦Ñ¥v I wouldn¡¦t speculate any combination of OBI products with TKI until meaningful study. I¡¦m lucky to knwo the combination of Atezolizumab+cobimetinib merely because I own some Exelixis(EXEL). There¡¦re lots of study about the combination of TKI + anti-PD1 etc. going on in ESMO abstracts. Can¡¦t type in Chinese now. Sorry to everyone! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/9/12 ¤W¤È 09:53:54²Ä 2497 ½g¦^À³
|
T^T¥S¹ïAtezolizumabªº±M·~µo¨¥¥O¤H¦L¶H²`¨è §Ú´¿Åª¨ì¥h¦~Roche¦bESMOªºÀÉ®× www.roche.com/irp150928.pdf P23~P25 Atezolizumab»P¤ÆÀøÁp¦XªvÀø Roche»¡¹D¡G 1.Pre-clinical data suggests chemotherapy alters tumor immune status to transiently increase inflammation 2.Combinations of chemotherapy and atezolizumab may extend the inflammatory state for durable responses 822»P¤ÆÀø¤§¶¡À³·í¦p¦ó¬Û»²¬Û¦¨¬°¨Î¡H ¯à§_¼·¤¾¤À¨É±zªºÄ_¶Q·Qªk ÁÂÁÂ^^ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/12 ¤W¤È 09:53:41²Ä 2496 ½g¦^À³
|
ÁÂÁÂT¤jªº¸Ñ»¡¤ÎªÈ¥¿ ·Q¥²T¤j¤DÂåÃĬɪº±M·~¤H¤h ½Ð±Ð±z¤@Ó°ÝÃD ¤HÅé°w¹ï§Üì¤Þ°_§K¬Ì¤ÏÀ³ªº¯à¤O,¯à¨Æ«e´ú©w¶Ü? ¤S¤HÅé¹ï¤£¦P§Üì,©Ò¤Þ°_ªº§K¬Ì¤ÏÀ³·|¦³®t²§¶Ü? ÁÙ¬O®t¤£¦h? °²¦p±z¦£,´N½Ð¤£¥Î²z·|¤p§Ìªº°ÝÃD¤F ÁÂÁ±z! ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/9/12 ¤W¤È 09:44:21²Ä 2495 ½g¦^À³
|
¡yS.26 ¤½¥q»¡: ¤G´ÁÁ{§É¬ã¨s¦b¦h°ê¦h¤¤¤ß¶i¦æ¡A¥Øªº¦bµû¦ô¦w¥þ©Ê¡F ³o©M§Ú©Ò»{ÃѪºP2¬O¤£¦Pªº¥Øªº¡A·|¤£·|ªº¬O¦b¥Ø«e¨S¦³efficacy¤U¤@ºØ©e°ûªº»¡ªk?´NÀRÆ[¨äÅÜ¡C¡z ª©ÀY³£»¡n¡u¥ß½×¦³¾Ú¡v¤F ¬Ý¨ì¤@Ó°T®§»P¦Û¤vªº»{ª¾¦³²§¡A¦h¤è¬dÃÒ«á¦A¨Ó½èºÃ¬O¬ì¾Çªº°ò¥»ºA«× S26¤¤^¤åª©¥»¹ï·Ó¤@¤U¤£·|ªá¤Ó¦h®É¶¡§a¡I |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/12 ¤W¤È 09:33:57²Ä 2494 ½g¦^À³
|
short response to ²q·Q I say ®Éµ{, which means timing and progress not only times. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/12 ¤W¤È 08:18:25²Ä 2493 ½g¦^À³
|
¤½¥q¥i¯à¥Ñ©ó©x¥qªºÃö«Y Åܱo§C½Õ ¨Æ±¡¥¼µo®i¨ì¦¨¼ô ´NÀRÀq¤£»¡ ©M¤§«eªº§@·¤j²§¨ä½ì ³o¤]Åý¥~¤H¦³¦U¦Ûªº·Q¹³ªÅ¶¡ ¨Ï±o¦³¯à¤Oªº¤j¤HÀH¨ä·N§Ó ª©¤W¤j¤j ±N®É¶¡µ¥«Ý¦C¬°³Ì¤jÅÜ¼Æ ¤p§Ì¤]¤£§_»{ ¦ý³o¦¤w¦b¤p§Ì¤ß¤¤ µM¦ÓÃĮĤ§¸ÑŪ ¤H¨¥¤H®í ¨ì©³¥¼¨Ó·|¦p¦ó §Ṳ́£ª¾ Ó¤H»{¬°³o¬O¥D®_®É¶¡Åܼƪºn¨¤ T ¤jÆ[¹î¥J²Ó¨Ã»¡ " S.26 ¤½¥q»¡: ¤G´ÁÁ{§É¬ã¨s¦b¦h°ê¦h¤¤¤ß¶i¦æ¡A¥Øªº¦bµû¦ô¦w¥þ©Ê¡F ³o©M§Ú©Ò»{ÃѪºP2¬O¤£¦Pªº¥Øªº¡A·|¤£·|ªº¬O¦b¥Ø«e¨S¦³efficacy¤U¤@ºØ©e°ûªº»¡ªk?´NÀRÆ[¨äÅÜ¡C " ´N¦p«e±©Ò¨¥ ¤½¥q¬O§C½Õªº T¤j¤§¨¥ ¤p§ÌÁx´±±N¤§§ï¬° (±N"¨S¦³efficacy"§ï¬°"ÁÙ¨S¦³½T»{efficacy") ³o©M§Ú©Ò»{ÃѪºP2¬O¤£¦Pªº¥Øªº¡A·|¤£·|ªº¬O¦b¥Ø«eÁÙ¨S¦³½T»{efficacy¤Uªº¤@ºØ»¡ªk?´NÀRÆ[¨äÅÜ¡C ¤£¬O§Ú«r¤åÀï¦r ¦ý¥¦«o¥Nªí¤£¦Pªº·N¸q ¦Ü©ó¤½¥q¿ì¬ã°Q·| ³o¸Ì±¦³¦ó·N²[ ·|©MÂyªÌ¤j¤@¼Ëªº·Qªk¶Ü? §Ú·Q¤j®a¤ß¸Ì¥²¦³¦Û¤vªº¬Ýªk ¨¥¤£¤Î¸q ¶È¨Ñ°Ñ¦Ò ¦Ã¬Vª©± ¦VCliff¤j®¦¼wPºp ¤]ÁÂÁ¤j®a! |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/12 ¤W¤È 01:26:43²Ä 2492 ½g¦^À³
|
A¼L¥Öªº¦^ÂÐ¥e¤Fª©±¡A¹ï cliff«Ü©êºp §ë¸ê¥»¨Ó´N¬O¨CÓ¤H¦Û¤vªº¨Æ¡A¹ï¤½¥q¦³ºÃ¼{¡A¤£¥Nªí§Ú¨S¶¢¿ú &©Ó¾á·ÀI¯à¤O¡A¨CÀɪѲ¼¥»´N¬O risk/reward µû¦ô«á¤~¨M©w°t¸m¦h¤Ö¸êª÷¡A§Ú»{¬°Globo-H¦³¼ç¤O¦¨¥\¡A¦ý¤£¤@©w¤@¦¸´N¥i¥H¡A¤]¤£¤@©w´N¬O¨ÅÀù¡A¯E¹©´N¬O§Ú¦hÀɥͧުѤ¤ªº¤@Ó¡A©Ò¥H©Î³\§Ú¤£¹³ª©¤W³\¦h¤H§ë¤J·P±¡»P±H±æ¡C ·x·x ±z´£¨Ñªº³sµ² mops.twse.com.tw/nas/STR/417420160907M002.pdf S.26 ¤½¥q»¡: ¤G´ÁÁ{§É¬ã¨s¦b¦h°ê¦h¤¤¤ß¶i¦æ¡A¥Øªº¦bµû¦ô¦w¥þ©Ê¡F ³o©M§Ú©Ò»{ÃѪºP2¬O¤£¦Pªº¥Øªº¡A·|¤£·|ªº¬O¦b¥Ø«e¨S¦³efficacy¤U¤@ºØ©e°ûªº»¡ªk?´NÀRÆ[¨äÅÜ¡C S34 ¤½¥q½ĶRugoªºµû½×¤£ª¾¹D±qþ¤@¬q¥X¨Óªº¡A©Î³\¬O§Ú¨S¾÷·|±µÄ²¨ì¡A¤£¹L§Ú©ÒÅ¥¨ìªºRugoªº»¡ªk©úÅã¬O«üÁÙ¦³«Ü¦h¬ã¨sªÅ¶¡¡A§K¬ÌÀøªk¦³Àø®Ä¬Oºî¦X¤F¨ä¥LÃĪ«¡A¨Ã¤£¬O»¡ÃÒ¹ê¤F(¥D°Ê)§K¬ÌÀøªkªºÀø®Ä! |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/9/11 ¤U¤È 11:44:13²Ä 2491 ½g¦^À³
|
T¤j:§Ú¤]¤£¬OFDA,©Ò¥H¨S¿ìªkÀ°§A¦^µª¨ì©³µ²ªG¦n¤£¦n,¦ý§A¤]¤£¬O³½,«çª¾³½§Ö¤£§Ö¼Ö?!¤£¹L§Ú¬d¹LÂû»L¸òÂû¯Íµ´¹ï³£¬OÂû¦×,®³¨Ó¿LÂû´ö¥\®ÄÀ³¸Ó¬O¤@¼Ë¦nªº! T¤j»PÂy±©¤j¾á¼~nªá§ó¦hªº®É¶¡,¬Û«H¤j®a¦b¦Uª©¤]°Q½×¹L~T¤j´£¥Xªº½×ÂIµ´¹ï¬O¤FµL·s·N! ³Ì«á,¬JµMÃhºÃ¤½¥q¸Û«H,¨º¦ó¤£¦¦§Ñ¤F³o¤äªÑ! |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2016/9/11 ¤U¤È 11:35:37²Ä 2490 ½g¦^À³
|
¤µ±ß¥©¼ö¾x⋯,³á «¢«¢⋯,¦A¸g¾ú±q2¤ë19¦Ü5¤ë20«eªº²l¤õ³s3¤ë«á¡A T¥ý¥ÍÁÙ¥H¬°¡u¯E¹©¡v¥D¨ÆªÌ¡A¨Ì¦æ¨Æ¦p©õ°Ú¡H §g¤£¨£²{¦b¥«³õ°T®§´X¥G¯Ê¦p¡A¨S¦³¡u¯u¥¿¡vªº¼Æ¾Ú¥X¨Ó«e¡A ¤½¥q¤w¸g¤£¦A¡u¥D°Ê¡v¥h¹w´Á¥¼¨Ó¡A®í¤£ª¾¡u¨HÀq¡v¦¹®É¬O¯E¹©¸ÀÅܪº «e«µ¡A²£«~¬ãµo¹Lµ{¨H±I¨Ç¦n¡A¤Ö©Û¸Á¤Þ½º¡Aµ¥®³¨ì¯u¥¿¨}¦n¼Æ¾Ú ¡A®³¨ìFDA¸ê®æ©ÎÃĵý¡A¦A¨Ìªk¤½§i¡A ¦A¨Ó³o¥y⋯, ¡u¥t¥~§Ú¤@ª½¹ï¤½¥qªº¸Û«H¦³ºÃ¼{¡A¬°¤°»ò²£«~ÁÙ¨S(approved)¤W¥« ´Nªá¤j¿ú¥h¿ìsatellite symposium? ³o¦bÂå¬É¬O«Ü¨u¨£ªº¡v¡A ÂyªÌ¥u¯à»¡¡A§O·W ¡u³yª«ªÌ¦w±Æ¡A¦Û¦³¹D²z¡A¤]´N¬O¡u¨ä¤¤¥²¦³缘¬G¡v°Õ⋯, ¯¬ºÖ©Ò¦³¤HÂyª«º¡¦æÅn Ây ªÌ |
|
|
·|û¡GÂyªÌ°ß±©10142617 µoªí®É¶¡:2016/9/11 ¤U¤È 11:09:59²Ä 2489 ½g¦^À³
|
T^T ¥ý¥ÍÁÂÁ±zªº¦^ÂСC§Ú»{¬°¹ï¯E¹©§ë¸êªÌ¡]¤£¬O¯E¹©¤½¥q¡^¨Ó»¡¡A³Ì¤jªº·ÀI¦b®É¶¡¡A¯E¤Í̹綠¥q¥Ó½ÐBTD¬Æ©Î±ÂÅv¤ÎFDA½Í§P®É¶¡³£¤Ó¼ÖÆ[¡C²{¦b¤½¥q³sEOP³£ÁÙ¨S¶}¡AªÉ½×¤T´ÁÁ{§É¸òFDAªº°Q½×¡C¤@¥¹®Éµ{¤£¦p¯E¤Í¹w´Á¡A¥¢±æ©Ê½æÀ£¤S±N¶}©l¡C«Ü¯u¸Û§Æ±æ²³¯E¤Į̦́ۨª¬ªp¨Óµû¦ô¯E¹©§ë¸ê¡C¦]¬°¸òFDA¤Î±ÂÅv½Í§P©Òªá®É¶¡±N¬Oº©º©ªø¸ô¡C ºô¸ô«Ü¯«©_¡A§Ú¥i¥H¦b¤£¦P®É¶¡¦aÂI¸ò¤£¦P¦~¬ö¾·~ªº¤H°Q½×¾Ç²ß¡C«Ü§Æ±æT¤j¯à¦b¦Ê¦£¤§¤¤¤À¨É±zªº¨£¸Ñ¬Ýªk¡A§Ú¬Û«H¬O²³¯E¤Í¤§ºÖ¡C |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/11 ¤U¤È 10:41:21²Ä 2488 ½g¦^À³
|
ÂyªÌ°ß±© ¤j ¥¤ßÀR®ð°Q½×¦³®É¶¡¬OOKªº¡A¤£¹L¤u§@«Ü¦£¡A¤£±`¤W¨Ó! §ÚÓ¤H»{¬°³Ì¤j§xÃø¦b®Éµ{¡A¦pªG³o¦¸P2/3 ªºfinal results¤£°÷¦n(©Ò¿×ªº°÷¦n¤£¬Oºô¤Í¤Î¤½¥q»{©wªº¡A¦Ü¤ÖnFDA±µ¨üNDA)¡AÁÙnªá¦h¤Ö¿ú©M®É¶¡°µ¤U¤@Ótrial¡A³o¦¸ªºtrialªá¤F§Ö5¦~¥Ø«eÁÙ¨Sµ²ªG¡M¦b²£«~approved¤§«e¡A·|¦³¦h¤Ö¨ä¥LÃĪ«¤w¸g¤W¥«¤F¡A¨º¥«³õ³W¼Ò¤Î©w¦ì(¤]´N¬O°â»ù)´Nn«·s¦ôºâ! ¥t¥~§Ú¤@ª½¹ï¤½¥qªº¸Û«H¦³ºÃ¼{¡A¬°¤°»ò²£«~ÁÙ¨S(approved)¤W¥«´Nªá¤j¿ú¥h¿ìsatellite symposium? ³o¦bÂå¬É¬O«Ü¨u¨£ªº! |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/11 ¤U¤È 10:18:24²Ä 2487 ½g¦^À³
|
¨þ¨þ! §Ú¤]¬Ý¦n¯E¹©¦³¾÷·|¡A¦ý¬O¬ì¾Ç(Á{§É¹êÅç)¥»¨Ó´N¬O¹ê¨Æ¨D¬O¡A²q´ú¹êÅçµ²ªG·íµM¥i¥H¡A¦ýµL½]ªº¨¥½×·íµMn´£¿ô¤@¤U¡A§Ú¨S¦³«ü¦W¡A¦ý¦³¨Ç¨I¤£¦í®ðªº´N¸õ¥X¨Ó¤F¡Aª©¤W§N¨¥¼ö¿Ø§Ú¤]·í¯º¸Ü¬Ý! PS: §Úªºµû½×¬O°w¹ï¥H¤U³o¥y Ibrance ÁöµM¦b¤¤¦ì¼Æ¯e¯fµL´c©Ê¦s¬¡´ÁMPFS 20.2Ó¤ë ,¦ý¬O¤¤¦ì¼ÆÁ`¦s¬¡´ÁMOS¥u¦³37.5Ó¤ë ,¹w¦ô±N»·§C©ó¨ÅÀùÃÄOBI822 ( °Ñ¦Ò2016 ASCO P13 ) |
|
|
·|û¡GÁÙ¯u10138289 µoªí®É¶¡:2016/9/10 ¤U¤È 11:18:14²Ä 2486 ½g¦^À³
|
S¤p©j±µ¨ü822ªvÀø¬O¦b2014¦~3¤ë¶}©l, ±o¨ìNEDÃÒ©ú¬O¦b2014¦~8¤ë, NED¦Ü¤µ2016¦~9¤ë¤w¬O2¦~¤F |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/9/10 ¤U¤È 05:04:19²Ä 2485 ½g¦^À³
|
¦P¼Ë³£¬OÂû¡A¥i¬O«~ºØ¤£¤@¼Ë¡A¤f·P¤£¤@¼Ë¤]¡C |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/9/10 ¤U¤È 01:10:37²Ä 2484 ½g¦^À³
|
Âû»L©MÂû¯Í¯×ªÕ§t¶qÁöµM¤£¦P,¦ý³Á·í³Ò³£½æ§Ú¤@¼Ëªº»ù¿ú£°!¤£ª¾T¤j«ç»ò¬Ý? ÁÙ¦³,¦Y¶i¨{¤l¸Ì¤£³£¬OÂû¦×¶Ü?Ãø¹D©Ô¥X¨Óªº¤j«K·|ªø¤£¤@¼Ë¶Ü?ÁÙ½ÐT¤j¸Ñ´b! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/10 ¤U¤È 12:58:46²Ä 2483 ½g¦^À³
|
¦Ñ¥v¤jªº¾ã²z ¬Û·í²`¤J§¹µ½ T¤j§A¦³¥»¨Æ¥h¬Ý¨º¨Ç^¤å³ø§i §ä¥X¨º¨Ç¼Æ¦r¨Ó ¦A¨Ó¦R¼Ñ §Ú¬O¨S¬Æ¥»¨Æ ³o¸Ì°ª¤â«Ü¦h ³£ª¾¹DAÃĸòBÃĪº¹êÅçÀø®Ä³ø§i ¤£¯àµ¥¦P¬Û¤ñ ³o¬OBASIC ¦Ó¦Ñ¥v¤j¾ã²z¸ê®Æ À³¸Ó¬On´£¥Ü¤j®a ¹L¥h¤wª¾ÃĪ« ¹êÅç²ÕMOS¼W¥[¦h¤Ö HR´î¤Ö¨ì¦h¤p ´N¥i¥H¹F¨ìÅãµÛ Àò±oFDAÃÄÃÒ ¦Ó¤wª¾822´Á¤¤¤ÀªRµ²ªG HR´î¤Ö¬°0.79 PÈ .289 ¹êÅç²ÕMOS¼W¥[¦h¤Ö¥¼ª¾ ¦pªG ÀH®É¶¡±À²¾ HRÄ~Äò´î¤Ö¨ì¦h¤Ö PÈ´N¥i¥HÅãµÛ ¡H °²©w¹êÅç²ÕMOS¼W¥[´T«×»PHR´î¤Ö´T«×¦¨¥¿¦Vªº½u©ÊÃö«Y ©Î§ó²³æ»¡¬O¥¿¤ñ «h¹êÅç²ÕMOS¼W¥[¦h¤Ö HR´î¤Ö¬°¦h¤Ö¼ÆÈ´N¨¬°÷.05ÅãµÛ¤ô·Ç¡H ¦AªÌ¬Ý³Ìªñªk»¡·|§ë¼v¤ù27¶ Y°²³]¥Îª½½u°jÂk¨Ó¬Ý¡]¹ê»Ú¤W «p§À®ÄÀ³ªºKM¦±½u ¦³®É¤£¾A¦X¥Îª½½u¦^Âk¨Ó¹GªñMOS ¡^ °²³]MOS¹êÅç²Õ52¤ë ¦w¼¢¾¯²Õ40¤ë¡]¨C¤Hµe½u³£¤£¦P³á ¡^ ³o¼Ë¹êÅç²ÕMOSªº¼W´T °÷¤j¶Ü¡H ¤j¨ìÅýHR°÷¤p¶Ü¡H ¦]¦¹ÅýPÈ.05ÅãµÛ¶Ü¡H ³o¬OÁ¼ÃD ¦Û¤v±À¦ôµª®× ¤d¸U§O¤p¬Ý¥v¤j³oÓ¾ã²z¸ê®ÆI«áªº¼Æ¾Ç§t·N ¥i¯à¯A¤Î¨ìHR¦ÛµM¹ï¼Æ¨ç¼Æ¦b¦s¬¡¾÷²v50¢Hªº·L¤À¤èµ{ ¦p¦³»¡¿ù ½Ð¦U¦ì°ª¤â«ü¥¿ |
|
|
·|û¡GÂyªÌ°ß±©10142617 µoªí®É¶¡:2016/9/10 ¤U¤È 12:07:57²Ä 2482 ½g¦^À³
|
T^T ¥ý¥Í´X¦¸ªºµo¨¥¡A¤pªºÄ±±oÆZ¦³·N«äªº¡CÀ³¸Ó¬O¸Ó¦æ¤º¤H¤h¡C¤£ª¾¹DT¥ý¥Í¦pªG¦³ªÅ¡A¯à§_ÀH·N¸ò§Ú³o¦ÑÀY²á²á¯E¹©²{¦b³Ì¤jªº§xÃø¡H ¥H³oӼƾڡA¦³µo®i¤U¥hªº¥i¯à©Ê¶Ü¡H §Ú¬Ý¦n¯E¹©¡A¦ý·Qťť¦hºØ¬Ýªk¡C¥ýÁÂÁ¤F¡C ¹j¾Àª©ªü®a¤§Ãþªº¤p´²¤áJ¨¥¶Ã»y´N§K¤F |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/9/10 ¤W¤È 11:09:47²Ä 2481 ½g¦^À³
|
¬YT¨ì©³¦A»¡¬Æ»ò§r ¤H®a¥v¤j§@ªº¬Osytematic review ........ ³o«Ü¨¯Wªº ¤£µM§A¨Ó¾ã²z ¦Ó¥B³o¬O§K¬ÌÀøªk ¤£¬O¬Æ»ò¥u¦³BC..... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/10 ¤W¤È 10:34:02²Ä 2480 ½g¦^À³
|
1¥v¤jnªí¹Fªº¬O¦¬®×¤H¼Æ¡Aµo¥Í¨Æ¥ó»PPȪºÃö«Y¡C¦pªG¬Ý¤£À´©Î»~¸Ñ§O¤H³Ì¦n»¡Án¹Dºp¡A³o¬O¬°¤H³B¨Æ³Ì°ò¥»ªº¹D²z¡C 2 ½Ö»¡³£¬O¨ÅÀùªº¤ñ¸û¡A¬Ý²M·¡¦Aµû½×! |
|
|
·|û¡G¦³¹Ú³Ì¬ü10141895 µoªí®É¶¡:2016/9/10 ¤W¤È 10:30:30²Ä 2479 ½g¦^À³
|
T¤jµo¨¥¯u¥i¯º¡A¦¹ªO¤£´N¬O¦b°Q½×Ävª§¹ï¤â¶Ü?¯u¤£À´©p¦b¿Ø¨ë¤°»ò?¥i§_´£¥X¦³·N¸qªº¨£¸Ñ?«¢ |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/10 ¤W¤È 09:54:30²Ä 2478 ½g¦^À³
|
¨C¹j¤@¬q®É¶¡´N·|¦³³oºØ®³¤£¦PÁ{§É¹êÅç¦s¬¡®É¶¡¨Ó¤ñ¸ûªºµo¨¥¡AÁÙ¬On´£¿ô¤@¤UÂû»L©MÂû¯ÍÁöµM³£¬OÂû¡A¦ý¬O¯×ªÕ§t¶q¬O¤£¯à¤ñªº! ÁöµM³£¬O¨ÅÀù¡A¦¬®×±ø¥ó¤£¦P®³¨Ó¤ñ¦Û²n¤@¤UµL§«¡A¦ý¬ì¾Ç¤W¬O¤£¥i¥Hªº! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/9 ¤W¤È 10:01:19²Ä 2477 ½g¦^À³
|
·PÁ¦ѥv¤j¥Î¤ß¾ã²z,MOS ¼W¥[¤ñ²v¥Ñ§C¦Ü°ª±Æ¦C¥i¬Ý¥X§K¬ÌÀøªkÃĪ«¼W¥[¤ñ²v°ª©ó³æ§ÜÃĩΤp¤À¤lÃÄ §K¬ÌÀøªk¦bÁ`¦s¬¡´Á¤è±ªº½T¨ã¦³Àu¶Õ , Ibrance ÁöµM¦b¤¤¦ì¼Æ¯e¯fµL´c©Ê¦s¬¡´ÁMPFS 20.2Ó¤ë ,¦ý¬O¤¤¦ì¼ÆÁ`¦s¬¡´ÁMOS¥u¦³37.5Ó¤ë ,¹w¦ô±N»·§C©ó¨ÅÀùÃÄOBI822 ( °Ñ¦Ò2016 ASCO P13 ), ¦w¥þ©Ê¤è±¨ÅÀùÃÄOBI822,¿W¾ð¤@¼m 2016¦~¦æ¬F°|¥Í§Þ²£·~µ¦²¤¿Ôij©eû·|(BTC)·|ij¡Ð³¬¹õ·s»D½Z ¡u±j¤Æ¥þ²y³sµ²¡B¾ã¦X¦b¦a³Ð·s»E¸¨¡v¨â¤jµ¦²¤ÂùºÞ»ô¤U ³sÄò¤T¤Ñªº¡u¦æ¬F°|2016¥Í§Þ²£·~µ¦²¤¿Ôij©eû·|ij¡v¦b¤µ¤Ñ¶¶§Qµ²§ô¡A¦æ¬F°|ªL¥þ°|ªø¦b³¬¹õ·|ij¤¤ªí¥Ü¡A¬°¦]À³²£·~Â૬¤Î·s¸gÀÙ§½±ªº»Ý¨D¡A¬F©²¿ï¾Ü¥Í§ÞÂåÃħ@¬°»OÆW¥¼¨Ó±À°Êªºµ¦²¤©Ê²£·~¡A¨Ã±N«ùÄò±j¤Æ»OÆW¦b¥þ²y¥ÍÂå»ùÈÃ쪺¦a¦ì¡A³Ð³yªþ¥[»ùÈ¡F³z¹L¥H¡u³Ð·s¡B´N·~¡B¤À°t¡v¬°®Ö¤ßªº¸gÀÙµo®i·s¼Ò¦¡¡A¨Ó±a°Ê²£·~ªºÄvª§¤O¡B§ïµ½¥ø·~ªº§Q¼í¡A¨Ã¦P®É´£°ª±q·~¤HûªºÁ~¸ê¡B¼W¥[·sªº¤u§@¾÷·|¡A§Q¥Î³Ð·s¨Ó±a°Ê»OÆW²£·~ªº¤É¯Å»PÂ૬¡C ¡@¡@¬°¥´³y»OÆW¦¨¬°¡u¨È¤Ó¥Í§ÞÂåÃĬãµo²£·~¤¤¤ß¡v¡A¤µ¦~BTC·|ij¤¤¡A¬F©²´£¥X¡u¨È¤Ó¥Í§ÞÂåÃĬãµo²£·~¤¤¤ß¤è®×¡v¡A¨Ã´£¥X¡u±j¤Æ¥þ²y³sµ²¡v¥H¤Î¡u¾ã¦X¦b¦a³Ð·s»E¸¨¡v¤G¤jµ¦²¤¡Cº¥ý¡A¦b¡u±j¤Æ¥þ²y³sµ²¡v¤è±¡A¬F°|±N¥[±j°ê»Ú¦X§@¡A¨ãÅé°µªk¥]¬A°w¹ï¥Í§Þ·sÃÄ¡B³]³Æ¡B§÷®Æµ¥»â°ì¡A±Ò°Ê¸ó°ê¬ãµo¦X§@¤ÎÁ{§É¸ÕÅçpµe¡F¦P®ÉÁÙn§l¤Þ°ê»Ú°ª¶¥¤H¤~¡B§Þ³N¡B¸êª÷§ë¤J¡F¨Ã¥B¿n·¥¶}©Ý°ê»Ú¥«³õ¡A¥]¬A«n¦V©Î°ªÄÖ¥«³õµ¥¡C ¡@¡@¨ä¦¸¡A¦b¡u¾ã¦X¦b¦a³Ð·s»E¸¨¡v¤è±¡A¬F°|±N³W¹º¦Û¥_¨ì«n¡A¦ê±µ¥Í§Þ´Y±a¡A¿ï©w¥x¥_«n´ä¡B·s¦Ë¦Ë¥_¡B¤¤¬ì¤Î«n¬ì¡AªuµÛ°ªÅK¤@¤é¥Í¬¡°é¡Aµ²¦X¦b¦a¯S¦â¡A§Î¦¨±aª¬ªº¡u¥Í§ÞÂåÃĬãµo²£·~»E¸¨¡v¡A¨Ã±N¥|»E¸¨³s¦¨¤@½u¡AÅý²£·~¡B¾Ç³N»P¬ã¨s³æ¦ì¡A©¼¦¹¤ä´©»P¥æ¬y¡A¦P®É¤Þ¶i°ê»Ú¤H¤~¡B§Þ³N¡B¸êª÷¡A§Î¦¨¤@Ó¦³§U©ó³Ð·sªº²£·~¥ÍºAÀô¹Ò¡A±N»OÆW¥´³y¦¨¬°¨È¤Ó¥Í§ÞÂåÃĪº«Âí¡C ¡@¡@ªL´}«ü¥X¡A¤µ¦~BTC¯S§O¿ï©w¡u§¹µ½¥ÍºAÅé¨t¡A¥H»OÆW§Q°ò±À°ÊµJÂI»â°ì¡v¬°¥DÃD¡A°w¹ïÃÄ«~¡BÂå§÷¤Î°·±dºÖ¬ç¤T¤jµJÂI»â°ìµo®i¡AÀòP¦h¶µ«nµ²½×»P«Øij¡C ¡@¡@¦b´¼¼z³Ð·s°ªÈÂå§÷¤è±¡A±N»EµJ§Q°ò»â°ì¾ã¦X¸ê·½¡A·V¿ïÂå§÷¬ãµo¥DÃD¡Aºc¿v§¹¾ã±M§Q§G§½¡A«ùÄò±j¤Æ¥xÆW°ªÈ§Q°òÂå§÷¬ãµo¯à¶q¡A¿n·¥±À°Ê²£¾Ç¬ãÂå¦@¦P¬ãµo¡A¥[³tÂå§÷°Ó«~¤Æ¡C¦b°ê»Ú¤Æ¤è±¡A±N¥[±j°ªÈÂå§÷¥þ²yÃìµ²¡A±j¤Æ°ê»ÚÃĬF¦X§@Ãö«Y¡AÃìµ²°ê»Ú³Ð·s¬ãµo¤Î³]p¶q¯à¡A´£¤É°ê»Ú¥«³õ¦û¦³²v¡C¹w´Á¥Ø¼Ð¬O¥´³y»OÆW¦¨¬°¡u³Ð·s°ªÈÂå§÷²£·~«Âí¡v¡A¹w¦ô2020¦~Àç·~ÃB¥i¹F2,000»õ¤¸¡A2025¦~Àç·~ÃB¥i¹F3,000»õ¤¸¡C ¡@¡@¦bÃÄ«~²£·~Â૬³Ð·s¤è±¡A±N»EµJ«ÂI»â°ì¡A¥[³t¶}µo·sÃĤΧQ°ò¥Íª«ÃÄ«~¡C¦P®É¬ãÀÀ¦X²z°·«Oµ¹¥I±¹¬I¡A¹ªÀy°ê²£·sÃĶ}µo¡C¦¹¥~¡A±N±À°Ê°ê¤º¾Ç¦WÃļtÂ૬¡A±j¤Æ°ê»Ú©Ý¾P¡C¹B¥ÎÀu´f±¹¬I¡A¹ªÀy¾Ç¦WÃļt§ë¤J§ï¨}«¬·sÃĶ}µo¡AÂ૬¬°¯S¦âÃļt¡C§l¤Þ°ê¥~¸êª÷§ë¸ê©Î°ê»Úµ²·ù¡A§ß´Ó°ê¤ºÃļt»P¸ó°ê»sÃĤ½¥q§Î¦¨¹Ù¦ñÃö«Y©Î¦¨¬°¨È¤ÓÁ`³¡¡C¹w´Á¥Ø¼Ð¬O¥´³y»OÆW¦¨¬°¡u¨È¤Ó¯S¦âÃÄ·~(Specialty Pharma)±M·~«Âí¡v¡A¹w¦ô2020¦~Àç·~ÃB¥i¹F1,200»õ¤¸¡A2025¦~Àç·~ÃB¥i¹F2,200»õ¤¸¡C ¡@¡@¦b°·±dºÖ¬ç³Ð·sªA°È¤è±¡A±N«Ø¥ß´¼¼z°·±d¥Í¬¡³Ð·sªA°È¼Ò¦¡¡A´£¨Ñ¥Á²³¥²n°·±d¸ê°T¤Î§ó¤Íµ½¤ä«ùÀô¹Ò¡A¥H´Â¦V°·±d¥Í¬¡¥Ø¼ÐÁÚ¶i¡C¹B¥ÎICT§Þ³N¤Î²§·~¾ã¦X¡A¶}µo²£«~»PªA°È¡A¥H¥ÃÄò¸gÀ窺¤è¦¡µo®i³Ð·s¦Û¶OªA°È¼Ò¦¡¡A¨ÃÂǥѽƻsÂX´²¡A§G§½°ê¤º¥~¥«³õ¡C¹w´Á¥Ø¼Ð¬O¥´³y»OÆW¦¨¬°¡u¨È¤Ó°·±dºÖ¬ç²£·~³Ð·s«Âí¡v¡A¹w¦ô2020¦~Àç·~ÃB¥i¹F1800»õ¤¸¡A2025¦~Àç·~ÃB¥i¹F2600»õ¤¸¡A¨Ã¥´³y5Ó°·±dºÖ¬çºXÄ¥«~µP¡C ¡@¡@BTC©eû«Øij¬F©²À³¸Ó³Ð³y§ó§¹µ½ªºªk³WÀô¹Ò¡A¥[³tªk³W§ï²¡A¹ªÀy¾Ç¬ã¾÷ºc³]¥ßl¥Í¤½¥q ¡B¥[³tÂåÃÄ«~¬dÅ礤¤ß(CDE)¦æ¬Fªk¤H¤Æ ¡B×¥¿¥Í§Þ·sÃĵo®i±ø¨Ò¡B¬ì§Þ°ò¥»ªk¡B·s³Ð¨Æ·~´îµ|±ø¨Ò¡B°·«Oªkµ¥¡C¦¹¥~¡AÀ³¥[±j»EµJ«¤j¬ã¨sijÃD¡A¦pÀù¯gºë·ÇÂåÀø¡A¥Hµo´§§Ú°ê¬ã¨s¶q¯à¡A´£¤ÉÀù¯gÀË´ú¡BÂåÀø»P·ÓÅ@¤ô·Ç¡CªL´}·|¤¤«ü¥Ü½Ð§d¬F©¾¬F°È©eû«ùÄò·þ¾É¡C ¡@¡@¥»¦¸·|ij³sÄò¤T¤Ñ¡A³z¹LBTC°ê¤º¥~©eû¡B¬ÛÃö³¡·|»P²£¾Ç¬ã¦U¬Éªº¼ö¯P°Q½×¡A¦¨ªGÂ׺ӡC»P·|ªÌ¦³¯S§O±q°ê¥~¦^¨Óªº±M®a¡A¥]¬A¬ü°êVivo Capital§ë¸ê¤½¥q¦X¹Ù¤H¤ÕÁc«Ø¡BLin & Associates¥þ²yÂåÃħ޳Nªk³WÅU°Ý¤½¥qÁ`µôªL¬î¶¯¡B^°êArchigen Biotech Ltd.¸³¨Æªø·¨¨|¥Á¡B·çµØÂåÃÄ°õ¦æ°ÆÁ`³¯²Ðµ`¡BApex Enterprises Inc.¸³¨Æªøð«n¬À¡B¥Í¯ß¥Íª«¬ì§Þ¤½¥q¸³¨Æªø³\¤¤±jµ¥¤H¡F¥t¥~°ê¤º¦U¬É±M®a¡A¥]¬A¤¤¬ã°|·s¥ô°|ªø¹ù«T´¼¡B¥x¥_Âå¾Ç¤j¾ÇÁ¿®y±Ð±Â¾Hõ©ú¡B¤WÄ˥ͧÞÅU°Ý¤½¥q±iÂE¤¯¸³¨Æªø¡B°·¨È¥Íª«¬ì§ÞªÑ¥÷¦³¤½¥q³¯¥¿Á`¸g²z¡B¥Í§Þ²£·~µo®i¨ó·|§õÁ麳¦WÅA²z¨Æªøµ¥¤H¡AÁÙ¦³¬ÛÃö³¡·|ºªø¡B²£¾Ç¬ã¦U¬É¥Nªí¡AÁ`p¬ù150¤H¦@¦P»P·|¡C ¡@¡@¥»¦¸·|ij©Ò¹F¦¨ªº¦@ÃÑ»Pµ²½×¡AªL´}«ü¥Ü¦æ¬F°|¬ì§Þ·|³ø¿ì¤½«Ç«áÄò¥l¶°¬ÛÃö³¡·|¡A¦bÀç³y¡u¤H¤~¡B¸êª÷¡B´¼°]¡Bªk³W¡B¸ê·½¡B¥DÃD¡v¥ÍºA¨t¡A¥H¤Î«Ø¸m¡u¨È¤Ó¥Í§ÞÂåÃĬãµo²£·~¤¤¤ß¡v¡A³]©w¨ã¬D¾Ô©Êªº¥Ø¼Ð¡A¥H«e¤§»Æ[µ¦²¤«äºû¡A¾¨³t´£¥X¨ã¦³°ê»ÚÄvª§¤Oªº¦æ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/9 ¤W¤È 08:10:07²Ä 2476 ½g¦^À³
|
¦Ñ¥v¤j¤j ·P®¦! ³o»òºë±m¦³¨t²Îªº¸ê®Æ Åý§Ú̱o¥H»{ÃѦhºØÃÄ«~ªºÁ{§É¼Æ¾Ú¨Ã´¢´úFDAªº«äºû ¤Ó·PÁ±z°Õ! |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/9/8 ¤U¤È 09:52:54²Ä 2475 ½g¦^À³
|
·PÁ¦ѥv¤j ¯Eª©¦³±z¯u¦n¡I |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/8 ¤U¤È 05:31:09²Ä 2474 ½g¦^À³
|
·PÁ¦ѥv¤j ¥un¨â²ÕMOSÄ~ÄòÂX¤j ÃÄÃÒ¦b±æ |
|
|
·|û¡Gyuki10141394 µoªí®É¶¡:2016/9/8 ¤U¤È 01:25:51²Ä 2473 ½g¦^À³
|
¦Ñ¥v¤jÁÂÁ±z¡A¸U·³!! |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/9/8 ¤U¤È 01:03:19²Ä 2472 ½g¦^À³
|
¦Ñ¥v¤j: ¦n¤[¨S¬Ý¨£±zªºµo¤å, ¯uÃh©À, ¤Ó¶}¤ß¤F. ªG¯u¤@¥X¤â´N¦³®Æ. Æg! ÁÂÁ±z¶O¤ß¾ã²z³o¨Ç¬ÛÃö¼Æ¾Ú, µ¥¥¼¨Ó822ªº¤U¤@ÓMOS¼Æ¾Ú¥X¨Ó®É, ´N¥i¥H¦n¦n¤ñ¸û¤F. ·PÁ !! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/9/8 ¤U¤È 12:50:54²Ä 2471 ½g¦^À³
|
¨â²ÕMOS¤ë MOS¼W¥[¤ñ¨Ò HR PÈ ¨â²Õ¦º¤`¤H¼Æ ¨â²ÕÁ{§É¤H¼Æ Ibrance 37.5/33.3 12.6% 0.813 0.2105 30/31 84/81 Tykerb 17.5/15.1 15.9% 0.87 0.210 168/173 207/201µù1 Keytruda10.4/8.5 22.4% 0.71 0.0008 172/193 344/343µù2 Kadcyla 30.9/25.1 23.1% 0.682 0.0006 149/182 495/496µù3 Imlygic 23.3/18.9 23.3% 0.79 0.0494 101/190 141/295µù4 Opdivo 25/19.6 27.6% 0.73 0.002 183/215 410/411µÇ²ÓMÀù Opdivo 12.2/9.4 29.8% 0.73 0.0015 190/223 292/290«DÅ쪬NCSLC Perjeta NR/37.6 NR 0.66 0.0008 113/154 402/406µù5 Perjeta 56.5/40.8 38.5% 0.68 0.0002 168/221 402/406´Á¥½¤ÀªR Keytruda12.7/8.5 49.4% 0.61 <0.0001 156/193 346/343µù6 Opdivo 9.2/6 53.3% 0.59 0.00025 86/113 135/137Å쪬NCSLC Yervoy 10/6.4 56.2% 0.68 <0.001 306/119 403/136 Yervoy 10.1/6.4 57.8% 0.66 0.003 100/119 137/136 Keytruda14.9/8.2 81.7% 0.54 0.0002 58/86 139/152µù7 Keytruda17.3/8.2 111% 0.50 <0.0001 60/86 151/152µù8 µù1¡G¥é³æMOS¥»¥H75¶g/64.7¶gªí¥Ü¡A§Ú§ï¥H¤ë¼Æªí¥Ü µù2¡GNSCLC¥¼¿zPD-L1ªí²{²v¡A2mg²Õ µù3¡G²Ä¤@¦¸´Á¤¤¤ÀªRªºµ²ªG¥¼¹F¨Æ¥ý³]©wªº´£¦°±¤î¸ÕÅçÃä¬ÉÂI¡C¦Ó©óOS²Ä2¦¸´Á¤¤¤ÀªR®É¡A¤w¸gµo¥Í¤F331Ó¦º¤`¨Æ¥ó¡C¦¹¶µ¤ÀªRµ²ªG¹F¨ì¤F¹w¥ý³]©wªº¦]Àø®Ä´£¦°±¤î¸ÕÅçÃä¬ÉÂI(HR=0.73©Îp=0.0037)¡COS²Ä¤G¦¸´Á¤¤¤ÀªRµ²ªGÅã¥ÜKadcyla²Õªº¦s¬¡´Á¤¤¦ì¼Æ¬°30.9Ó¤ë¡Alapatinib¨Ö¥Îcapecitabine²Õ¬°25.1Ó¤ë µù4¡GImlygic(T-Vec)¥Ó½ÐÃÄÃҮɡAPÈ=0.0511¡A´Á¥½¤ÀªR¹êÅç²Õ¼W¥[¤@¦W¦º¤`¡APȤU°¬°0.0494 µù5¡G¶i¦æ³Ì²×PFS¤ÀªR®É¡AOS¸ê®Æ¤£¨¬¥B´Á¤¤OS¤ÀªRªºµ²ªG¨Ã¥¼¹F¨ì²Îp¤W©úÅã§ïµ½ªº¹w©w¤¤¤î¬É½u¡C©óÃB¥~°lÂÜ1¦~«á¶i¦æªº²Ä2¦¸OS´Á¤¤¤ÀªR¡Aµ²ªGÃÒ¹ê²Îp¤W©úÅ㪺OS§ïµ½Á`¦s¬¡´Á²Ä2¦¸´Á¤¤¤ÀªRªº·ÀI¤ñ¤ÎpȹF¨ì¹w©wªºÀø®Ä¤¤¤î¬É½u¡]·ÀI¤ñ≤ 0.739¡Ap≤0.0138¡^ µù6¡GNSCLC¥¼¿zPD-L1ªí²{²v¡A10mg²Õ µù7¡GNSCLC¿z¿ïPD-L1ªí²{²v¶W¹L50%¡A2mg²Õ µù8¡GNSCLC¿z¿ïPD-L1ªí²{²v¶W¹L50%¡A10mg²Õ PÈ·|¨ü¨ìÁ{§É¤H¼Æ»Pevent¼Æ¥Øªº¼vÅT¡AYervoyªºÁ{§É»¡©ú¤H¼Æ¦hªº¦bPȦ³Àu¶Õ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/8 ¤U¤È 12:38:38²Ä 2470 ½g¦^À³
|
èè¬Ý¨ì·¨¨|¥Á½×z¡A¯u¬O¥Í§Þ¬Éªº¥ýª¾¡A ¥L¹ï¥¼¨Ó¥Í§ÞÁͶդF¦p«ü´x¡A¥i»¡¬OÁͶձM®a¡A³o¦ì¸ó»â°ì¤H¤~¦³¨ä¼e¼sµø³¥»P¥@¬ÉÆ[¡A§óÃø¯à¥i¶Qªº¬O¤ßô¥xÆW¥Í§Þµo®iªºµ½¤ß»P·O´d¤ß¡C ·j´M: ¨â©¤¥ÍÂå¦X§@ ´Á«ÝÃöÁä¤U¤@³¡ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/8 ¤W¤È 11:23:08²Ä 2469 ½g¦^À³
|
¦æ¬F°|¬ì§Þ·|³ø 2016¦~¦æ¬F°|¥Í§Þ²£·~µ¦²¤¿Ôij©eû·|(BTC)·|ij¡Ð9¤ë6¤é 7¤é ·s»D½Z www.bost.ey.gov.tw/news.aspx?n=5331137415276DD6&sms=4C8F2E9B5908645D ¬ì§Þ³¡¥Í¬ì¥q¥qªø½²¤Ö¥¿©ó·|¤¤³ø§iªí¥Ü¡A¥Ø«e§Ú°ê¥Í§ÞÂåÃIJ£·~¥ÍºAÅé¨t¤´¦³§ïµ½ªÅ¶¡¡A ¦]¦¹¬F©²°w¹ï¡u¤H¤~¡B¸êª÷¡B´¼°]¡Bªk³W¡B¸ê·½¡B¥DÃD¡vµ¥¤»Ó±¦V¡A¿n·¥´£¥X¹ïÀ³¸Ñ¨M¤è®×¡A¥]¬A¡G (1).¤H¤~°ö¨|¡G©µÅó³Ð·s¬ãµo»P²£·~¸gÀç°ª¶¥»â¾É¤H¤~ (2).´¼°]«OÅ@¡G±j¤Æ´¼¼z°]²£«OÅ@¡B´£¤É§Þ³N²¾Âà®Ä¯à (3).ªk³W§¹µ½¡G±À°Ê°ê»Ú¼Ð¬ñªk³W¼Ð·Ç¨ó¦X (4).°òª÷¶Ò¶°¡GÀç³y¤Íµ½¸gÀçÀô¹Ò¡B«P¶i©Û°Ó¤Þ¸ê (5).¸ê·½¾ã¦X¡G¾ã¦X¥ÍÂå®Ö¤ß³]¬I»P¸ê·½¤¤¤ß¡B¤ä´©¥Í§Þ²£·~³Ð·s¬ãµo (6).¥DÃD·V¿ï¡G·V¿ïÂåÃIJ£«~¬ãµo¥DÃD¡B»EµJ¤Î´x´¤ªF¨È¯e¯f¤§¯S®í°·±d·ÓÅ@¡C §Æ±æÂǥѳo¤»¤j¦æ°Ê±¹¬Iªº±À°Ê¡A°·¥þ¥Í§ÞÂåÃIJ£·~ªº¥ÍºAÅé¨t¡A¥H¹F¦¨¨È¤Ó¥Í§ÞÂåÃĬãµo²£·~¤¤¤ß¤§¥Ø¼Ð¡C |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/9/7 ¤U¤È 08:22:18²Ä 2468 ½g¦^À³
|
mops.twse.com.tw/nas/STR/417420160907M002.pdf |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/9/7 ¤W¤È 10:37:28²Ä 2467 ½g¦^À³
|
èè¬Ý¤F¯E¹©°Ñ¥[2016 ESMO ¦~·|ªº·s»D¤½§i¡A¤~ª¾¹D¯Î±Ò´fªº²{¾¡C Chi-Huey Wong, Ph.D. Professor of Chemistry Department of Chemistry California Campus The Scripps Research Institute ¥¼¨Ó¦pªG¯Î«e°|ªøÀò±o¿Õ¨©º¸¼ú¡A°òª÷·|µo¥¬ªºÂ²¤¶¥i¯à´N¥Î³oÓ²{¾¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/5 ¤U¤È 12:13:20²Ä 2466 ½g¦^À³
|
999¤j §A¦³¤@ÂI«Øijªº«Ü¦n¡A§Æ±æ¤½¥q¸ÑŪÁ{§É¼Æ¾Ú®É¯àºÉ¶q¥Î¥Õ¸Ü¡AÅýªÑªF³£¯àÅ¥À´¡C ¤½¥qªºÁ{§É¼Æ¾Ú¨Ì¾Ú¤»¤ë¤½¥q»¡©«¡A¥Î¥Õ¸Ü»¡´N¬O³Ì¦nªº¼Æ¾Ú¯d¦b³Ì«á¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/9/5 ¤W¤È 11:45:56²Ä 2465 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡G ¾é¸Ñ... §Ú¸ò¤½¥q·¾³qªº·N¨£¬O§Æ±æ¤½¥qESMO·|«á¤]¯à¤ñ·ÓASCO·|«á¡A¤½§i¹Ïªí¡AÅýªÑªF̤]¯à¾é¸Ñ³°Äò¸Ñª¼§ó²M·¡ªº¼Æ¾Ú¡C ÁÂÁ±z¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/5 ¤W¤È 09:42:50²Ä 2464 ½g¦^À³
|
BTC©úµn³õ ªk³WÃP¸j¤j«GÂI 1 ÃÄ«~¬dÅ礤¤ß±Nªk¤H¤Æ¡A¼W¥[·sÃĬdÅç¼f¬d¤H¤O¡A¤j´TÁYµu·sÃĤW¥«®Éµ{ 2 ¦P®É¹ªÀy°ê¤ºÂå°|¦h¨Ï¥Î¥xÆWÂåÃIJ£«~ ³o¨âÂI¹ï·sÃĤ½¥q¨Ó»¡¼vÅT²`»· |
|
|
·|û¡G´¡ªá¤G10142127 µoªí®É¶¡:2016/9/5 ¤W¤È 02:22:39²Ä 2463 ½g¦^À³
|
www.esmo.org/Conferences/ESMO-2016-Congress/Registration |
|
|
·|û¡G¤p²ø10140417 µoªí®É¶¡:2016/9/5 ¤W¤È 12:14:22²Ä 2462 ½g¦^À³
|
è¬Ý¤F¤@¤UESMO 2016ªº¸`¥Øªí¸Ì±¦n¹³¨S§ä¨ì¦³Ãöobi-822¬ÛÃöªº½×¤åµoªí»¡¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/9/4 ¤U¤È 10:05:14²Ä 2461 ½g¦^À³
|
ESMO 2016ªº¸`¥Øªí¤w¸g¥X¨Ó¡C ¡uwww.esmo.org/Conferences/ESMO-2016-Congress/Programme ¡v ¥ý¥h§ì¡uDownload the latest programme (PDF)¡v¡A°O±o¤ß¥®ð©M®É¦A¥hŪ¡C «Üªøªº¸`¥Øªí¡A298¶¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/4 ¤U¤È 03:16:49²Ä 2460 ½g¦^À³
|
999¤j ¾Ç³N¬Éµoªí½×¤å³£¦³¤@©w³W½d¡A¤£©y¾Þ¤§¹L«æ¡A·Q·Q°²³]¤»¤ëASCO§â©Ò¦³822¤G/¤T´ÁÁ{§É¼Æ¾Ú¥þ³¡µoªí¡AÁÙ·|¦³¤Q¤ëªìªºESMO¶Ü? §ó¤£¥i¯à¦³¥þ²y«e´X¦Wªº´Á¥Zµoªí¡A¸Ñª¼¬O¤@¨t¦C¤½§iµ²ªGªº¹Lµ{¡A¯E¹©¦bÀç³y¤@ºØ©Ò¿×ªº¶Õ¡A·í®ð¶Õ§Î¦¨¡A¶¶·¦Ó¤W¡A¾U¤£¥i·í¡C ¤»¤ëªÑªF·|¦³Ãö´Á¥Zµoªíªºì«h¶¶§Ç¤½¥q¤w¦³ ½×z |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/9/3 ¤U¤È 01:39:01²Ä 2459 ½g¦^À³
|
½Ñ¦ì¤j¤j¡A½Ñ¦ì«e½ú¡G ¤p§Ì¦b¦¹¸ÛÀµ³Ò½Ð²³¤j¤j¦@Á¸²±Á|¡A§Q¥Î¦UºÞ¹D¡A¬Æ¦Ü½Ð¯Î°|ªøÂ൪¡A¤H¤H¤@°T½Ð¤½¥q¦bESMO·|«á¯àºÉ¶qªº¥H¤f¥Õªº¤è¦¡¡A¹ï¥xÆW¦U¬É§ó¤½§i³Ì·s¦U¶µ¼Æ¾Ú¡A¥H¨Æ¹ê°µ³Ì¦³¤Oªº¼á²M»~¸Ñ¡C ¤p§Ì¥h¹q»Pµo¨¥¤H§õ¸g²zªí¹F»P·¾³q......¯u«ÜµL©`¤]¥O¤H®ðµ²...¬Æ¦Ü¬Oµª®×¬O·|«á¡A·|¤£·|¦pASCO·|«áªº¤½¶}¤½§i¡A¤]¬O¤£¤@©wªºµª®×¡H ¦p²³¤j¤j¤]»{¦P¤p§ÌªºÆ[ÂI¡A½Ð³Ò¾r¦@Á¸²±Á|¡C ÁÂÁ¤j®a¡C |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/9/1 ¤U¤È 01:39:05²Ä 2458 ½g¦^À³
|
¤£ª¾¹D¬O¯u¤£À´ÁÙ¬O°²¤£À´¡AÁÙ¬O´£¿ô¤@¤U Industry-Sponsored-Satellite-Symposia ¦³¿ú´N¥i¥H¿ì¤F! ¯uªº¤£¥²¦³®Ä¡A¿ì¤F¥H«á²£«~½æ±o¦n¤£¦n§ó¬O¥t¤@¦^¨Æªº! ¥t¥~¿ì³oºØ·|±`±`´N¬O¦b¹S±ePI, co- PI, study persons¡A¬Ý¬Ý´N¦n |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/1 ¤U¤È 12:59:17²Ä 2457 ½g¦^À³
|
5619 ¤j ¸g±z³o»ò¤@»¡ ¤p§Ì»~·|¤F ¦V±z»¡Án¹ï¤£°_ ¤j¤å¥E¬Ý¤§¤U ®e©ö»~¸Ñ §Ú¬O©È¬°¤H»~¥Î ©Ò¥H¶¶«KµoªíÓ¤Hªº©å¨£ ¤¤©M¤@¤U ©êºp¤F ÁÂÁ±zªº»¡©ú ÁÂÁ¤j®a! |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/9/1 ¤U¤È 12:40:20²Ä 2456 ½g¦^À³
|
²q·Q¤j¡A±z¥i¯à»~·|¤p§Ìªº·N«ä¤F¡C ¦pªG¤p§Ì¬OºÞ²z°O¿ý°w¾¯¥Î¶qªº¤pû¤u¡]¦³³oÓ¾¦ì¶Ü¡H¡^¡A¤p§Ì¥i¯à¦b¸Ñª¼«e¡A«Ü¦¤§«e¡A´Npºâ¤F¡A²q¤F¡C¶}ª±¯ºªº¡A³o¤£¬O«ÂI¡C ¨ä¹ê¤p§Ì·Qªí¹Fªº¬O¡A¡§¤º½u¥æ©ö¡¨³oÀɨơA¦b¥xÆW¤£°·¥þªºªkªv¤U¡A¸g±`¬O³\¦h¯u¹êµo¥Íªº¡A¨S³Q°»¬dÁ|³ø¼f§P¡C¬Û¹ïªº¡A¤£¨º»ò½T¤Áªº¡AµL¥ø¹ÏµL´c·Nªº¡A¤Ï¦Ó³Q¦³¤ß¤Hµ²¦X¼Æ¦r©P¥Z³yÁÁ¾Þ§Ë©ñ¤j»z³´¡C¦pªG¤½¥qªv²z¨S¤Wy¹D¡A¤£¤p¤ß»~IJ¡A¹³¯Î°|ªø©M±i¸³¡A´N§ó¦Ê¤f²öÅG¡C ªk«ß¹ï¸g²z¤H¤º³¡¤H¸³ºÊ¨Æ¤jªÑªFªº¶R½æªÑ²¼ªº±i¼Æ´Á¶¡¥Ó³øµ¥¦³³W©w¡C´N¬Oµe¤@±ø¬õ½u¡C½ò¨ì¬õ½u´N¬O¹Hªk¡C¬õ½u¤§¥~¡A²{¹ê±ÁÙ¦³¥Õ½u¶À½uÂŽuºñ½uµ¥µ¥¡A¥i»¡¬O¼Ò½k¦a±a¡C¤p¾û¡A¥N²z°Ó¡A«È¤á¡A³f¹B¦æ¡A§Ö»¼¦æ¡A¬Æ¦Ü¥~¥]ªº²M¼ä¤u¡AÅ@¤h¡A¬ÝÅ@¡A³£¥i¯à¦b¦U¦Û¾³d¤º¡A±µ¦¬¨ì¤@¨Ç¤@¤â°T®§¡C¦U¦Û¸ÑŪ¡A¤£¦h°Ý¡A¤£¶Ç¼½¡A¦U¦Û²q¡A¤p©@¶q¤£¤j¡C³o³¡¤ÀÄY®æ»¡¨Ó¨S¦³½ò¨ìªk«ßªº¬õ½u¡C§ë¸ê¯E¹©¡A¬Ý«ªº¬O·sÃIJ£·~Ävª§¤O¡A»·¤jªº§»¹Ï¡C«ÂIÁÙ¬OÃĮġAµu´Á¤º´N¬OOS §ïµ½ÁͶաA´Á«Ý¤U¤@¦¸ªºOS´Á¤¤¤ÀªR¤½§G¡C¤p§Ì©Ò¨¥Y¦³¿ù»~¡AÅwªïªÈ¥¿¡AÁÂÁ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/1 ¤W¤È 10:33:18²Ä 2455 ½g¦^À³
|
¤p§Ì¤µ¤Ñ¤~¬ÝÀ´ 5619¤j ¦b¼g¤°»ò ³o¼Ë¤£¦n°Õ! µM¦Ó, ¬J¬O" ²q " , ´N¬O¤£¯à½T©w §ÚÌ¥±`¤]·|¨Ì¤@¨Çµïµ·°¨¸ñ¨Ó²q´ú ¦ý½Ð°Ý±z²q¹ï¤F¦h¤Ö? ¹³822, ¬ÝPFS µ±¦b¤@°_ ,¦ýOS¬Ý°_¨Ó¦³¾÷·| ¥¼µoªí«e,½Ð°Ý±z²q¹ï¤F¶Ü? ¦nÃø§r ¹ï¤£°_¤F ÁÂÁ¤j®a! |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/31 ¤W¤È 10:02:00²Ä 2454 ½g¦^À³
|
¸ÕÅç³]p¬OªvÀø´Á¶¡41¶gªº«e 37¶gª`®g¤E¦¸¡C ³ø§i´¦ÅS¡A¥ÎÃIJÕ224¤H¥u¦³104¤H§¹¦¨¤E¦¸ª`®g(46.4%)¡A¹ï·Ó²Õ124¤H¥u¦³64¤H§¹¦¨¤E¦¸ª`®g(51.6%). ·§j¯ó°Ê¡AªÑ»ù¤U¶^¤¤¡C·s»D¤S´£°_¤º½u¥æ©öºÃ¶³¡C¤p§Ì·Q¨ì³oÓ¡§¤E°w¡¨¡C¥u¦³46.4%¥ÎÃIJկf±w§¹¦¨¤E¦¸ª`®g¡C53.6%ªº¯f±w¤¤³~°±¤îª`®g¡A°²³]³o¨Ç¤H¥§¡ª`®g5¦¸¡A·N¨ý¤j¬ù¥u¥Î±¼76%¬°¸ÕÅç·Ç³Æªº°w¾¯¡A³Ñ¾l24%¡C¦pªGª¾¹D³oÓ¡A´N¥i²q´ú¨ºÓ¡C¦¹«D«ÂI¡A«ÂIÁÙ¬OOSªº§ïµ½ÁͶաC |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/30 ¤U¤È 11:07:57²Ä 2453 ½g¦^À³
|
¤p©_¤j¡AÁÂÁ±z¸ÔºÉªº¸Ñ»¡¡C°é°é»P¶¥±è¡A¤p©_¤j¤w§¹¥þåªR¡A³ôºÙ¥v¤W³Ì±jåªR¡C¥uµ¥¤½¥q²Ä¤G¦¸¤½§GOS´Á¤¤¤ÀªR¡A©¡®ÉÃĮħó²M´·¡C ¤p§Ì¤S¬Ý¤F¤½¥qªº6/15 ASCOªk»¡·|§ë¼v¤ù¡A³o¦¸¹ï¡§¥´§¹¤E°w¡¨ªºPFS¤ÀªR¨º±i(p.28)¦³ºÃ¤ß¡A¤ñ¹ï¤F¨â¤À²Õ»P¤T¤À²Õªº¤ÀªR¡AºÃ¼{¥[²`¡C¥H¤U²¤z¤ß±o¡A½Ð¤p©_¤j©M²³«e½úÌ«ü±Ð¡C p.28¼ÐÃD¡§¯f±w§¹¦¨¤E¦¸ª`®gÀøµ{Åã¥Ü¨Ï¥ÎOPT-822/821ªºPFS¨ã§ïµ½ÁͶա¨¡C¥ÎÃÄ²Õ vs ¹ï·Ó²Õ¡A¨Æ¥óÁ`¼Æ 50/104 (48.1%) vs. 36/64 (56.3%), M PFS 22.5 ¤ë vs. 18.1¤ë¡C³æ¯Â¬Ý¼Æ¾ÚÅã¥Ü¡A½T¹ê¡§¨ã§ïµ½ÁͶա¨¡Aªí±¤W¦ü¥G¦p¦¹¡A¦ý¬O»Ýn²`¨s¡C ¸ÕÅç³]p¬OªvÀø´Á¶¡41¶gªº«e 37¶gª`®g¤E¦¸(p.24)¡C µ²ªG¡A¥ÎÃIJÕ224¤H¥u¦³104¤H§¹¦¨¤E¦¸ª`®g(46.4%)¡A¹ï·Ó²Õ124¤H¥u¦³64¤H§¹¦¨¤E¦¸ª`®g(51.6%).¡C¥ÎÃIJդñ²v¸û§C¡AÀ³¬O¦´Á®û¼í²{¶H¾ÉP»~§PPD¦Ó°±¤î¥Î°w¡CÄY®æ»¡¨Ó¡A¥¼§¹¦¨¤E¦¸ª`®gÀøµ{ªº¯f±w¡A¬OµL®Ä©Î¦³·å²«ªº¼Ë¥»¡A¤£¸Ó¦C¤J¥¿¦¡ªº²Îp¼Æ¾Ú¡A¥u¯à°Ñ¦Ò¡C¤½¥qªº³ø§i¡A¦ü¥G§â¥þ³¡ªº¯f±w¼Æ¾Ú¡]¦@348¤H¡^·í¥¿¦¡¡A¦Ó§â§¹¦¨¤E¦¸ª`®gªÌ¡]¦@168¤H¡^ªº¼Æ¾Ú·í°Ñ¦Ò¡CÄYÂÔ¡H¤£ÄYÂÔ´NÃø¥H½×Â_ÃĮġC Æ[¹îPFS¡A¥i¥H±À´ú¡§§¹¦¨¤E¦¸ª`®gÀøµ{ªº¯f±w¡¨¤j¦h¬O¡§¨Åé±ø¥ó¤ñ¸û¦nªº¯f±w¡¨¡C¥B¤Þ¥Ó¥X¤@Ó²q·Q¡G¡§¨Åé±ø¥óªº¦nÃa¡A¹ïPFSªº¼vÅT¤j©ó¥Î¤£¥ÎÃÄ¡¨¡CYªG¡A³o¤S·|¶Ë®`ÃĮĪº½×Â_¡C¨S¦³§¹¦¨¤E¦¸ª`®gÀøµ{ªº¯f±w¡A¤£¬O¥D°Ê°h¥X¡A´N¬O³~¤¤PD¤F¡C¤ñ¹ï¦U±iPFS KM¹Ïp.26, p.28, p.29¡A¥i¥Hµo²{¡A40¶g¥H«á¡A³Ñ¤UªºÃnÀI¤H¼Æ«êµ¥©ó¡§¥´§¹¤E°w¡¨ªºÃnÀI¤H¼Æ¡C¬°¤°»ò¬O40¶g¡Hª`·N¡AªvÀø´Á¶¡ª`®g¤E¦¸»Ý®É 37¶g¡C ¥ÎÃIJէ¹¦¨¤E¦¸ª`®gªÌ¡A°£¤F¨Åé±ø¥ó¸û¨Î¡AÅÞ¿è¤W¤]¤ñ¸û¯à²£¥Í§ÜÅé®Ä»ù¡CÆ[¹î¤ñ¹ïp.28©Mp.29¡A¥i¥Hµo²{¡G¥ÎÃIJէ¹¦¨¤E¦¸ª`®gªº104¤H¤¤¬ù¦³¤T¤À¤§¤G¡A66%¡A69¤H¡A¦b¤T¤À²Õ¤¤Âk¦b°ª¤ÏÀ³²Õ¡A¦û¤ñ69/112=61.6%¡F¥ÎÃIJէ¹¦¨¤E¦¸ª`®gªº104¤H¤¤¬ù¦³¤T¤À¤§¤@¡A34%¡A35¤H¡A¦b¤T¤À²Õ¤¤Âk¦b§C¤ÏÀ³²Õ¡A¦û¤ñ35/112=31.3%¡C¹ï·Ó²Õ§¹¦¨¤E¦¸ª`®gªº64¤H¡A¦b¤T¤À²Õªº¹ï·Ó²Õ¦û¤ñ64/124=51.6%¡CÅã¥Ü°ª¤ÏÀ³²Õ¸Ì±¡A¡§¨Åé±ø¥ó¤ñ¸û¦nªº¯f±w¡¨¤ñ¨Ò¤ñ¸û°ª.¡A¦û¤F«K©y¡CÆ[¹îp.29 PFS%¦b40¶g¥H«áªº¤U°±×²v¡A°ª¤ÏÀ³²Õ/§C¤ÏÀ³²Õ/¹ï·Ó²Õ¤T±ø¤U°½u¤@ª½©Ô¤£¶}¡COSªºµo®iÁͶիo¬O©úÅã©Ô¶}¡CÅã¥Ü822ªº¸ÕÅ礤¡APFS ¤£¬O¤@Ó¦nªºÆ[¹î«ü¼Ð¡AOS ¤~¬O¡C ¥H¤W©Òz¡A©Ô©ÔÂøÂø¡A±ø²z¤£²M¡AÁÙ½Ðì½Ì¡C¤p§Ì¹Á¸Õ¾ã²z´XÓÆ[ÂI¡G 1. ¥´§¹822¤E°w¡A¥u¦³¤T¤À¤§¤G¯f±wÀò±oIgG§ÜÅé®Ä»ù>= 1:160¡A¨ä¥L¤T¤À¤§¤@¯f±wªºIgG§ÜÅé®Ä»ù< 1:160¡C °ª¤ÏÀ³²Õ112¤H¡A¨ä¤¤¦³69¤H¬O§¹¦¨¤E°wªÌ¡A¥t43¤H¥¼§¹¦¨¡C³o43¤H¥i¯à¥´¤F5/6/7/8°w´NPD¤F¡A¦ý¬O§ÜÅé®Ä»ù¹F¨ì1¡G160.¡C§C¤ÏÀ³²Õ¦³35¤H§¹¦¨¤E°wÀøµ{¡A¦ý¬O¥Ñ©óÅé½è©M§Üìªí²{Ãö«Y¡A§ÜÅé®Ä»ù¨S¦³¹F¨ì1¡G160.¡C 2. ¤½¥q²³øªº¤T¤À²Õ¡A¥HIgG§ÜÅé®Ä»ù1:160§@¬°¦³µLªº¬É¡A²q·Q¥u¬O«ê¦n±N224¦W¯f±w§¡¤À¨â²Õ¡A¤è«K¤ñ¸û¡A¦Ó¨S¦³¬ì¾Ç©ÎÂå¾Ç¤Wªºµ´¹ï·N¸q¡C¤]³\40ªº·N¸qÁÙ¤j¨Ç¡AIgG§ÜÅé®Ä»ù>= 1:40ªº¯f±w¥i¯à¤j©ó80%¡A´N¬O°|ªø©M¤½¥q´¿½Í¤Îªº¦³Àø®Ä¤H¼Æ¤ñ²v¡C·Ç¦¹¡A¤p§Ì·¥¤£¯à²z¸Ñ¤½¥q¦b¦p¦¹¥¿¦¡ªº¤å¥ó¸Ì¡A±NIgG§ÜÅé®Ä»ù>= 1:160ªÌ©w¸q¬°¡§¤ÏÀ³ªÌ¡¨¡A±NIgG§ÜÅé®Ä»ù< 1:160ªÌ©w¸q¬°¡§µL¤ÏÀ³ªÌ¡¨¡C«Ü©Ç¡A¦ü¥G¦Û§ä³Â·Ð¡A¦Û§Ë²V²c¡A¹º¦a¦Û¡H¡H 3. p.29 PFS ¤T¤À²Õªº¤ÀªR¡A«e¬q40¶g¤§«e¡A¨ü®û¼í©M©µ¿ð¤ÏÀ³ªº¼vÅT«Ü¤j¡AÄY«¥¢·Ç¡C40¶g¤§«á¤ñ¸û²Å¦X¹ê»Ú¡A©ÒÅã¥Üªº¬O°ª¤ÏÀ³²Õ/§C¤ÏÀ³²Õ/¹ï·Ó²Õ¤T±ø¤U°½u¡A40¶g¤§«á¡Aªø®É¶¡©Ô¤£¶}¡Cp.25 Á{§É¸ÕÅçµ²ªGºKn©Ò¦Cªº¡§±µ¨ü¬Ì]ª`®g¥BªvÀø´Á¶¡´¿¥X²{¹ïOPT-822²£¥ÍIgG§ÜÅé®Ä»ù>=160¯f±w¡A¨äPFS¤Î¨ä¤¤OS©úÅãÀu©ó¦w¼¢¾¯²Õ¤Î¬°²£¥Í§K¬Ì¤ÏÀ³ªº¯f±w¡¨¡C³oÓµ²½×¡A¤p§Ì»{¬°½×Â_°ò¦¤£¨c¾a¡COS ³¡¤À¬O¦¨¥ßªº¡A¦ý¬OPFS ³¡¤ÀªºÃÒ¾ÚÁ¡®z¡AÅ޿褣áC 4. 822ªºÀø®ÄÅã²{¦bOS¡C¥HASCO¤½§Gªº2015/10 data lock¼Æ¾Ú¡AÀø®Ä¥DnÅã²{¦b16~28Ó¤ë°Ï¬qªº¦º¤`²v¡C«ö¤p©_¤jªºåªR¡A16~28Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³34Ó°é°é¡B7Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³39Ó°é°é¡B6Ó¶¥±è¡F¹ï·Ó²Õ¦³39Ó°é°é¡B15Ó¶¥±è¡C§ë¼v¤ùp.27 ¡§´Á¤¤Á`¦s¬¡´Á - ¨ã§ïµ½ÁͶա¨¡A½T¹ê¦¨¥ß¡C¥ÎÃIJթM¹ï·Ó²Õªº%®t¶Z¡A¦b¦¹°Ï¬q©úÅã©Ô¶}¡C¤U¤@¦¸OS´Á¤¤¤ÀªR¡A¹w´Á¥i¬Ý¨ì¥ÎÃIJէó©úÅ㪺Àu¶Õ¡A¦Ó½T»{ÃĮġC |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/30 ¤U¤È 10:26:58²Ä 2452 ½g¦^À³
|
Where Does Adagloxad Simolenin Fit in? ÁÞ¤k±¡Âk¦ó³B ²³¤j¤j ¯E¹©2016¦~10¤ë10¤é ESMO industry satellite symposium Agenda ®Éµ{ªí¤¤¤å½Ķ ô¥»«¢®Ú»P¥xÆW®É®t¡G¥V¥O®É¶¡(¨C¦~10¤ë¤§³Ì«á¤@Ó¬P´Á¤é¶}©l)ºC7¤p®É¡A®L¥O®É¶¡(¨C¦~3¤ë¤§³Ì«á¤@Ó¬P´Á¤é¶}©l)ºC6¤p®É( ¬ù2016 ¦~10¤ë10 ¤È©]12ÂI ³ø¨ìµn°O ±ßÀ\ ) 18.00 ¡V 18.30 Registration and Dinner ³ø¨ìµn°O ±ßÀ\ 18.30 ¡V 18.35 Welcome and Introduction Moderator: Stephen Johnston, MA, PhD, FRCP PÅwªïÃã»P¤¶²Ð·|ij¥D«ù¤H 18.35 ¡V 18.55 The Globo Series: Carbohydrate Tumor-Specific Antigens : ¸~½F¯S²§Globo ¨t¦CÁÞ§Üì Chi-Huey Wong, PhD «e°|ªø¯Î±Ò´f 18.55 ¡V 19.15 Rationale and Development of the Active Immunotherapy Adagloxad Simolenin ¥D°Ê§K¬ÌÀøªk Adagloxad Simolenin(OBI 822)ªºµo®i»P°ò¥»ì²zÄÄz 19.15 ¡V 19.35 Adagloxad Simolenin in Metastatic Breast Cancer:Results from the OBI-822-001 trial OBI-822- 001Á{§É¸ÕÅç¦bÂಾ©Ê¨ÅÀùªºÁ{§É®ÄªG Chiun-Sheng Huang, MD ¶À«T¤É Âå®v 19.35 ¡V 19.55 Panel Discussion: The Future of Immunotherapy in Oncology: Where Does Adagloxad Simolenin Fit in? ¤p²Õ¬ã°Q·|:Àù¯g§K¬ÌªvÀøªº¥¼¨Ó:Adagloxad Simolenin OBI822 ÁÞ¤k±¡Âk¦ó³B? Moderator: Stephen Johnston, MA, PhD, FRCP Heather L. McArthur, MD, MPH Chiun-Sheng Huang, MD Chi-Huey Wong, PhD 19.55 ¡V 20.00 Closing Remarks Moderator: ¥D«ù¤H³¬¹õÃã Stephen Johnston, MA, PhD, FRCP ¸É¥R: Stephen Johnston, MA, PhD, FRCP ^°ê¼C¾ô¤j¾Ç¤T¤@¾Ç°|²¦·~ ^°êÛ´°¤j¾ÇÀù¯g¬ã¨s°|³Õ¤h Âಾ©Ê¨ÅÀùªvÀø±M®a µoªí¤F¶W¹L250½g¨ÅÀù¬ÛÃö½×¤å©ó¦P¦æµû¼fªº´Á¥Z¡A¨Ã¦b°ê®a©M°ê»Ú·|ij¸g±`¨üÁܽЪºÁ¿®v¡C¥L¬O¦hÓ¬ì¾Ç©eû·|©MÅU°Ý©eû¡A´¿¥ô¬ü°êÁ{§É¸~½F¾Ç·|¡A¸t¦wªF¥§¶ø¨Å¸¢Àù¬ã°Q·|ºKn¼f¬d©eû, ²{¥ô¨Å¸¢Àù¬ÛÃö°ê»Ú´Á¥Z°Æ¥D½s peer-reviewed ¦P¦æµû¼f: ¤@¦ì§@ªÌªº¾Ç³NµÛ§@©Îp¹º³Q¦P¤@»â°ìªº¨ä¥L±M®a¾ÇªÌµû¼f Heather L. McArthur, MD, MPH ¸~½F¬ìÂå¥Í,P¤O©ó¨ÅÀù¯f¤H·ÓÅ@,¦o±Mª`©ó¨ÅÀù²©R©Ê¶EÂ_»PªvÀøªº¬ã¨s, ¯S§O¹ï³Ð·sªº§K¬ÌÀøªkµ¦²¤·P¨ì¿³½ì, ¥v¶©³Í¯SµYÀù¯g¤¤¤ßMSKCCû¤u¡A¬ü°êÁ{§É¸~½FÂå¾Ç¾Ç·|»P¬ü°êÀù¯g¬ã¨s¨ó·|ªº¦¨û¡C 1 ¾ãÓ¬ã°Q·|ªø¹F90¤ÀÄÁ 2 Á{§Éµ²ªG³ø§i®É¶¡¬O20¤ÀÄÁ ¤ñ2016 ASCO ¨¬¨¬¦h¤F8¤ÀÄÁ , ¦h8¤ÀÄÁ¨¬¥HÀ³¥I¼W¥[»P§ó·sData©Ò¼W¥[ªº®É¶¡, ¨S¦³·sµo²{,·sData ¯à¯¸¤W¼Ú¬w¸~½FÂå¾Ç·|ªº°ê»ÚªZ¥x¶Ü ? 3 »P·|ªº¾ÇªÌ±M®a¨ÓÀY¤£¤p www.esmo.org/Conferences/ESMO-2016-Congress/Exhibition-Satellite-Symposia/Industry-Sponsored-Satellite-Symposia ½n¶¯¤j 1ªÑªF·|¤½¥q´£¨ì¡G¡yì¨Ó¦³¤@Ón¨Ó½Íªº¡A¥L·Qn½Í¥þ²yªº±ÂÅv¡A¥i¬O§Ú̧Ʊ浹¥Lªº¥u¦³¥Lªº°ê®aªº±ÂÅv¡A¦]¬°¥Lªºdealªºvalue«Ü®t¡A©Ò¥H§Ṳ́]¤£¬O«Ü«æ¡K§Úı±o°ò¥»¤W§â¡uÁ{§Éªº»ùȶ}³Ð¥X¨Ó¡v¡Aµ¥dealªºvalue§ó¦n¡A¤j®a¹ï¥Lªº«~½è¦³ªÖ©w¡A¨º§ÚÌ´N·|Ä~Äòªº½Í (Amy¬O¦bÁ¿¦×¬r±ìµß¯Àªº«~½è»P±ÂÅvµ¦²¤ ¤£¬OOBI 822) ¦×¬r±ìµß¯À¤]¥i¥H±ÂÅv |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/30 ¤W¤È 10:37:43²Ä 2451 ½g¦^À³
|
5619¤j¡A 1.2015/10 dada lock ®É¡A³Ì±ß°_¶]°¨©ÔªQªº¤w¸g¶]¤F15¤½¨½¡A¦b15¤½¨½¤§«eªº¤£¬OˤU´N¬O±óÁÉ¡A©Ò¥H0¡ã15¤ë°Ï¶¡ªº°é°é³£¬Odrou outªÌ 2.¨ä¥¦·sÃĸÕÅ窺ºD¨Ò¡AOS ´Á¤¤¤ÀªR·|¤½§G´X¦¸¡A¤p§Ì¤£ª¾¹D¡C¦ý¥H¯E¹©ªº¨Ò¤l¡A¦A¤½§G¤@¦¸OS´Á¤¤¤ÀªR¡AÃĬO§_¯àÀ°§U¥ÎÃIJձwªÌ©µªø¥Í©R¤w¸g©³©w¡A³Ì«áªº¡§´Á²×¤ÀªR¡¨¥u¬O§â¼Æ¾Ú¸É»ô¡A¥H¥Ø«e¼Æ¾Ú©Ò§e²{¥XªºÁͶաA§Ú²q¦A¤@¦¸OS´Á¤¤¤ÀªR´N°÷¤F¡C ¥xÁÞ¤j¡A ¤p§Ì°µªº¬O¹Ï«¬ªº¸ÑŪ ¨S¦³¥´ºâ²q´ú¥¿¦b¡BÁÙ¦bµo¥Íªº¨Æ 32Ó¤ë¥H«áªº¹Ï¡A¦A¹L¤@°}¤l¡A¤½¥q·|§i¶D§Ú̪º ¨º¬O822°£¤F¦w¥þ©Ê¤§¥~³Ì¦³»ùȪº¼Æ¾Ú |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/29 ¤U¤È 11:40:01²Ä 2450 ½g¦^À³
|
¦U¦ì¤j¤j ¯u©êºp¡A¦³¤@Ó¶¥±è¼Æ¿ù¤F¡I §C¤ÏÀ³²Õ¦b¤j¬ù33Ӥ릳¤@Ó¤j¶¥±è¤U° ±q60.5%¤U°¨ì52.99%¡A¤j¬ù¤U°7.5% 쥻¥H¬°¬O¨âӨƥó¦P®Éµo¥Í ¦ý¹ê»Ú¤W¬O¦bnumber at risk=8ªº®ÉÔµo¥Í¨Æ¥ó¡A ¦]¦¹¦b¤j¬ù33Ó¤ë®É´N¥u¦³¤@Ó¶¥±è «¼Æ¤F§C¤ÏÀ³²Õªº¶¥±è¼Æ¥Ø §C¤ÏÀ³²Õ¦b32Ó¤ë¥H«á¥u¦³¤@Ó¶¥±è 16~28Ó¤ë³o°Ï¬q¦³7Ó¶¥±è¡A38Ó°é°é ¯S¦¹§ó¥¿ ¨ä¥Lªº¤ÀªR¨S¦³¤£¦P |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/29 ¤U¤È 11:09:40²Ä 2449 ½g¦^À³
|
¤p©_¤j ·PÁ¤p©_¤j¤µ¤Ñªá«Üªø®É¶¡¥Î¤ß¤ÀªR 2016 ASCO P17, ¤p§Ì¯uªº¾Ç¨ì«Ü¦h,¦]¬°¨S¦³¤ÀªR¨ì 2016 ASCO P13 ªº°é°é»P¶¥±è,©Ò¥H§Ú§â°ª¤ÏÀ³²Õªº°é°é+§C¤ÏÀ³²Õªº°é°é¡B§â°ª¤ÏÀ³ªº¶¥±è+§C¤ÏÀ³²Õªº¶¥±è,¦A§â°Ï¬q¾ã¦XÅܦ¨¨â¬q¨C¬q16-17Ó¤ë¥H§Q¹êÅç²Õ»P¹ï·Ó²Õ®É¶¡µ¥¶Z¤j PK ¤U¦Cªº¾ã¦XÀ³¸Ó·|Åܦ¨2016 ASCO P13 ¦U°Ï¬q¾ã¦X«áªº°é°é»P¶¥±è? ¤£ª¾¬O§_¥i¥H³o¼Ë¾ã¦X? 0~16 Ó¤ë°Ï¬q¡A ¹êÅç²Õ¦³30Ó°é°é¡B31Ó¶¥±è¡F¹ï·Ó²Õ¦³15Ó°é°é¡B17Ó¶¥±è 16~33Ó¤ë°Ï¬q¡A ¹êÅç²Õ¦³99Ó°é°é¡B19Ó¶¥±è¡F¹ï·Ó²Õ¦³52Ó°é°é¡B18Ó¶¥±è 33-48Ó¤ë°Ï¬q ¹êÅç²Õ¦³XXÓ°é°é¡BXXÓ¶¥±è¡F¹ï·Ó²Õ¦³XXÓ°é°é¡BXXÓ¶¥±è ¤W± 2016 ASCO P13 ¦U°Ï¬q¾ã¦X«áªº°é°é»P¶¥±è¦³¬Ý¥X¤°»òºÝÙ? ¯à¼ÒÀÀ¹w¦ô33-48Ó¤ë°Ï¬q ¹êÅç²Õ»P¹ï·Ó²Õ°é°é»P¶¥±èªºÁͶÕ? ±q16~33Ó¤ë°Ï¬q¹êÅç²Õ¦³19Ó¶¥±è¡F¹ï·Ó²Õ¦³18Ó¶¥±è ¦]¬°¹êÅç²Õ¦³224¤H,¹ï·Ó²Õ124¤H , ¬Û®t100¤H ¦p¤p©_¤j©Ò¨¥ ±q16~33Ó¤ë°Ï¬q¹êÅç²Õªº½Tµo´§ÃÄ®Ä §A¬Ý33-48Ó¤ë°Ï¬q ¹êÅç²Õ¶¥±è»P¹ï·Ó²Õ¶¥±è¤jPK ¯à§_¼ÒÀÀ¹w¦ô? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/29 ¤U¤È 04:07:31²Ä 2448 ½g¦^À³
|
¤p©_¤j¤j ¤Ó¤Óºë±m¤F ÁÂÁ±z³o»ò¸ÔºÉªº¤ÀªR ·P¨Ø±zÅÞ¿èÂk¯Çªº¯à¤O ÁÙ¦³±z¥Î¤ß¼ö¸Ûªº¯ÝÃh ¤p§Ì¯uªºÃø¥H§Î®e¤º¤ßªº·P°Ê©MÁ·N ¦A¦¸·PÁ±z ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/29 ¤U¤È 03:27:39²Ä 2447 ½g¦^À³
|
0~16Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³5Ó°é°é¡B13Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³25Ó°é°é¡B18Ó¶¥±è¡F¹ï·Ó²Õ¦³15Ó°é°é¡B17Ó¶¥±è 16~28Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³34Ó°é°é¡B7Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³39Ó°é°é¡B6Ó¶¥±è¡F¹ï·Ó²Õ¦³39Ó°é°é¡B15Ó¶¥±è 28~32Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³17Ó°é°é¡B1Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³9Ó°é°é¡B3Ó¶¥±è¡F¹ï·Ó²Õ¦³13Ó°é°é¡B3Ó¶¥±è 32Ó¤ë¥H«á°Ï¬q¡A¥u¦³§C¤ÏÀ³²Õ¦b¤j¬ù33Ӥ릳2Ó¶¥±è¡A°ª¤ÏÀ³²Õ»P¹ï·Ó²Õ³£¬O°é°é 0~16Ó¤ë¬O¤w¸g99%½T©wªº¹Ï¡A¥u¦³2014/7¦¬®×ªº¤Ö¼Æ´XÓ¤´³B¦b³]ª¬ºA¡AÀHµÛ®É¶¡·|§ïÅÜ¡C ¬Ý0~16Ó¤ë³o®É¶¡°Ï¬q¡A822µo´§¤F¤°»ò§@¥Î¡H ¬ÝP13ӹϡA822¦b0~16Ó¤ë´X¥G¨S¦³Àø®Ä¡AÀËÅç¤@¤U³oӰϬqªº°é°é©M¶¥±è¼Æ¥Ø¡A¬Ý¬Ýµ²½×¬O§_¤@¼Ë¡H ¹êÅç²Õ¦@¦³13+18=31Өƥó¡A224¤H¶i¤J³o°Ï¬q¡A31¤H¥¼³q¹L¦ÒÅç¡A¨Æ¥óµo¥Í²v31/224=13.8%¡F¹ï·Ó²Õ¦³17Өƥó¡A124¤H¶i¤J³o°Ï¬q¡A17¤H¥¼³q¹L¦ÒÅç¡A¨Æ¥óµo¥Í²v=17/124=13.7% ¹êÅç²Õ¦@¦³5+25=30Ó³]¡A³]¤ñ²v=30/224=13.4%¡F¹ï·Ó²Õ¦@¦³15Ó³]¡A³]¤ñ²v15/124=12.1% ¹êÅç²Õ»P¹ï·Ó²Õ¦b¦¹°Ï¬qªº¨Æ¥óµo¥Í²v´X¥G¤@¼Ë¡A³]¤ñ²v¤S·¥±µªñ¡AÃø©Ç¦b16Ӥ몺¥Í¦s¾÷²v´X¥G¬Û¦P¡A¦]¦¹822¦b16Ó¤ë¨S¦³µo´§Àø®Ä¡C 0~16Ӥ몺°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¡B¹ï·Ó²Õ¤ñ¸û¡G °ª¤ÏÀ³²Õ¨Æ¥óµo¥Í²v=13/112=11.6%¡F§C¤ÏÀ³²Õ¨Æ¥óµo¥Í²v=18/112=16.1%¡F¹ï·Ó²Õ¨Æ¥óµo¥Í²v=17/124=13.7% °ª¤ÏÀ³²Õ³]¤ñ²v=5/112=4.5%¡F§C¤ÏÀ³²Õ³]¤ñ²v=25/112=22.3%¡F¹ï·Ó²Õ³]¤ñ²v=15/124=12.1% °ª¤ÏÀ³²Õ¦b¦¹°Ï¬qªº¨Æ¥óµo¥Í²v©M³]¤ñ²v³£¦û¤F«K©y¡A¾ÉPP17¹Ï¤¤¡A¦b16Ó¤ë®É¡A°ª¤ÏÀ³²Õ=88%ªº¦s¬¡²v¡A¹ï·Ó²Õ=84%ªº¦s¬¡²v¡A§C¤ÏÀ³²Õ=80%ªº¦s¬¡²v¡A§C¤ÏÀ³²Õ¦Y¤F´eÁ«¡C ³o´N¬O¤À²Õ³y¦¨ªº²Îp°¾®t¡A¥i¯à¦³³¡¤Àªº¡u¬ÛÃö©Ê¡v(¬D°ª¤ÏÀ³ªº¬°¤@²Õ¡A¥i¯àÅé½èµy¦n¤@¨Ç¨Ç¡A¦ýY¤ÀªR¦pP11ªºbaseline characteristics¡A¥¼¥²·|§e²{²Îp¤Wªº®t²§)¡A¤]¥i¯à¦³immortal tome bias¡A¾ÉP°ª¤ÏÀ³²Õ¦b16Ó¤ë³o®ÉÂIªº¦s¬¡²v°ª©ó¹ï·Ó²Õ4%¡A§C¤ÏÀ³²Õ¦b16Ó¤ë³o®ÉÂIªº¦s¬¡²v§C©ó¹ï·Ó²Õ4%¡A³Ì¥Dnªº²Îp°¾®t´N¦b0~16Ó¤ë³o°Ï¬qµo¥Í¤F¡C ¦b16Ó¤ë®É¡A°ª¤ÏÀ³²Õ±aµÛ¸û¹ï·Ó²Õ°ª4%ªº¦s¬¡²v¶i¤J16~28Ӥ몺¦ÒÅç¡A§C¤ÏÀ³²Õ±aµÛ¸û¹ï·Ó²Õ§C4%ªº¦s¬¡²v¶i¤J16~28Ӥ몺¦ÒÅç¡A¥B¬Ý¦ÒÅ窺µ²ªG¦p¦ó¡C 16~28Ó¤ë©Î³\»¡16~32Ó¤ë¡A¬O¤K¤E¤£Â÷¤Q½T©wªº¹Ï¡A¦³200/348=57.5%¤H¤w¸g¸g¾ú¤F28Ӥ몺¦ÒÅç¡A¥t¦³42.5%ªº¤HÁÙ¥¼§¹¦¨28Ӥ몺¦ÒÅç¡C ¤@Ó²³æªº°²³]¡A¦¦¬®×»P±ß¦¬®×ªº±wªÌªº¦s¬¡¾÷²v¤À¥¬¤jP¬Û¦P¡A»P¥ÀÅé¤]¤jP¬Û¦P¡C ¥H°ª¤ÏÀ³²Õ¨Ó»¡¡A¦¦¬®×ªº¦³53¤H³q¹L¤F28Ӥ몺¦ÒÅç¡A±N°¨©ÔªQªº¨½µ{¼Æ±À¦V28¤½¨½¥H¤W¡A¦ý¦b16~28Ӥ몺°Ï¬q¡A¦³7Өƥóµo¥Í¡A34ӱߦ¬®×¤´µM¦b¦ÒÅ窺³]¸ê®Æ¡C³o7Өƥó¡A¦³¥i¯à¬O7Ó¥þ¬O¦¦¬®×µo¥Íªº¨Æ¥ó¡A±ß¦¬®×=0¡F¤]¥i¯à¦³6Ó¬O¦¦¬®×µo¥Íªº¨Æ¥ó¡A±ß¦¬®×=1¡F·íµM¤]¥i¯à¦³5Ó¬O¦¦¬®×µo¥Íªº¨Æ¥ó¡A±ß¦¬®×=2¡C·íµM7Ó¥þ¬O¦¦¬®×©Î5Ó¥H¤U¬O¦¦¬®×³£¤ñ¸û¤£²Å¦X¤Wzªº°²³]¡A¦]¬°¦¦¬®×¤w¸g¦³53Ó³£¸g¾ú¹L¡A±ß¦¬®×ªº¥u³Ñ34ÓÁÙ¦b¸g¾ú¤¤¡A7Өƥó²zÀ³¤À°t¸û¦hªº¨Æ¥ó¦b¦¦¬®×¡A¥Î6:1©ÎªÌ5:2³£ÄݦX²z¡A³oùØ¿ï¾Ü6:1¨Ó°µ¤ÀªR¡C °ª¤ÏÀ³²Õ¤¤¡A¦¦¬®×¦³53Ó¤w³q¹L28Ӥ몺¦ÒÅç¡A¦³6Ó¦b16~28Ӥ몺°Ï¬qµo¥Í¤F¨Æ¥ó¡A¦]¦¹¦b16~28Ӥ몺°Ï¬qªº¨Æ¥óµo¥Í²v=6/(6+53)=10.1% §C¤ÏÀ³²Õ¡B¹ï·Ó²Õ¥H¦¹Ãþ±À¡A §C¤ÏÀ³²Õ¦b¦¹°Ï¬q¦³6Өƥóµo¥Í¡A¦b¦¹¿ï¾Ü5:1Ó¦¦¬»P±ß¦¬¤ñ¨Ò¡A§C¤ÏÀ³²Õ¦¦¬®×ªº¦³24¤H³q¹L28Ӥ몺¦ÒÅç¡A¦ý¦³5Ó¦b16~28Ӥ몺°Ï¬qµo¥Í¤F¨Æ¥ó¡A¦]¦¹¦b16~28Ӥ몺°Ï¬qªº¨Æ¥óµo¥Í²v=5/(5+24)=17.2% ¹ï·Ó²Õ¦b¦¹°Ï¬q¦³15Өƥóµo¥Í¡A¦b¦¹¿ï¾Ü11:4Ó¦¦¬»P±ß¦¬¤ñ¨Ò¡A¹ï·Ó²Õ¦¦¬®×ªº¦³38¤H³q¹L28Ӥ몺¦ÒÅç¡A¦ý¦³11Ó¦b16~28Ӥ몺°Ï¬qµo¥Í¤F¨Æ¥ó¡A¦]¦¹¦b16~28Ӥ몺°Ï¬qªº¨Æ¥óµo¥Í²v=11/(11+38)=22.4% ¥i¥H¦b¦¦¬»P±ß¦¬ªº¨Æ¥óµo¥Í¤H¼Æµy°µ½Õ¾ã¡A¦ý¤ÀªRªºµ²ªG¤è¦V¬O¬Û¦Pªº ¦C¥X°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¡B¹ï·Ó²Õ¦b16~28Ӥ몺¨Æ¥óµo¥Í²v¡A¥i¥H¬Ý¥X822¦b°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¤À§OªºÀø®Ä¡A °ª¤ÏÀ³²Õ¨Æ¥óµo¥Í²v=10.1%¡A§C¤ÏÀ³²Õ¨Æ¥óµo¥Í²v=17.2%¡A¹ï·Ó²Õ¨Æ¥óµo¥Í²v=22.4%¡A ¦b16~28Ó¤ë¤w¸g¨S¦³immortal tome biasªº¼vÅT¡A°ª¤ÏÀ³²Õ»P§C¤ÏÀ³²ÕÅé½èªº¼vÅT¤]·L¥G¨ä·L¡A¦U²Õªº¨Æ¥óµo¥Í²v¥þ¾a¯u¥»¨Æ¡Aµ²ªGµo²{¡A°ª¤ÏÀ³²Õªº¨Æ¥óµo¥Í²v»·»·§C©ó¹ï·Ó²Õ¡A¤]»·§C©ó§C¤ÏÀ³²Õ¡A§C¤ÏÀ³²Õªº¨Æ¥óµo¥Í²v¤]§C©ó¹ï·Ó²Õ¡A822¦b16~28Ӥ몺°Ï¬q¦b°ª¤ÏÀ³¦³°ªÀø®Ä¡A¦b§C¤ÏÀ³²Õ¦³´¶³qÀø®Ä¡C §C¤ÏÀ³²Õªº´¶³qÀø®ÄÅý§C¤ÏÀ³²Õ¦b16Ó¤ë®É¿éµ¹¹ï·Ó²Õ4%ªº¦s¬¡²v¡A¨ì¤F28Ó¤ë®É¤Ï¦Ó¦s¬¡²v¶W«e¡A°ª¤ÏÀ³²Õªº°ªÀø®Ä«hÅý°ª¤ÏÀ³²Õªº¦s¬¡²v¦b16Ó¤ë®Éµy·LŦb°_¶]ÂI¡A¨ì¤F28Ó¤ë®É»·»·³Ó¹L§C¤ÏÀ³²Õ»P¹ï·Ó²Õ¡C 28~32Ó¤ë¦b¦U²Õ¤´¦³¨Æ¥óµo¥Í¡A¥i¥Hµy°µ¤ÀªR¡A¦ýºë½T«×·|¤ñ16~28Ó¤ë§C¡C ¨Ì¤Wz¤èªk±À½×¡A¦¦¬®×ªºY¥þ³¡¶]§¹32Ӥ몺¦ÒÅç(2015/10ºI¤î¤´¦³³¡¤À¦b28~32Ó¤ë¤W³])¡A¦b28~32Ӥ몺°Ï¬q¡A°ª¤ÏÀ³²ÕÀ³¸ÓÁÙ¦³1Өƥóµo¥Í¡A§C¤ÏÀ³²Õ¥i¯à0~1Өƥóµo¥Í¡A¹ï·Ó²Õ¥i¯à0 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/29 ¤U¤È 02:33:14²Ä 2446 ½g¦^À³
|
¥xÁÞ¤j¤j ÁÂÁ±zªº¦n·N ¤p§Ì¤gªk½m¿ûªº¸Õºâªí¡AÓ¤H»{¬°¥¦Áö²Â©å¡A¥Î°_¨ÓÁÙ®t±j¤H·N°Õ °²¤é¥DnÁÙ¬O¦b°Ù®Ñ¡A¼ÒÀÀ¨Ã¥¼¦û¥Î¤Ó¦h®É¶¡ ¦Û¤v§ó°Ê¼Æ¾Ú¡A©Î¤ñ¸û¦³§U©ó´x´¤¥¦ªºÅܤƩÎÁÍ¶Õ ¬Ý¬Ý10¤ëªºESMO¦³µL³Ì·sªºKM¹Ï¡A©Î§ó¯à¤F¸Ñ822ªº¯à@ ÁÂÁ±z ¡I ¾å¦à¤j ±z¬JµMª¾¹D³oºØÀøªk¡A·Q¥²¹ï¥¦¦³¤@©wªº¤F¸Ñ©M´x´¤ ¦ó¤£§â±zªº¸ê®Æ©Î¤ß±o¡A¥ý¤À¨Éµ¹¤j®a ¦A¬Ý¤j®a¦³µL¿³½ì°Q½×¦p¦ó¡H ÂåÀø±M·~ªùÂe¤Ó°ª¡A°£«D¦³¾Ç¦³±Mºë¡A§_«h·Q¿s¨ä°ó¶ø¤£©ö n¥Ö¤ò¦a¤F¸Ñ822¡A¤w¸gªá±¼¤j³¡¤À®É¶¡ºë¤O ¤p§Ìªº·Qªk¬O ¥ýµ¥822¯à§_µo´§«pªø§Àªº¯S©Ê¡A©¡®É¦A¨Ó¬ã¨s¥¼¨Ó¥i¯àªº¹ï¤âÃħa ´N¹³QQ¤jªºÁÞ°ò¶K¤å Ó¤H«Ü¤[¥H«e¡A´Nı±o¥un822¯à¦¨¥\½æ®y ÁÞ°ò®Ú¥»¤£·|¬O¹ï¤â¡A¦Ó¬O§U¤â ©¡®É¯E¹©¨ÖÁÞ°òªº¾÷·|«Ü¤j ²¦³º¤jªÑªF«Å|¡A§Þ³N¨Ó·½¬Û¦P ´N¥xÆWªº¾Ô²¤Æ[ÂI¡A¥u¦³¥S§Ì¦X¤O¡A¤~¯àÂ_ª÷ ¦n¤£®e©ö¯Î°|ªøªºÁÞ§Þ³N»â¥ý°ê»Ú¡A°Z¥i¥O¨ä¤À´²¤O¶q¡A¦U¦Û¬°¬F ¤p§ÌªºÆ[ÂI©Î¥¢¤§¥DÆ[¡A¤í¯Ê¦¨¼ô ¦³½Ð¤j®a«ü¥¿¨Ã®ü²[ ÁÂÁ¤j®a¡I |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/8/29 ¤U¤È 01:15:44²Ä 2445 ½g¦^À³
|
ÁÞ°ò¤â´¤¤W¦Ê±M§Q ·m§ð°ê»Ú ¤¤¬ã°|§Þ³N¹Î¶¤»âx ©ú¦~©é¤TÃĶi¤J¬ü°êÁ{§É 2016-08-29 ¡i¸gÀÙ¤é³ø 2016-08-29 °OªÌ¶À¤å©_¡j www.ibmi.org.tw/client/NewsDetail.php?REFDOCID=0ocn2wi7ggkkzsn7 ³¯¨}³Õ¡A²£¾Ç¨â´Ï ¸ê¾ú¶Æ¤H 2016-08-29 ¡i¸gÀÙ¤é³ø 2016-08-29 °OªÌ¶À¤å©_¡j www.ibmi.org.tw/client/NewsDetail.php?REFDOCTYPID=0o4dd9ctwhtyumw0&REFDOCID=0ocn3f8ejkxba8qy&Page_Num=1 Å¥¹LÁÞ°òªºªk»¡, °í¹êªº¹ï¤â, ¨Ã«D¥S§Ì. ¯E¹©n§ó¥[ªo¤F !!! |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2016/8/29 ¤W¤È 11:03:58²Ä 2444 ½g¦^À³
|
Å¥»¡¥¼¨Ó¤Q¦~¡A RNA Àøªk·|¿³°_¡AÅܱo«D±`«n¡C þ¦ì¤j¤j¥i¥H±Ð±Ð¦³ÃömRNA ÃĪ«¾÷¨î¶Ü¡H ¯E¹©©Î¥xÆWþ®a¤½¥q¦³°µ¶Ü¡H ªø»·¬Ý·|¦M¤Î¯E¹©²£«~¶Ü¡H ÁÂÁ¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/29 ¤W¤È 09:47:36²Ä 2443 ½g¦^À³
|
²q·Q¤j 1 ¬Q±ß§Ú¸Õ¹Ï¦^µª¼Æ¾Ú¦¨¼ôªº·N²[,¨ÃÁ|Perjeta ÃÄÃÒªº¨Ò¤l,¤j®a³£ª¾¹D³oÁûÃÄ®³ÃÄÃÒ¬O°ò©óPrimary outcome measure (PFS),§Ú¥u¬O¦bªí¹FÁ`¦s¬¡´Á¥i¥H¦bÃÄÃÒ®Öã«á¦A¤½§G»P¼Æ¾Ú¦¨¼ôªº·N²[,§Ú̲{¦bªº°ÝÃD¦b©óªk³W: ¤@ÁûÃĦw¥þ©Ê»P»P¥Í¬¡«~½è°ªªºÃÄ,¯à¤£¯à¥HSecondary outcome measure(os)¨Ó¨ú¥NPrimary outcome measure(PFS)Àò±oÃÄÃÒ, §Ú¬ã§P¬O¥i¥Hªº,§Úªº«äºû§i¶D§Ú:Á{§É¼Æ¾Ú´x´¤¦b¯E¹©¤â¤¤,Á{§Éªk³W¦³½Ö¤ñ¯E¹©²M·¡, ¦pªG¤£¥i¥H¦ó¨Ó2¤ëªk»¡¤½¥qªº½×z¨ìªº conditional approval (¬Ý¬ü°êFDA ªº³Ì«á¨M©w) 2 ·ÀI¤ñªº 95% «H¿à°Ï¶¡¡A·|¦]KM¹ÏªºÅܬ°¦³§Q¸ÕÅç²Õ¦ÓÅܦn¡A·N«ä¬O»¡¥unÃÄ°÷¦n¡A¨â²Õ²£¥ÍÃĮĪº®t²§,·í¨Æ¥ó¼Æ¼W¥[ ´N¯à±N95% «H¿à°Ï¶¡±±¨î¦b1¥H¤º,¥t¥~ P Ȥ]·|Åܤp 3²q·Q¤jªº¼ÒÀÀ´£¨ì: 822Yµo´§«pªø§Àªº¯S©Ê¡AASCO p 13 ªº¨â²Õ PÈ¡A´N·|¦³¤p©ó0.05ªº¼ç¤O ¥un¥¼¨Óµo¥Íªº event ¼Æ¬ùµ¥(¬ù¦b20 ~ 25 ??? )¡A PÈ ´N·|ÀH®É¶¡±À²¾¡A¦Ó¤p©ó0.05 ·íµM°Õ¡AY¸ÕÅç²Õ¥¼¨Óµo¥Íªº event ¼Æ¤ñ¸ÕÅç²Õ¤Ö¡APÈ´N·|¶V§Ö¤p©ó0.05 ®t¶V¦h¡A¤p¶V§Ö ²q·Q¤jªº¼ÒÀÀ«áµo²{ªºì«h¬O¥¿½Tªº 4 ¥i¥H´£¨ÑASCO p 13 ªº¨â²Õ¤£¦Pªº¨Æ¥ó¼Æ ½Ð¯E§J¤j¥ÎSPSS ³nÅé¶]¶]¬Ý,´N¤£·|¤Ó²Ö¤Ó¨¯W¤F 5 ²q·Q¤j§â«ÂI©ñ¦bASCO p 13 ´Á¤¤Á`¦s¬¡´Á¡]·N¹ÏªvÀø±Ú¸s¡^ ªº½T¬O§ì¨ì«ÂI, ASCO p 17 ¥i¥H¤£¥Î¾á¤ß ¦]¬°ASCO p 13 ¹êÅç²Õ¦³Àø®Ä, §ë¼v¤ù17 ²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS) ¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160) ²z½×¤WÀø®Ä·|§ó¨Î (¦³²£¥Í¨¬°÷§ÜÅé´N·|¦³§ó¦nªºÀø®Ä) |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/29 ¤W¤È 06:47:58²Ä 2442 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼w »P ¥xÁÞ¤j¤jªº¤j¤å¡A±Ò}¤j®a ¦A½Ð±Ð¤j®a¤@Ó¤p§ÌªººÃ°Ý ·ÀI¤ñªº 95% «H¿à°Ï¶¡¡A·|¤£·|¦]KM¹ÏªºÅܬ°¦³§Q¸ÕÅç²Õ¦ÓÅܦn¡A·N«ä¬O»¡ ¥un°÷¦n¡A´N¯à±N95% «H¿à°Ï¶¡±±¨î¦b1¥H¤º¡A¡]Áö²{¶¥¬q¦³ªº¤´¥¼¹F¼Ð¡^¡H ¦]¬°¤p§Ì»{¬° ¡]Æ[©À¤£ª¾¥¿½T§_¡H ½Ð¤j®a«ü¥¿¡^ 95%«H¿à°Ï¶¡¡A¬O¥ÑÆ[¹îȪº¥§¡È(A) ©M ¼Ð·Ç®t ¡]S) ¥H ¡]A + - 1.96S ¡^ºâ±oªº ©Ò¥H§Ú·Q¡A ¥unÆ[¹îȦ³§ó°Ê ¡A A ¤Î S §¡±NÀH¤§ÅÜ°Ê 95%«H¿à°Ï¶¡¤]·|ÀHµÛ§ïÅÜ¡H °²¦p¬O³o¼Ë ¨º»ò²{¶¥¬qKM¦s¬¡¹Ï·ÀI¤ñªº95%«H¿à°Ï¶¡¡A±N¨Ó³£¦³¥i¯à¦b1¥H¤º¡H¥un822«pªø§À°÷±j ³o¼Ë·Qªk¹ï¶Ü¡H½Ð¤j®a¨ôµû ÁÂÁ¤j®a¡I L |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/29 ¤W¤È 01:10:18²Ä 2441 ½g¦^À³
|
Perjeta ¦b2012/06/08ÃÄÃÒ®Öµo¨ç¤¤©ú½T´£¨ì¡AÃÄÃÒ¬O°ò©óPFS¹F¼Ð¡F¦]¬°PFS¬O¥¦¤T´Á¸ÕÅ窺Primary outcome measure¡AOS«h¬OSecondary outcome measure¡C©Ò¥H®ÖµoÃÄÃҮɤ£¥²²z·|OS¡C 822ªºPrimary outcome measure ¤]¬OPFS¡A¦ý¡K¡K 2012/06/08¡GFDA®ÖµoÃÄÃÒ·s»D½Z¡G¡uFDA Approves Pertuzumab¡v¡]www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm307592.htm ¡^ ¡u¡KA statistically significant 6.1 month improvement in median progression-free survival (PFS) was observed in patients receiving pertuzumab compared to those receiving placebo [HR 0.62 (95% CI: 0.51, 0.75), p< 0.0001, log-rank test]. The median PFS was 18.5 and 12.4 months for patients on the pertuzumab and placebo arms, respectively. At the time of PFS analysis, a planned interim analysis for overall survival (OS) was performed [HR 0.64 (95% CI: 0.47, 0.88), p=0.0053]. However, the HR and p-value for the interim analysis of OS did not meet the pre-defined stopping boundary (HR ≤ 0.603, p ≤ 0.0012).¡K¡v ¤T´Á¸ÕÅç³]p¦b³oùØ¡G CLEOPRA Phase III for Perjeta¡G ¡uclinicaltrials.gov/ct2/show/NCT00567190?term=CLEOPATRA&rank=1 ¡v ¸ÕÅç³]p¡G Primary Outcome Measures: Progression-free Survival (PFS) Determined by an Independent Review Facility¡v Secondary outcome measure¡G 1. Overall Survival 2.Progression-free Survival (PFS) Determined by the Investigator 3.Objective Response Determined by an Independent Review Facility 4. Duration of Objective Response Determined by an Independent Review Facility 5. Time to Symptom Progression 2012/01/12¥ýµoªí¸ÕÅçµ²ªG©óNEJM¡G¡uwww.nejm.org/doi/full/10.1056/NEJMoa1113216#t=article ¡v Primary Outcome Measures¡G FPS by central read: ¡uThe median independently assessed progression-free survival was prolonged by 6.1 months, from 12.4 months in the control group to 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval [CI], 0.51 to 0.75; P<0.001)¡v Secondary outcome measure¡G FPS by local read: ¡uThe median investigator-assessed progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio, 0.65; 95% CI, 0.54 to 0.78; P<0.001).¡v ´Á¤¤ªºOS data·í®É©|¥¼¦¨¼ô¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/28 ¤U¤È 11:25:31²Ä 2440 ½g¦^À³
|
6 PERJETA®»P trastuzumab ¤Î docetaxel ¨Ö¥Î©óªvÀøÂಾ«á¥¼´¿¥H§Ü HER2 ©Î¤Æ¾ÇÀøªkªvÀø¤§ HER2 ¶§©ÊÂಾ©Ê¨ÅÀù¯f±w,¯f±w¬O¦³¸g¹L¿ï¾Ü, ¨ÅÀùOBI22¯f±w¯f¨S¦³¿z¿ï¨È«¬»PGlobo H ,PERJETA®»P trastuzumab ¤Î docetaxel ¬O¤TÃÄÁp¦XªvÀø, ¨ÅÀùOBI22Áö¦³¥Î¤ÆÀøÃĨӴ£°ª§K¤O,¦sÄݳæÃĪvÀø,¥t¥~¯E¹© ¬°Åý¤j³¡¥÷¯f±w³£¯à¥Î¨ìOBI822 ±Ä¨ú2:1¦¬®×¤è¦¡ ¤]¼vÅT¨ìPÈ, ¥H¤W¤ÀªR¤]¯à¬Ý¨ìOBI8222ªº¼ç¤O |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/28 ¤U¤È 10:49:19²Ä 2439 ½g¦^À³
|
Unpolished pearls never shine OBI822¬ãµo¹Lµ{§t¨¯¯øW ²×±Nµo¥ú 1¼Æ¾Ú¦¨¼ôªº·N²[:¥d´¶Äõ ±ö¬ù¦±½u¤£¥²µ¥¨â²ÕOS ³£¤U°¦Ü¦Ê¤À¤§50¦ì¸m»P®É¶¡¶b¥æ¤eªº®É¨è¨ÓÁ{,¥un¨ä¤¤¤@²Õ¤U°¦Ü ¦Ê¤À¤§50¦ì¸m»P®É¶¡¶b¥æ¤e¥BP È,·ÀI¤ñ, «H¿à°Ï¶¡ªº¹F¨ììqªº¼Ð·Ç´N¬O¼Æ¾Ú¦¨¼ôªº·N²[ (Ó¤H¸ÑŪ ¶È¨Ñ°Ñ¦Ò) 2012¦~ 2¤ë7¤é¬ü°êFDA §åã Perjeta Priority Review Àu¥ý¼f¬d 2012¦~ 6¤ë8¤é¬ü°êFDA §åã Perjeta (pertuzumab) ÃÄÃÒ 2014¦~ 9¤ë 28¤é Perjeta ¥d´¶Äõ ±ö¬ù¦±½uMOS ¤~¦bESMOµoªí(Á`¦s¬¡´Á¥i¥H¦bÃÄÃÒ®Öµo«á¤~¤½§i ®³ÃÄÃÒ«á2¦~3Ó¤ë¤S20¤Ñ«á¤~¤½§iMOS) www.perjeta.com/hcp/clinical/efficacy/overall www.esmo.org/Conferences/Past-Conferences/ESMO-2014-Congress/News-Articles/Final-Overall-Survival-Analysis-from-the-CLEOPATRA-Study-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer 2 ¬ü°êªk»¡·|p28:¯f±w§¹¦¨¤E¦¸ª`®gÀøµ{Åã¥Ü¨Ï¥ÎOBI-822/821ªºPFS¨ã§ïµ½ÁÍ¶Õ ( 22.5Ó¤ë PK 18.5Ó¤ë) ÁöµMp28¦]¨â²Õ¤H¼Æ¤£§¡µ¥, ¦bP È»P«H¿à°Ï¶¡¤]¨Ç¨Ç¿ò¾Ñ ,¦ý¬O·å¤£±»·ì 3 ¬ü°êªk»¡·|p29:¬Û¸û©ó¦w¼¢¾¯²Õ©ÎµL§K¬Ì¤ÏÀ³ªÌ¨ã§K¬Ì¤ÏÀ³ªº¨ü¸ÕªÌPFSÀò©úÅã§ïµ½ÁÍ¶Õ 50%¨ü¸ÕªÌ¨ãÅãµÛ§K¬Ì¤ÏÀ³(IgG §ÜÅé®Ä»ù≥ 1:160) ¨ã§K¬Ì¤ÏÀ³²ÕPFS¬ù12Ó¤ë,¦w¼¢¾¯²ÕPFS¬ù8.1Ó¤ë, ·ÀI¤ñ 0.71(0.52 ¡V0.97) p = 0.0295 ¨ã§K¬Ì¤ÏÀ³²ÕPFS¬ù12Ó¤ë,µL§K¬Ì¤ÏÀ³²ÕPFS¬ù5.6Ó¤ë ·ÀI¤ñ 0.51(0.37 -0.70) p = <0.0001 ¨ã§K¬Ì¤ÏÀ³²ÕPFS¬ù12Ó¤ë¤w¶W¹L822ì©w¥Ø¼Ð9Ó¤ë 4 ³o¨â±i¬O¦V¥þ²yªí¹F¤@ºØ±j¯Pªº°T®§: §K¬ÌÀøªk¨ã¦³«p§À®ÄÀ³¥un«ùÄò¥´¤£¤¤Â_ Åý§ÜÅé®Ä»ù«ùÄòºû«ù¨¬°÷,¯f±w°£¤F Á`¦s¬¡´ÁOS Àu¶Õ¥~, ¯e¯fµL´c¤Æ¦s¬¡´ÁPFS ¤]¯àÀò©úÅã§ïµ½ÁÍ¶Õ 5 Á{§É¼Æ¾Ú´x´¤¦b¯E¹©¤â¤¤,Á{§Éªk³W¦³½Ö¤ñ¯E¹©²M·¡,¦h¦~¨Ó§Ú¿ï¾Ü¬Û«H¤½¥q¦p¦P¤j¦h¼Æ¤j¤j¤@¼Ë°í§Ô, OBI822¬ãµo¹Lµ{§t¨¯¯øW ²×±Nµo¥ú |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/28 ¤U¤È 06:01:37²Ä 2438 ½g¦^À³
|
¨â¤Ñ³£ªw¦b¹q¸£¸Ì ¥Ñ¤p©_¤j¤jªº«ü¤Þ¡A «ä¦ÒµÛ822Á{§É¼Æ¾ÚªººØºØ ¤ßôªº¬O¡A 822¯à§_µo´§«pªø§Àªº¶´©Ê¡A §â¹ï·Ó²ÕKO P. 28/50 §¹¦¨¤E°wPFSªºKM¹Ï¡A ³Ì¦³¥i¯à¥ý¹F°}( PȤp©ó0.05) ¸Ó¹Ï¤¤¤´¦³48¤H³B©ó³](¤w¦©°£¶W¹L2¦~ªº34¤H) ¡AÀHµÛ event ¼Æªº¼W¥[¡A PȩαN¤p©ó0.05 (¤p§Ì¤£ª¾¦b²Îpªº»{©w¤W¡A³o¼Ëªº¨ú¼Ë¦³µL°¾®tªº°ÝÃD¡A ·Pı¤W³o²Õ¹ÏÀ³¬O¸ÕÅç²Õ»P¹ï·Ó²Õ¤¤¡Aª¬ªp³Ì¦n¤HªºPK) ¦AªÌ P. 27/50 ªº¨â²Õ OS KM ¹Ï¤¤ ¥Ñ¥d¤èȪº¤½¦¡ X^2 = (O1 ¡V E1)^2/ E1 + (O2 ¡V E2)^2/ E2 ¦b¦Û¥Ñ«×¬°1ªº¸ÕÅ礤¡A ¶È¦³¸ÕÅç²Õ»P¹ï·Ó²ÕªºO(Æ[¹îÈ) ©M E (´Á±æÈ)¡A ¤]´N¬O¤W¦C¤½¦¡§Y¥i¥Nªí (O1¡B E1 ªí¸ÕÅç²Õ ., O2¡B E2 ªí¹ï·Ó²Õ) | (O1 ¡V E1) | ·|µ¥©ó | (O2 ¡V E2) | ¡A | n | ªí¥Üµ´¹ïÈ E ¬O¥ÑÆ[¹îȤ¤ ©Òºâ¥Xªº´Á±æÈ¡A¬O¥Ñ¦U²Õ¦³event³B¡A¤À§Oºâ¥X e ( i ) ¡A¦A²Ö¥[¦¨ E ©Ò¥H X^2 n¼W¤j ¥²¤]| (O1 ¡V E1) | n°÷¤j¡A¤~¯à¹F¨ì ¨Ì·Ó¤p§Ì²Ê²¤ªº¼ÒÀÀ 822Yµo´§«pªø§Àªº¯S©Ê¡AP. 27/50 ªº¨â²Õ PÈ¡A ´N·|¦³¤p©ó0.05ªº¼ç¤O ¥un¥¼¨Óµo¥Íªº event ¼Æ¬ùµ¥(¬ù¦b20 ~ 25 ??? )¡A PÈ ´N·|ÀH®É¶¡±À²¾¡A ¦Ó¤p©ó0.05 ·íµM°Õ¡A Y¸ÕÅç²Õ¥¼¨Óµo¥Íªº event ¼Æ¤ñ¸ÕÅç²Õ¤Ö ¡APÈ´N·|¶V§Ö¤p©ó0.05¡A ®t¶V¦h¡A ¤p¶V§Ö §Ú·Q(¤£¤@©w¥¿½T)¡AÃöÁä´N¦b©ó(¨S¤ÏÀ³²Õ)©M¹ï·Ó²ÕªºPK Y¥¼¨Ó¡A(¨S¤ÏÀ³²Õ)µo¥Íªº event ¼Æ¡A¯à«r¦í¹ï·Ó²Õªºevent ¼Æ¡A¤j¥\©Î¥i§i¦¨? ·íµM¡A Y(¨S¤ÏÀ³²Õ)¯àÀu©ó¹ï·Ó²Õ¡A «h³t«×·|§ó§Ö Cliff ¤j®¦¼w§â822§Î®e¬°µ}¦³ ²¦³º¡A¤@ºØ¬Ì]¯à²£¥Í¤TºØ¦³¥Îªº§ÜÅé¡Aª®±þÀù²ÓM©ÎÀù·F²ÓM ¦ÓGH¤S¦³¥i¯à¬O¤@ºØ§K¬ÌÀˬdÂI©M¦åºÞ¼W¥Íªºn¨¤ ³o¬Û¼ªº®ÄªG¡AÃø¹D¤£¯à³y´N«pªø§Àªºµ²ªG¶Ü? ¥t¥~½Ð±Ð¤j®a P. 27/50 ¹Ïªí¤¤ ªº·ÀI¤ñ 0.79 ¡A ¬O«ç»òºâªº Y¤Ó½ÆÂø ¡A ½Ð´f¤©ºô§} ¡A ¤p§Ì¦Û¤v¬Ý´N¦æ ¥H¤W¡A½Ð¤j®a«ü¥¿ ÁÂÁ¤j®a! |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/28 ¤U¤È 05:43:26²Ä 2437 ½g¦^À³
|
¤p©_¤j¡AÃö©ó°é°é¡A¤p§Ì¤S¦³°ÝÃD»Ýn½Ð±Ð±z¡CÀµ½Ð«ü¾É¡C 0~16Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³5Ó°é°é¡B13Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³25Ó°é°é¡B18Ó¶¥±è¡F¹ï·Ó²Õ¦³15Ó°é°é¡B17Ó¶¥±è 1. 822¸ÕÅ窺³Ì±ß¦¬®×¤j¬ù¦b2014¦~7¤ë¡C2015/10 dada lock ®É¡A³Ì±ß°_¶]°¨©ÔªQªº¡A¦pªG¨SˤU¡AÀ³¸Ó¤w¶]¤F15Ó¤ë¡C¹Ï¤¤³Ì¦ªº°é°é¥X²{¦b2¤½¨½¡]2Ó¤ë¡^³B¡A¤p§Ì²q·Q0¡ã12¤ë°Ï¶¡ªº°é°é¨ä¹ê³£¬Odrou outªÌ¡H¡H 2. ¸ÕÅ窺¤H¼Æ¤£°÷¦h¡A³æ¤@®É¶¡å±ªº¡§¶¥±è¡A°é°é¡¨¤À§G¹Ï¥u¯àÂaÄg¬Ý¥X¤À²Õªº¦s¬¡®t²§¡APȤ´¤£ÅãµÛ¡C¨ä¤¤©Î¦³¼Ë¥»¤À²Õ±ø¥ó¤£¥§¡ªº¥i¯à¡AY¦³¤@¦~¥b¸ü¤§«áªº²Ä¤GӮɶ¡å±ªº¡§¶¥±è¡A°é°é¡¨¤À§G¹Ï¡A´N¯à¬Ý¥X¦U²Õªº®É¶¡¦ÒÅç¡A©ú½T¹îª¾¦s¬¡ÁͶթMÀø®Ä¡]¦p¥xÁÞ¤j©Ò¨¥¡A¹w´Á¸ÕÅç²Õ¦b«á¥b¬qªº¤U°±×²vÁͽw¡^¡C¯E¹©¤£¤½§G§ó·s¼Æ¾Ú¡AÅýªÑ»ù©M¤ß²z«ÜªÈµ²À£§í¡C´Á«Ý2016/ 10¤ëªì ESMO·|¤W¤½§G·sªº¡§¶¥±è¡A°é°é¡¨¤À§G¹Ï¡A§Æ±æ¬O2016/08 ©Î2016/06 dada lock ªº·s¼Æ¾Ú¡C½Ð±Ð±z¡A¥H·sÃĸÕÅ窺ºD¨Ò¡]¦pªG¦³¡^¡AOS ´Á¤¤¤ÀªR·|¤½§G´X¦¸¡H©Ò¦³¯f¤H³£°l踪¤¦~¡A¤p§Ì·Q¡§´Á²×¤ÀªR¡¨»Ý®É¤Ó¤[¡A¥¢±Ñ©Î¦¨¥\¦b³~¤¤´N©³©w¤F¡C¦ý¬O¦pªG¤£»{¿é¡A¨º»òOS ´Á¤¤¤ÀªR±N¤£¤î¤@¦¸¡A¯E¹©¦ü¥G´N¬O³o¼Ë¡C¥H¤W½Ð±z«ü¥¿¡CÁÂÁ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/28 ¤U¤È 03:19:45²Ä 2436 ½g¦^À³
|
¤p©_¤j¤j ¥xÁÞ¤j¤j Faith ¤j¤j ¤p§Ì¦V¤T¦ì¤j¤j¤Î¤j®aPºp µ¹¤p©_¤j¤j¤ÎFaith ¤j¤j P·qªº·R¤ß¬O¬õ¦âªº¡A¤£¬O¦Çªº ¤é¬Q¤p§Ì¬O¥Î iPad µo¤åªº¡A·q·Rªº¤ß¬O¬õ¦âªº¡A¤µ¤é¥Î®à¤W¹q¸£¡A¤~ª¾Åã¥Ü¦Ç¦â¡A¯uªº©êºp·¥¤F¡A½Ð¨â¦ìì½Ì ¥t¥~¦V¥xÁÞ¤j¤j¤Î¤j®a¹ï¤£°_¡A¤é¬Q¼ÒÀÀ¤åªºµ²½×¡A¥Ç¤F¦³°÷Â÷ÃЪº¿ù»~¡A½Ð¤j®a´N·í§@¨S¬Ý¨ì¡@ ½Ð¬ãŪ¤p©_¤j¤jµ¹¤p§Ìªº«ü¾É¤j¤å´N¦n ÁÂÁ¤j®aªºì½Ì! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/27 ¤U¤È 11:49:24²Ä 2435 ½g¦^À³
|
²q·Q¤j ¨Ì³]¸ê®Æ»P¨Æ¥ó¸ê®Æ«e¸m©Î«á¸m¤§¤£¦P , ©Ò¤ÞPªº PÈÅÜ¤Æ , ¯u¬Oµ±ºÉ¸£¥Ä,²`«ä¼ô²v,¥O¤H¨ØªA ¤p©_¤j 8¤ë26¤é°w¹ï§ë¼v¤ù17 ¶K¤å( °é°é»P¶¥±è ) Æ[¹î¤J·L ¥O¤HÅå©_ ¥t¥~7¤ë1¤éªº¶K¤å¤]¦³´£¨ì§ë¼v¤ù13ªº½×z: ³\¦h§K¬Ì¤ÏÀ³ªºOSªºKM curve¡A¦b«á¥b¬q±`¥i¬Ý¨ìcurveªº±×²vÅܱo¸û¥½wªº²{¶H¡A¤]´N¬O P13¹êÅç²ÕªºOS¤]¥i¯à¦b«á¥b¬q±×²vÅܱo¥½w¡A¦]¦¹M OS·|¤ñTony¥Î±oª½½uªk¨Ó±o°ª¡C±À²zȱo«~¨ý ¯E§J¤j7¤ë2¤éªº¶K¤å¦X¥GÅÞ¿è»P¤p©_¤jªº½×z«e«á©IÀ³: ¨Ì·Ó§K¬ÌÀøªkªº«p§À²{¶H¨Ó»¡ ´N¬O¥NªíKM¦±½uªº«áºÝ¤£¬O«eºÝ±×²v¤U°ªºÁÍ¶Õ ¦Ó¬O±×²v¨«¥ªºÁÍ¶Õ ©Ò¥H¥Îª½½u¦^Âk¨Ó¹w´úMOS «Ü¥i¯à·|¥Ç§C¦ôªº¿ù»~ ¤×¨ä¥Î¨Ó¹w¦ô°ª§ÜÅé¤ÏÀ³²Õ §ó¬O¤£©y Ó¤H¸É¥R: §ë¼v¤ù17ªº½T¥O¤HÅåÆA ,§ë¼v¤ù13 ˦Y¥Ì½©, º¥¤J¨Î¹Ò ,¯E¹©6¤ëªÑªF·|¬ãµo¹Î¹ï¹ï³o¦¸Á{§Éµ²ªG»PHope Rugo ¤À§O¨Ï¥Îexciting ,provocative¨Ó¦æ®e,À³¸Ó¬O«ü³o¨â±i§ë¼v¤ù,¯à§_ºÉ§Ö®³¨ìÃÄÃÒ¤W¥«±Ï¤H»P³o¨â±i¹Ï¹F¼Ð±K¤£¥i¤À ,¥xÆW¼fÃijæ¦ì¤ô·Ç«Ü°ª, ªk³W»P¥@¬É¥ý¶i°ê®a¦P¨B,¤@¤Á¨Ì·Óªk³W¦æ¨Æ,¥xÆW¦Û¦æ¬ãµoªºÃÄ¥un¦w¥þ¦³Àø®Ä ªk³W³æ¦ì¤]·|¨Ìªk®ÖãÃÄÃÒ,¦¤é¤W¥«±Ï¤H ³\¤j¥À¿Ë³Ì¾A¦XªºÃĬOOBI822 §Æ±æ©ú¦~¯àµ¥¨ì³oÁû°ª¦w¥þ©ÊªºÀÙ¥@¨}ÃÄ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/27 ¤U¤È 12:57:57²Ä 2434 ½g¦^À³
|
²q·Q¤j ±z¤Ó¹LÁ¾µê¤F¡A ¤p§Ì¤~¬Oª¾ÃÑ«á½ú ¤p§Ì¬O¥ý§ë¸ê¯E¹©¡A±ß¤@ÂI¤~µo²{¦³³\¦hªº«e½ú¦bÁÞ¬ì¾Çªº»â°ì¤£Â_ªº±´¯Á ¤p§Ìªº©Òª¾©Ò¾Ç³£¬O¨Ó¦ÛCliff¤j¡B±z¡B¥xÁÞ¤jµ¥¤j¤j(ÁÙ¦³³\¦h¨ä¥L¼ö¸Ûªº¤j¤j)µL¨pªº¤À¨É KM¨ç¼Æ¤ÎPȪºpºâ¤£´N¬O±z¤§«e©Ò§ä¨Óªº¸ê®Æ¶Ü¡H ¤p§Ì°J¤ß¦a·PÁ±z ¤]°J¤ß·PÁ©Ҧ³µL¨p¤À¨Éª¾ÃѪº¼ö¸Û¤j¤j §â§ë¸ê¯E¹©¤£¥u¬O·í§@¤@ÀɪѲ¼§ë¸ê ÁÂÁ±z¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/27 ¤W¤È 06:29:27²Ä 2433 ½g¦^À³
|
¤p©_¤j¤j ¤Ó·PÁ±zªº«ü¾É©Mq¥¿¡AÅý¤p§Ì±o¨ì¥¿½Tªº»{ª¾ ¬Û¹ï©ó±zªº¦nŪ®Ñ¨D¬Æ¸Ñ¡A¤p§Ì¦³µÛ¤ÖŪ®Ñ¤S¤í«ä¦Òªº½§²L ¬Ý¨Ó¡A¤p§Ì±o¦A¦n¦n¬ã¨s³o¨Ç¹Ïªí¤Wªº²Îp±M¦³µü ¬Ý¬Ý¯à¤£¯à¸ò¤W±z¤§¤@¡B¤G ❤❤❤❤❤❤❤❤❤------ ¤EӤߥNªíµÛ·q·R±z¤[¤[ §Ú·Q¤Ö¦³¼ö¸Û¦p±z¡]ÁÙ¦³¨ä¥L«e½ú¤j¤j¡^¡AÄ@·N¤£¹½¨ä·Ð¦a«ü¾É¦p¤p§Ì¯ëªºª¾ÃÑ«á½ú ¤j®a¦P¨B¨«¦b¯E¹©ªº¸ô¤W¡A¦³¤F±zÌ´£携¡AÅã±o·ÅÄÉ·P¤H¤S©¯ºÖ°í©w °J¤ß¦a·PÁ±z¡I ¤]ÁÂÁ¤j®aªº®ü²[¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/26 ¤U¤È 07:26:41²Ä 2432 ½g¦^À³
|
¦³¤@±Æ¼Æ¦r¥´¿ù¤F §ó¥¿¦p¤U¡G ¡u16~28Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³34Ó°é°é¡B7Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³39Ó°é°é¡B5Ó¶¥±è¡F¹ï·Ó²Õ¦³39Ó°é°é¡B11Ó¶¥±è¡v À³§ó¥¿¬° ¡u16~28Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³34Ó°é°é¡B7Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³39Ó°é°é¡B6Ó¶¥±è¡F¹ï·Ó²Õ¦³39Ó°é°é¡B15Ó¶¥±è¡v |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/26 ¤U¤È 07:16:18²Ä 2431 ½g¦^À³
|
²q·Q¤j¡A ±z§Ñ¤Fºâ¥d¤èȪº¤½¦¡°Õ¡I¡H X^2 = (O1 ¡V E1)^2/ E1 + (O2 ¡V E2)^2/ E2 ¨â²Õªº¹ê»ÚÈ»P´Á±æȦ³®t²§ªº¸Ü¡A¥d¤èÈ´N·|¼W¥[¡ApÈ·|Åܤp (O1 ¡V E1)»P(O2 ¡V E2)¬O²Ö¿nÈ¡A¦³¨Æ¥óµo¥Í®É¡A¹êÅç²Õ»P¹ï·Ó²Õ³£n¦U§Oºâ¤@Ó (O1 ¡V E1)»P(O2 ¡V E2)¡A³Ì«á²Ö¿nȦAºâ¥X¥d¤èÈ¡C¦]¦¹¤@©wn¦³¨Æ¥óµo¥Í®É¤~·|²Ö¿n¡A¥Ø«eªº¼Æ¾Ú¡A0~16Ó¤ë¨â²Õ¨S¦³®t²§(p13)¡AÁöµM¦b0~16Ӥ몺°Ï¬q¦³³\¦hªº¨Æ¥ó¡A¦ý¨â±ø¦±½u´X¥GÂH¦b¤@°_¡A¦b0~16Ӥ몺°Ï¬q¹ï(O ¡V E)ªº²Ö¿nÈ°^ÄmÁͪñ©ó0¡A16Ó¤ë¥H«á¨â±ø¦±½u¤~¤À¶}¡A³o®É«áµo¥Íªº¨Æ¥ó¹ï(O ¡V E)²Ö¿nȪº¼W¥[¤~¦³À°§U¡A¦ý16~32Ӥ몺°Ï¬q¦]Æ[¹î®É¶¡µuµo¥Íªº¨Æ¥óÁÙ¤£¨¬¡A32Ó¤ë¥H«á¥u¦³§C¤ÏÀ³²Õ¦³2Өƥóµo¥Í¡A¥un®É¶¡©Ôªø¡A¨Æ¥ó·|«ùÄòµo¥Í¡A¨C¥X²{¤@Өƨ£´N¥iºâ(O ¡V E)²Ö¿nÈ¡A¥d¤èÈ´N¤£Â_Åܤj¡APÈ´NÅܤp¤F¡C ¥H¤U´£¨Ñ¤p§Ì¼Æªº¶¥±è»P°é°é¨Ñ±z°Ñ¦Ò¡G 0~16Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³5Ó°é°é¡B13Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³25Ó°é°é¡B18Ó¶¥±è¡F¹ï·Ó²Õ¦³15Ó°é°é¡B17Ó¶¥±è 16~28Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³34Ó°é°é¡B7Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³39Ó°é°é¡B5Ó¶¥±è¡F¹ï·Ó²Õ¦³39Ó°é°é¡B11Ó¶¥±è 28~32Ó¤ë°Ï¬q¡A°ª¤ÏÀ³²Õ¦³17Ó°é°é¡B1Ó¶¥±è¡F§C¤ÏÀ³²Õ¦³9Ó°é°é¡B3Ó¶¥±è¡F¹ï·Ó²Õ¦³13Ó°é°é¡B3Ó¶¥±è 28Ó¤ë¥H«á°Ï¬q¡A¥u¦³§C¤ÏÀ³²Õ¦b¤j¬ù33Ӥ릳2Ó¶¥±è¡A°ª¤ÏÀ³²Õ»P¹ï·Ó²Õ³£¬O°é°é ¥H¹ï·Ó²Õ¦b0~16Ӥ몺°é°é¼Æ¡B¶¥±è¼Æªº¤ñ¨Ò°µ°Ñ¦ÒÈ¡A¤ñ¸û°ª¤ÏÀ³²Õ»P§C¤ÏÀ³²Õ¤À §O¦b¸Ó°Ï¬qªº°é°é¼Æ»P¶¥±è¼Æ¤ñ¨Ò¡A¥i¥H¬Ý¥X¬O§_¦³½²±Ð±Â»¡ªº¡u¬ÛÃö©Ê¡v¥H¤Î¬O§_¦³¡uimmortal tome bias ¡v¦bùØÀY¡C ¥H¹ï·Ó²Õ¦b16~28ªº¤ë°Ï¬qªº¦º¤`µo¥Í¤ñ¨Ò·í°Ñ¦ÒÈ¡A¬Ý°ª¤ÏÀ³²Õ¦b16~28¤ëªº¦º¤` µo¥Í¤ñ¨Ò°°±o¦h§C¡A¥i¥H±oª¾822¦b16~28Ó¤ë³o°Ï¬qµo´§¤F°ªÀø®Ä¡F¬Ý§C¤ÏÀ³²Õ¦b 16~28¤ëªº¦º¤`µo¥Í¤ñ¨ÒĹ¹L¹ï³ø²Õ¡A¨Ï±o§C¤ÏÀ³²Õ¦b0~16Ó¤ëÁöµM¦]¬°¤À²Õ¦Y¤FÁ«¡A ¦b16~28Ó¤ë°Ï¬qùØ¡A¦³¤F822Àø®Äªº¥[«ù¡A¤]¦b28Ó¤ë®É¦b¥Í¦s¾÷²vªïÀY»°¤W¡C 28~32Ó¤ë°Ï¬q¡A§C¤ÏÀ³²Õªº¦º¤`¤ñ¨Ò¤S¼W¥[¤F¡A¹ï·Ó²Õ¤´¨Ì¤@©wªº¤ñ¨Òµo¥Í¡A°ª¤ÏÀ³²Õ¤´µM¬O·¥§Cªºµo¥Í¤ñ¨Ò¡C 32Ó¤ë¥H«áªº¡A°£¤F§C¤ÏÀ³²Õ¦b¤j¬ù33Ӥ릳2Ó¶¥±è¡A¥Ø«e¨S¦³¶¥±è¥i¨Ñ§PŪ¡C ¥H¤W¬O¤p§Ì¼Æªº°é°é©M¶¥±è¡A¤£¤@©w¨CӰϬq³£¼Æ¹ï¡A¦ýÁ`¼Æ¬O¹ïªº¡C ¥H¤W¤]¬O¤p§Ì¹ï°é°é»P¶¥±èªºªºÅé·|¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/26 ¤W¤È 08:18:35²Ä 2430 ½g¦^À³
|
¥xÁÞ¤j¤j «D±`·PÁ±zªº¤ß±o¤À¨É ¥Î¤p©_¤j¤j´£¥Ü , ¨Ì¹Ï©Ò«Ø¥ßªº¸Õºâªí , °ò¥»¤W«Dì©l¼Æ¾Ú , ¥²¦³®t»~ ¥[¤W³oºØ«Ø¥ßªº¹Lµ{ , ¤gªk·Ò¿û«Ü¬O¨¯W , ¤p§Ì¥u¦³«Ø¥ß P. 13 ªº¸Õºâªí ¥H¦¹ªñ¦üºâªí©Òpºâªº P Ȭ° 0.265 , »P¤½¥qµ¹ªº¥¿½TÈ 0.289 , ®tªñ¤@¦¨ ¤p§Ì¦b¼ÒÀÀ¤¤ , ¨Ì¸ê®Æ«e¸m©Î«á¸m¤§¤£¦P , ©Ò¤ÞPªº PÈÅÜ¤Æ , ¬ù²¤¦p¤U : ( ¸ÕÅç²ÕºÙ¥Ò , ¹ï·Ó²ÕºÙ¤A ) ³]¸ê®Æ«e«á¦ì¸m¤w¤jP©w®× , ¥uÀH®É¶¡±À²¾¦Ó¦V«á¥²¾ , ¦b¦¹²¤¤§ ¦Ü©ó¨Æ¥ó¸ê®Æªº¼vÅT (1) ¥Ò¤A¬Ò¸m©ó¦P¤@®É¬q , P ÈÅܤƤ£¤j , ¦ý©ñ¦b«e± , ¥d¤èȸû¤j , ¶V©¹«á¶V¤p (2) ¥Ò¸m«e , ¤A¸m«á , ¥d¤èȬҤñ«e (1)¶µ¬°¤j (3) ¥Ò¸m«á , ¤A¸m«e , ¥d¤èȬҤñ«e (2)¶µ§ó¤j ¨Æ¹ê¤W , ³]¸ê®Æªº«e«á¸m¹ï P ȪºÅܤÆÁÍ¶Õ , ¬ù²¤»P¨Æ¥ó¸ê®Æ¬Û²Å °ß¿W¨Æ¥ó¸ê®Æªº¥d¤èȬҤñ³]¸ê®ÆªÌ , ©ñ¤j¤£¤Ö ©Î³\¼Æ¾Ú¦¨¼ôªº·N²[ , °£¤F«ü¹F¨ìMOS¥~ , P Ȫº¦Ò¼{©Î¤]¥]§t¦b¤º? ¦p¤p©_¤j¤j©Ò±À½× , «e16Ó¤ë´X¤w©w®æ¤£ÅÜ 16Ó¤ë¥H«áªºK-M¹Ï¦p¦ó¨« , ¤£ª¾ , þ¤@Ó³]¸ê®Æ·|Âର¨Æ¥ó , ¤£ª¾ , ¤À¥¬§ó¬O¤£ª¾ , ¤]´N³y¦¨ P ȼÒÀÀªº§xÃø , ¼ÒÀÀ´XµL·N¸q Y¤j®a·Qª¾«Ü²Ê²¤ªºª¬ªp , ¦ü¥i´`¤WzÅܤÆÁÍ¶Õ , ¨Ì¦UºØ±¡§Î¨Ó±À´ú ¦³¤@Ó±¡ªp , °²¦p¸ÕÅç²Õªº³]¸ê®ÆÂର¨Æ¥óªº¼Æ¥Ø¤ñ¹ï·Ó²Õ¤Ö«Ü¦h , ´N©ö³y¦¨¤p P È ¥H¤W¦Û¨¥¦Û»y , ©Î»P¨Æ¹ê¬Û¥h¬Æ»· , ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/25 ¤U¤È 11:09:30²Ä 2429 ½g¦^À³
|
²q·Q¤j §ë¼v¤ù17 ²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS) ¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160)§e²{ªº¼Æ¾Úªº½T¦³¼ÖÆ[ªº²z¥Ñ 1¹êÅç²Õ»P¹ï·Ó²Õ: p È =0.0399 , ·ÀI¤ñ§ó§C¨ì 0.57 , «H¿à°Ï¶¡ 0.33-0.97) ¦b¥h¦~10¤ëData lock ®É ¹êÅç²Õµo¥Í¦º¤`¨Æ¥óªº¤ñ²v¤ñ¹ï·Ó²Õ´î¤Ö43% 2¦³§K¬Ì¤ÏÀ³»PµL§K¬Ì¤ÏÀ³²Õ: p È =0.0207 , ·ÀI¤ñ§ó§C¨ì 0.51 , «H¿à°Ï¶¡ 0.28-0.90 ¦b¥h¦~10¤ëData lock ®É ¦³§K¬Ì¤ÏÀ³²Õµo¥Í¦º¤`¨Æ¥óªº¤ñ²v¤ñµL§K¬Ì¤ÏÀ³²Õ´î¤Ö49 % 3 ±q·ÀI¤ñ¨Ó¬Ý¦]¬°«H¿à°Ï¶¡ < 1 ©Ò¥H³oÓ·ÀI¤ñ¬O½T»{ªº ±q¥h¦~10¤ë¨ì²{¦b¤S¹L¤F11Ó¤ë p È,·ÀI¤ñ,«H¿à°Ï¶¡ ²z½×¤W·|¦]®t²§©Ô¤j³vº¥Åܪº§ó¤p 4§ë¼v¤ù13 p È =0.289 , ·ÀI¤ñ0.79 «H¿à°Ï¶¡ ( 0.51 -- 1.22 ) ¦b¥h¦~10¤ëData lock ®É¹êÅç²Õ224¤Hµo¥Í¦º¤`¨Æ¥óªº¤ñ²v¤ñ¹ï·Ó²Õ124¤H²Õ´î¤Ö29 % ¦ý¦]¨â²Õ¦º¤`¨Æ¥ó¼Æ¤£¨¬ «H¿à°Ï¶¡ > 1 ©Ò¥H³oÓ·ÀI¤ñ¦b¥h¦~10¤ëData lock ®ÉÁÙ¥¼½T»{ §E³Õ´£¨ìªºÀ³¬O«ü¥¼¨Ó¦¡: ¨â²Õ¦º¤`¨Æ¥ó¼Æ¨¬°÷ ,¦p²q·Q¤j©Ò´£³]¸ê®Æ°§C, p È´N·|¹F¼Ð Ó¤H¬d¨ìªº¸ê°T¬O: ·í«H¿à°Ï¶¡< 1 ®É ·ÀI¤ñ¤~¯à³Q½T»{ 5 °²³]§ë¼v¤ù13±q¥h¦~10¤ë¨ì©ú¦~¤G¤ë¼Æ¾Ú¦¨¼ô (¤S¹L¤F16Ó¤ë)¥un¥À¸sÅ骺¯u¥¿®ÄªG¦³®t異¡A¬ã¨sµ²ªGªºpÈ´N·|ÀH µÛ¬ã¨s¼Ë¥»數¼W¥[¦Ó¶V來¶V¤p ½Ð±Ð²q·Q¤j: 1 °²³]§ë¼v¤ù13 ¹êÅç²ÕMOS 52Ó¤ë ¹ï·Ó²ÕMOS 38Ó¤ë p È·|¤p©ó0.05¶Ü ? ®t¶Z14Ó¤ë¤]¤£¤Ö 2 ¸Õºâªí¦³¤¡B¤»¦Ê¦æ ¦³¦óºë´ïªº«ÂI¤À¨É? ¥H¤W¤À¨É ´£¨Ñ°Ñ¦Ò ¦p¦³¿ù½Ð§ó¥¿ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/25 ¤U¤È 09:40:48²Ä 2428 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡G ¤p§ÌÀ´±zªº¶Ç¹F¡AÁÂÁ±z...©e¹ê¬O¤Ó¦hªø´Á§ë¸êªº¯E¤Í¦b³oªÑ»ù§C°g¤§»Ú¡A¯É¯É°±§Q¡A°±·l¥X³õ¡A¤ß¤¤«Ü¤£±Ë... ¦]¤p§Ì¦Û¤v¤]¬O¥Í§Þªù¥~º~¡A©Ò¥H°Ý¤@¨Ç¥i¯à¬O³\¦h¯E¤Í¤]¤£¬O¨º»ò¦³«H¤ßªº°ÝÃD¡A©ß¿j¤Þ¥ÉªºÅý±M׫e½úÌ¡A¦A¤@¦¸ªºÀ°¤j®a½Æ²ß¹L¥h³£°Q½×¹L¤]¤w¦³ªºµª®×¡C ¤]¬O²q·Q¤j«e½úªº´£ÂI¡G¡iÁÙ¬O°ò¥»±¥i·R¡j¡I ¨¯W«e½ú±z¤F¡I ¤]ÁÂÁÂCliff¤j«e½ú ,¤p©_¤j«e½ú¡AÅó±ø±ø¤j«e½ú¡A ¨£¨ì³\¦h¼w°ª±æ²³ªº«e½ú̦A¤@¦¸¶°µ²ªº½Æ²ß¯E¹©°ò¥»±... ¨þ¨þ¡I§Ú¦ò·O´d¡A§Ú¦ò·O´d...·PÁ½Ѧh«e½ú¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/25 ¤U¤È 07:46:40²Ä 2427 ½g¦^À³
|
¥xÁÞ¤j¤j ÁÂÁ±z¦A¦¸¬°¤p§Ì¸Ñ»¡ ·ÀI¤ñ¥i¥HÅý§ÚÌ©úÁA¾ãÓ¹êÅç¹Lµ{¤¤¡A¨CÓ³æ¦ì®É¶¡¥Í¦s²vªº¤ñ¸ûª¬ªp¡A¤]¸û¥i¥H®ø«Ú¿ï¾Ü°¾®t¡H¡I ¤p§Ì¦b¸Õºâªíªº¼ÒÀÀ¤¤¡A´¿Æ[¹î¨ì ¦b©T©wªº¸ÕÅç¼Æ¤U¡A³]¸ê®Æ¦h¡A·|©Ô§C¥d¤èÈ¡] p ȸû¤j ¡^ Y±N³]¸ê®Æ§ï¬°¨Æ¥ó ¡] event ) ¼Æ¡A¥d¤èÈ·|Åܤj ¡] ¦b¼ÒÀÀ¤¤¡A¬Û®tÁÙ¤£¤p ¡^ °ò©ó¸Õºâªí¦³¤¡B¤»¦Ê¦æ¡A¤£«K¦b¦¹¶K¥X ¥»¨Ó¤p§Ì¤]¤£ª¾§Úªº¼ÒÀÀµ²½×¬O§_¦³»~ ¦ý¸g±z½Ð±Ð¤½¥q§E³Õ«á¡A¦ü¥G±o¨ì¦LÃÒ ¦A¦¸·PÁ±z ·q½Ð¤j®a«ü¥¿¡AÁÂÁ¤j®a |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/25 ¤U¤È 06:36:12²Ä 2426 ½g¦^À³
|
²q·Q¤j 1¨º¤Ñ¦³¦n´X²Õ¤H¦b°Ý°ÝÃD, «á±¤S©ñRugo ªº¼v¤ùÁnµªº¤zÂZ, §Æ±æ¨S¦³·|¿ù·N! ¤£¹L±q : ¹ê¥Î¹êÃÒÂå¾Ç¡A¦p¦ó§P讀²ÎpÀË©w ¡X p Ȫº°g«ä ¤¤¦³´£¨ì: p ȬO®Ú¾Ú¥ÀÅé¯u¥¿®ÄªG¨S¦³®t異ªºµêµL°² 說來pºâ¡A©Ò¥H¡G¦pªG¥À¸sÅé¯u¥¿®ÄªG¨S¦³®t異¡A¬ã¨sµ²ªGªºp ȱNÀH¾÷¥X²{¦b0 ¨ì1 ¤§¶¡¡A¸ò¼Ë¥»數¤j ¤p¨S¦³Ãö«Y¡C¥i¬O¥un¥À¸sÅ骺¯u¥¿®ÄªG¦³®t異¡A¬ã¨sµ²ªGªºp È´N·|ÀHµÛ¬ã¨s¼Ë¥»數¼W¥[¦Ó¶V來¶V¤p P13 ¼Æ¾Ú»Ýn¦Aµ¥µ¥ 2§ë¼v¤ù17 ²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS) ¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160)§e²{ªº¼Æ ¾Ú§ë¼v¤ù17 ªº½T¦³¼ÖÆ[ªº²z¥Ñ (¹êÅç²Õ»P¹ï·Ó²Õ: pȤw¸g¤p©ó 0.0399 , ·ÀI¤ñ §ó§C¨ì 0.57 , «H¿à°Ï¶¡ 0.33-0.97) (¦³§K¬Ì¤ÏÀ³»PµL§K¬Ì¤ÏÀ³²Õ: pȤw¸g¤p©ó 0.0207 , ·ÀI¤ñ §ó§C¨ì 0.51 , «H¿à°Ï¶¡ 0.28-0.90) |
|
|
·|û¡G¶³²H·»´10142966 µoªí®É¶¡:2016/8/25 ¤U¤È 05:12:18²Ä 2425 ½g¦^À³
|
¥x¿}¤jÁ¿±o«Ü¹ï ¾A¥Î50% °Æ§@¥Î§C À³²Å¦X±ø¥ó¤F ¦pªGOBI-822³Q¥´ºj ¨º¥H«á¥i¯à¨S¦³ßÓ¼tÄ@·N¿N¿ú¹Á¸Õ§K¬ÌÀøªkªº¬ã¨s¤F§a |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/25 ¤U¤È 04:41:40²Ä 2424 ½g¦^À³
|
¤p©_¤j¤j ÁÂÁ±z¬Ý¨ì¥L¤H©Ò¤£¯à¨£ªº±Ð¾Ç ¬Ý¹Ï»¡¬G¨Æ¡AÁ`ª½«üI«áªº®Ö¤ß«äºû ¤Ó·PÁ±z¤F ¥xÁÞ¤j ±zÂèp¤F ³o»ò¸g¨åȱo³sÁ¿¤d¦¸ªºµ²½×¡A«ç¤£¦»¡©O ¡u......¦o½T»¡·ÀI¤ñ¤w¸g«ÜÅãµÛ¤F¡Aµ¥¨â²Õµo¥Í¨Æ¥ó¼W¥[®ÉP value ´N·|¤U°¡C¡v ®`±o¤p§Ì¤é«ä©]·Q¡A¸Õºâªí¼ÒÀÀ¨ì±á©üÄAË¡A¦n¤£²Ö¤H§r «¢¡I¶}ª±¯ºªº¡A½Ð§O¦b·N ÁÂÁ±zµL¨pªº¤À¨É³o»ò«nªºµ²½× ¤ÓÁÂÁ±z°Õ ¦P®É¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/25 ¤U¤È 02:46:55²Ä 2423 ½g¦^À³
|
999¤j §Aªº°ÝÃD§Ú¨S¦³¦^µª¬O¦]¬°³o¤£¬O°ÝÃD¡A¤ñ50%¾A¥Î¤H¤f³£¤ÖªºÃij£¯à®³ÃÄÃÒ¤F¡A¹³Her2¶§©Ê¨ÅÀùn¤w¤W¥«¨º»ò¦hÁûÃÄ¡A¾A¥Î¤H¤f¤]¥u¦³20%-25% ¡A§O¦AJ«ä¶Ã·Q§xÂZ¦Û¤v¡A§A»¡¹ï¤£¹ï? ±K¤Á°lÂܧë¼v¤ù13»P17ªºpÈ´N¥i¥H¤F¡A¥Í§Þ®i®É§Ú°Ý§E³Õ³o¨â±i¹Ï¡A§Ú»¡P value ÁÙ¨S¦³<0.05¡A¦o½T»¡·ÀI¤ñ¤w¸g«ÜÅãµÛ¤F¡Aµ¥¨â²Õµo¥Í¨Æ¥ó¼W¥[®ÉP value ´N·|¤U° ¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/25 ¤U¤È 01:56:01²Ä 2422 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡G §Ú¤]¹ï·Ó¤F³\¦h¤w®ÖãÃÄÃÒªºÃĹ靈®Ä±wªÌªº¤ñ¨Ò... ·§«ü822/821¦pªG¦³50%ªº±wªÌ¦³Àø®Ä...¬°¦ó¥Ó½ÐÃÄÃÒ·|¦³ºÃ¼{¡H °ß¤@§ä¨ìªº²z¥Ñ¬O¯E¹©¤£¬O°ê»Ú¤jÃļt¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/25 ¤U¤È 12:36:48²Ä 2421 ½g¦^À³
|
¤p©_¤j QQ¤j ·N¥~µo²{: ®³ÃÄÃÒ¤£¥²©Ò¦³¯f¤H³£Æ[¹î¤¦~ ¥H¶P¯e§´ª`®g²G¬°¨Ò¤l PERJETA® +trastuzumab +docetaxel n=402 Ãij满©ú®Ñ (¦³»¡©ú®Ñªí¥ÜÃĤw¤W¥«) ·íªì»P¬ü°êFDA©wªº·ÀI¤ñ¬O0.739 p ≤ 0.0138 ( ¹ê»Ú¬O·ÀI¤ñ¬O0.66 p ≤ 0.0008 ) ¨£Á`¦s¬¡´Á²Ä2¦¸´Á¤¤¤ÀªRªº·ÀI¤ñ¤Îp ȹF¨ì¹w©wªºÀø®Ä¤¤¤î¬É½u p13 ¹êÅç²Õ¦@ 402¤H ¥uÆ[¹î¨ì 113¤H¦º¤`¨Æ¥ó¼Æ (28.1%) ¹ï·Ó²Õ406¤H ¥uÆ[¹î¨ì 154¤H¦º¤`¨Æ¥ó¼Æ (37.9%) (¤£¥²©Ò¦³¯f¤HÆ[¬d¤¦~ ¤w¸g®³¨ìÃÄÃÒ¤F) www.ktgh.com.tw/Public/tbDrug/201506151552555334.pdf «Ü¥©ªº 2016 ASCO §ë¼v¤ù13 ´Á¤¤Á`¦s¬¡´Á¡]·N¹ÏªvÀø±Ú¸s¡^ ¥Ø«e·ÀI¤ñ0.79 «Ü±µªñ¶P¯e§´ 0.739 ¦bµ¥ p È |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/25 ¤W¤È 11:40:18²Ä 2420 ½g¦^À³
|
ÁÂÁÂQQ¤j¥N¬°¦^ÂСI |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/8/24 ¤U¤È 11:49:07²Ä 2419 ½g¦^À³
|
¤p©_¤j: ¤ÏÂФ@ª½¬Ý±zªº¦^ÂÐ, Á`ºâ³q¤F. ÁöµM¹ï¾|¶wªº§Ú¦Ó¨¥½ÆÂø¤F¨Ç, ¦ý¬O°ò¥»ªºÅÞ¿è¤Î¶]¤½¦¡ªº·§©À§ó²M·¡¤F. ¦A¦¸·PÁ±z@¤ß«ü¾É, ·PÁÂ!!! ¶³²H·»´¤j: OS·|°lÂܤ¦~, ¬Oªº, ·|¤@ª½¦b¶]. ¦Ü©óESMO·|¤£·|¦³§ó·sªº¼Æ¾Ú¥X¨Ó, ¤½¥q¨S¤½§i, ©Ò¥H¨Ã¤£ª¾¹D. |
|
|
·|û¡G¶³²H·»´10142966 µoªí®É¶¡:2016/8/24 ¤U¤È 09:31:33²Ä 2418 ½g¦^À³
|
¤p©_¤j ¨º½Ð±Ð¤@¤U ¨º·Ó§A³o¼Ë¤ÀªR MOSÁÙ¬O¦³¦b¶]¶Ü ÁÙ¬O¨ì10¤ë¼Ú¬w¸~½F¨ó·| ¦b¤½¥¬·sªºMOS ½Ð°Ý10¤ë¤½¥¬¼Æ¾Ú«á ·|¦b«ùÄò°lÂܳo300¦h¤HªºMOS¶Ü ¤p§Ì¤£¤~ ½Ð½ç±Ð ÁÂÁ |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/24 ¤U¤È 08:55:37²Ä 2417 ½g¦^À³
|
¤p©_¤j¡A·PÁ±z¸ÔºÉªº¸Ñ»¡¡C°¨©ÔªQªº¨Ò¤lÁ|ªº«Ü¦n¡C¤p§ÌÁŵM¶}®Ô¡A©ú¥Õ¤F¡C¤p§Ì«ôÁ¡A¦A«ôÁ¡C·P®¦¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/24 ¤U¤È 07:35:21²Ä 2416 ½g¦^À³
|
5619¤j¡A Ãö©ó³]¸ê®Æ»Pnumber at riskªºÆ[©À¡A½Ð°Ñ¦Ò¡G ¤p©_10138298 µoªí®É¶¡:2016/6/13 ¤U¤È 05:54:50 ²Ä 1986 ½g¦^À³ ¡u°£¤F¦]¬°drou out¦Ó²£¥Í³]¡A¨º¨Ç¦]¬°Æ[¹î®É¶¡¤Óµu¦Ó³]ªº¡A·|¤£·|¦b®É¶¡±À²¾«á¡A¸Ñ°£³]¡H¡]ÅÞ¿è¤W¬O¡^¡H¡H¡v ±z¥i¥H§â³oÓ¦s¬¡¤ÀªR·Q¹³¦¨°¨©ÔªQÁɶ](¤ñ¨º¤@²Õ¶]¤ñ¸û»·ªº°¨©ÔªQ¡A¦Ó¤£¬O¤ñ¶]§Öªº°¨©ÔªQ)¡A¤À¦¨¹êÅç²Õ»P¹ï·Ó²Õ¡A¦ý³oÓ°¨©ÔªQÁÉ°Ñ»Pªº¶]ªÌ¯É¯É¦b¤£¦Pªº®É¶¡ÂI¶i¤J¤ñÁÉ(¶i¤JÁ{§Éªº®É¶¡³£¤£¬Û¦P)¡A¦ý³£±o±q°_ÂI¶}©l¶]¡A¨C¦ì¶]ªÌ³£¥H¬Û¦Pªº¡B¤@©wªº³t«×©¹«e¶]¡AµM«á´ú¶q¨C¦ì¶]ªÌ³Ì»·¶]¦h¤Ö¶ZÂ÷»·´N¦A¤]¶]¤£°Ê(¶]¤£°Ê´N¬ö¿ý¨Æ¥óµo¥Í¨Ã¥B¬ö¿ý¶]ªº¶ZÂ÷---OS)¡C¦³¨Ç¶]ªÌ¶]¤@°}¤l´N¨M©w±óÁÉ(¥Ã»·ªº³]¸ê®Æ¡A¤]´N¬Odrou out)¡A¦]¬°¶i¤J¤ñÁɪº®É¶¡¯É¯É¤£¦P¡A¦b2015/10(15ÂI10¤À)³oÓdata lock®É¶¡ÂIÆ[¹î¡A¤ñ¸û¦¶i¤J¤ñÁɪº¶]ªÌY¤£¬O¤w¸g¬ö¿ý¬°¶]¤£°Êªºµo¥Í¨Æ¥ó¡A´N¬O¦¨¬°28¤½¨½¥H«á¤´µMÄ~Äò¤ñÁɪº¶]ªÌ(28Ó¤ë¥H«áªº³]¸ê®Æ)¡F¤ñ¸û±ß¶i¤J¤ñÁɪº¶]ªÌ¡A¦]¬°¶i¤J¤ñÁɪº®É¶¡¸û±ß¡A¤j³¡¥÷¤´¦b16~28¤½¨½ªº¶]¹D¤W(¤´¬O16~28Ӥ몺³]¸ê®Æ)¡A¦pªG¨ì2016/10(16ÂI10¤À)°µÆ[¹î¡A³o¨Ç쥻¦b16~28¤½¨½(16~28Ó¤ë)ªº¶]ªÌ¡A¦³³¡¤À·|¶]¤£°Ê¦¨¬°OS¸ê®Æ¡A¶]±o°Êªº´N¯É¯É¶i¤J28~40¤½¨½Ä~Äò©¹«e¶](¦b2016/10ªº¤U¤@±iKM¹Ï¡A¨S¦³¦º¤`¨Æ¥óªº´N¦¨¬°28~40Ӥ몺³]¸ê®Æ)¡C ©Ò¥H¡AÆ[¹î®É¶¡¤Óµu¦Ó³]ªº¡A¨Ò¦p2015/10³oӮɶ¡ÂI¦b18Ó¤ëÓ³]ªº±wªÌ¡A¦pªG¦b2016/10³oӮɶ¡ÂI¡A¸g¹L¤@¦~¨Ó¨S¦³µo¥Í¦º¤`¡A¦b2016/10ªºOS¹Ï¤W¡A´N¦¨¬°30Ӥ몺³]¸ê®Æ¡A°£«D¦³µo¥Í¦º¤`¡A¤£µM´N¤@ª½³]¡A³]ªº¼Æ¾ÚȤ]¤£Â_¼W¥[¡C ¡u¦]¬°drou out¦Ó²£¥Í³]ªº¼Æ¶q¨S¨º»ò¦h¡A¨º»ò¨ä¥L¤j³¡¤À³]¬O¨Ó¦Û©ó¡§¦]¬°Æ[¹î®É¶¡¤Óµu¦Ó³]¡¨¶Ü¡H¡H¡v ¬O¡C ¡u§Ú̬ݨ쪺K-M curve Á`¦s¬¡´Á%¹Ïªí¡A¬O¨Ì¾Ú2015/10 data lockªº¸ê®Æ¡C¨º»ò¡A¹L¤F¤@¦~«á¡A°²³]¨Ì¾Ú¤µ¦~2016/10 data lockªº¸ê®Æ¡A©Òø»sªº·s¹Ïªí¦±½u·|¤£·|¾ãÓ¤£¦P¡H©ÎªÌ¬O«e¬q¡]0¡ã28Ó¤ë¡^¬Û¦P¡A¥u¦³«á¬q§ó·s¡H¡H¡]¦pªG³]¸ê®Æ¦]®É¶¡±À²¾¦Ó¸Ñ°£³]¡A¨º»ò¹Ïªí¦±½u·|¾ãÓ¤£¦P¤~¬O¡^¡v «e15Ӥ몺¹Ï«¬100%¬Û¦P¡A¤£·|¦AÅܰʤF¡C16~28Ӥ몺³¡¤À¡A¦]¬°2013/6¤ë¥H«e¦¦¬®×ªº¤j¬ù200¤H(200/348=57.5%)¤w¸g§¹¥þ¨«§¹28Ó¤ë¡A¤w¸gµe¤U¤F¥L̦b16~28Ӥ몺¦s¬¡¾÷²vªº¨¬¸ñ¡A±ß¦¬®×ªº¤j¬ù148¤H(42.5%)¦pªG¦s¬¡¾÷²vªº¨¬¸ñ»P¦¦¬®×ªº200¤H«Ü±µªñ¡A«h2016/10¦b16~28Ӥ몺¹Ï«¬·|«Ü±µªñ2015/10ªº¹Ï«¬¡A¥u¬O2015/10¬Ý¨ìªº¹Ï³q±`¬O´XÓ¥¦æªº°é°éµM«á¤@Ó¸û°~ªº¶¥±è¤U°¡A2016/10·|Åܦ¨¦³¸û¦hªº¤p¶¥±è¸H¨B¤U°¡A¦ý¦b16~28Ó¤ë¤w¸g¬Ý¤£¨ì³]ªº°é°é¤F¡C28~32Ó¤ëÁÙ·|¦³¨ÇÅÜ°Ê¡A¦]¬°¦¦¬®×ªº200¤H¤]ÁÙ¨S¨«§¹³oӮɶ¡°Ï¬q¡A32Ó¤ë¥H«áªº¹Ï«¬«h¨S¤Hª¾¹D¡C ¡uMOS«üªº¬O¤¤¦ì¼ÆªºÁ`¦s¬¡´Á¡C¥H°ª¤ÏÀ³²Õ©M§C¡]µL¡^¤ÏÀ³²Õ¦Ó¨¥¡A¬O²Ä56¦ì¦º¤`¨Æ¥óªÌªºÁ`¦s¬¡´Á¶Ü¡H¥HASCO¹Ïªí¼Æ¦r¨Ó¬Ý¡A§Y¨Ï¸g¹Lªº¤ë¼Æ¨ì60Ó¤ë©Î§ó¤[¡A¤]¨£¤£¨ì²Ä56Ó¦º¤`¨Æ¥ó¡A¦]¬°number at risk©Ò³ÑµL´X¡H¡H©ÎªÌ¡A³]¸ê®ÆªÌªº¦º¤`·|¯Ç¤J¨Æ¥ó¡]¶¥±è¡^¶Ü¡v ¦³³]¸ê®Æªº¸Ü¡A´N¤£·|¬O²Ä56¦ì¡A·|¤ñ²Ä56¦ì¦¤@¨Ç¡C2015/10¬Ý¨ìªº¹ÏÁÙ¤£¬O³Ì²×¹Ï«¬¡AÀHµÛ®É¶¡±À²¾¡A¥Ø«e¬Ý¨ìªº16~28Ӥ몺³]·|¶i¤J28~40Ó¤ë¡A28~56Ӥ몺³]·|¶i¤J40~68Ӥ몺¼Æ¾Ú¡A©Ò¥H¤U¤@±iOS¹Ï¦b4XÓ¤ë¡B5XӤ몺number at risk³£·|¤j´T¼W¥[¡C Neilwang¤j¡A ¦s¬¡¾÷²vªººâªk½Ð°Ñ¦Ò www.cde.org.tw/Content/Files/Knowledge/b0801107-dd21-41ef-8c7d-4c6c2edf1bd7.pdf stat.ethz.ch/education/semesters/ss2011/seminar/contents/presentation_2.pdf |
|
|
·|û¡Gneilwang10142859 µoªí®É¶¡:2016/8/24 ¤U¤È 06:21:48²Ä 2415 ½g¦^À³
|
¤p©_¤j¡G Y®Ú¾Ú ¦U¦ì¤j¤j¦b0-16Ӥ붡¼Æ¥Xªºµ²ªG 13Ó¦º¤`¨Æ¥óµo¥Í¡A5Ó³]µo¥Í ¨º¦b²Ä16Ó¤ëµo¥Í¦bOS¹ÏÁa¶bªº Á`¦s¬¡²v(%)ªººâªk¬O ²Ä16Ó¤ëÁ`¦s¬¡²v(%)=1-13/(112-5)=87.85% ³o¼Ëºâ¹ï¶Ü |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/24 ¤U¤È 02:39:36²Ä 2414 ½g¦^À³
|
¥xÁÞ¤j¤j¡G «e½ú¡AÁÂÁ±z¦A²`¤Á¸ÑÄÀ±Ð¾É±ß½ú¡C §Ú쥻¤]¬O¥H¦¹¹Ïªí¸ÑÄÀ¬°...´Á¤¤§Y«K¬O§C¤ÏÀ³²Õ¸ò¹ï·Ó²Õªº¹ï¤ñOS¤]¬O´Â¥¿¦Vµo®iªºÁͶÕ... ¦ó¨Ó¤§¦U¦Û¸ÑŪªºªÅ¶¡...¡H PFSÀ³¸Ó¥u¬O»XÃøªÌ³q©¹OSªº¾ô¬q...¥H¦Û¤vªº¸g¾ú§ó²`ª¾¨üÃøªÌ¦bªvÀø¹Lµ{¤¤...n»X¨üªº¬O¤°»ò¡H »Ýnªº¬O¤°»ò¡H¬ß±æªº¤S¬O¤°»ò¡H «e½ú¡G¥H§Ú¦Û¤v¤åª¼¦¡ªº¤ñ¹ï...¦Û¤v¦³Óµ²½×¡G OBI 822/821¥H³o¦¸Á{§É³]pÁö»¡¤£§¹µ½¡A¦ý¥H¼Æ¾Úµ²ªG...¤]¥i¥H»¡¬O¨C2Ó±wÃøªÌ¡A·|¦³¤@¦ì·|±o±Ï... ¤]´N¬O»¡¹ï50%ªº±wªÌ¬O¦³«D±`¦nªºÂåÀø®ÄªG¡C ¤£ª¾³oÓµ²½×¦¨¤£¦¨¥ß¡H ¦AªÌ´N®ÖãÃÄ«~¤W¥«¾÷ºc¡A¦b¹L©¹ªº¬ö¿ý¨Ó¤ñ¹ï... Á{§É¹êÅ窺µ²ªG¬O50%ªº±wªÌ¾A¥Î... ³o®Ö㪺¾÷·|°ª¶Ü¡H ¤p©_¤j«e½ú¡GÁÂÁ¡A¯uªºÁÂÁ±z̳o¨Ç¨ã¦³±M·~ª¾ÃѪº«e½ú¤@¸ôªº§ß«ù¡A±Ð¨|¡C ¥H¤wª¾ªº¼Æ¾ÚÅã¥Ü¹ï·Ó°_¨Ó¡A±ß½ú¥H³oºØ50%±wªÌªº¦³¥¿±Àø®Ä©Ê°µµù¸Ñ...¬O¥i¥H¦¨¥ß¶Ü¡H ½Ð«ü¾É¡CÁÂÁ±z... °w¹ï±ß½ú¦Û¤v¤gªk¹ï·Ó¤U¨Óªº¦Û§Ú¸ÑÄÀ...¦A¦¸¦b¦¹¸ÛÀµªº½Ð±Ðºô¤W½Ñ¦h±M¬ã«e½ú¡A°µ¦h¤è«ü¾É«ü¥¿¡C ·PÁ«e½úÌ¡C |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/24 ¤U¤È 01:57:27²Ä 2413 ½g¦^À³
|
¤p©_¤j¡A«D±`·P¿E±z¤£¹½¨ä·Ðªº¸Ñ»¡¡C¤p§Ì¥J²Ó¦a¼Æ¤F¦U°Ï¶¡ªº¶¥±è©M°é°é¡A³o³¡¤À²¤¦³©Ò±o¡C¦ý¬O¤p§Ìªº«ä·QÁÙ¦³¤@¨Ç¡§Ãö¸`¡¨¨S¦³¥´³q¡A¥HP©ó¾ãÅ骺§t¸q¤´µMÂaÄg¥¼¸Ñ¡A«Ü§xÂZ¤p§Ì¡C¤p§Ì«_¬N½Ð±Ð±z´XÓ°ÝÃD¡AÀµ½Ð±z«üÂI¡C¸U¤À·P¿E¡C number at riskªº¼Æ¦r¤U°¡A¬O¶¥±è¼Æ¥[°é°é¼Æ¬°´î¶µªºµ²ªG¡C¦Ó§Y«K¦b°ª¤ÏÀ³²Õ¡A³]¼Æ¦b16Ó¤ë«á¤]²r¼W¡A§Ö©ó¦º¤`¨Æ¥ó¼Æ¡A¨Ï±onumber at riskªº¼Æ¦r¨³³t¤U°¡C¤p§ÌªººÃ´b¬O¡G 1 °£¤F¦]¬°drou out¦Ó²£¥Í³]¡A¨º¨Ç¦]¬°Æ[¹î®É¶¡¤Óµu¦Ó³]ªº¡A·|¤£·|¦b®É¶¡±À²¾«á¡A¸Ñ°£³]¡H¡]ÅÞ¿è¤W¬O¡^¡H¡H 2. ¦]¬°drou out¦Ó²£¥Í³]ªº¼Æ¶q¨S¨º»ò¦h¡A¨º»ò¨ä¥L¤j³¡¤À³]¬O¨Ó¦Û©ó¡§¦]¬°Æ[¹î®É¶¡¤Óµu¦Ó³]¡¨¶Ü¡H¡H 3. §Ú̬ݨ쪺K-M curve Á`¦s¬¡´Á%¹Ïªí¡A¬O¨Ì¾Ú2015/10 data lockªº¸ê®Æ¡C¨º»ò¡A¹L¤F¤@¦~«á¡A°²³]¨Ì¾Ú¤µ¦~2016/10 data lockªº¸ê®Æ¡A©Òø»sªº·s¹Ïªí¦±½u·|¤£·|¾ãÓ¤£¦P¡H©ÎªÌ¬O«e¬q¡]0¡ã28Ó¤ë¡^¬Û¦P¡A¥u¦³«á¬q§ó·s¡H¡H¡]¦pªG³]¸ê®Æ¦]®É¶¡±À²¾¦Ó¸Ñ°£³]¡A¨º»ò¹Ïªí¦±½u·|¾ãÓ¤£¦P¤~¬O¡^ 4. MOS«üªº¬O¤¤¦ì¼ÆªºÁ`¦s¬¡´Á¡C¥H°ª¤ÏÀ³²Õ©M§C¡]µL¡^¤ÏÀ³²Õ¦Ó¨¥¡A¬O²Ä56¦ì¦º¤`¨Æ¥óªÌªºÁ`¦s¬¡´Á¶Ü¡H¥HASCO¹Ïªí¼Æ¦r¨Ó¬Ý¡A§Y¨Ï¸g¹Lªº¤ë¼Æ¨ì60Ó¤ë©Î§ó¤[¡A¤]¨£¤£¨ì²Ä56Ó¦º¤`¨Æ¥ó¡A¦]¬°number at risk©Ò³ÑµL´X¡H¡H©ÎªÌ¡A³]¸ê®ÆªÌªº¦º¤`·|¯Ç¤J¨Æ¥ó¡]¶¥±è¡^¶Ü¡H¨ä¹ê³o¬O¤Þµo¤p§Ì¤W¦CºÃ°Ýªº³Ìªì¨Ó¥Ñ¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/24 ¤U¤È 12:57:02²Ä 2412 ½g¦^À³
|
999¤j §ë¼v¤ù17 ¨ã§K¬Ì¤ÏÀ³¨ü¸ÕªÌ¨äOS ´Á¤¤Àò©úÅã§ïµ½ÁÍ¶Õ 1±q¨Æ¥óÁ`¼Æ¨Ó¬Ý¨S¦³²£¥Í¨¬°÷§ÜÅé®Ä»ùªº¦¸±Ú¸sµo¥Í¨Æ¥óÁ`¼Æ¤ñ²v¤ñ¦w¼¢¾¯²Õ(PBS)§C 2±q´Á¤¤Á`¦s¬¡´Á¥i¬Ý¥X§K¬ÌÀøªkOSÀu¶Õªº¯S©Ê ,¥þ²y¬ã¨s§K¬ÌÀøªkªº±M®a, FDA±M®a³£¤w¸gª¾¹D³oºØ²{¶H OPT-822/821 ¤ÏÀ³ªÌ (n = 112) ¨Æ¥óÁ`¼Æ 21 (18.75%) OPT-822/821 µL¤ÏÀ³ªÌ (n = 112) ¨Æ¥óÁ`¼Æ 29(25.89%) ¦w¼¢¾¯(PBS) (n= 124) ¨Æ¥óÁ`¼Æ 35 (28.23%) 3 ¤ÏÀ³ªÌvs. ¦w¼¢¾¯¤§ ·ÀI¤ñ 0.57 (0.33 ¡V0.97) p = 0.0399 ·ÀI¤ñ»PPȦb´Á¤¤¤ÀªR¥H´£«e¹F¼Ð ÀHµÛ¨Æ¥ó¼W¥[ ¦pªG®t¶Z¦A©Ô¤j PÈ»P·ÀI¤ñ¤]·|§ó§C 4 OPT-822/821¤ÏÀ³ªÌvs.µL¤ÏÀ³ªÌ 0.5104 (0.2887-0.9025) p = 0.0207 ·ÀI¤ñ»PPȦb´Á¤¤¤ÀªR¥H´£«e¹F¼Ð ÀHµÛ¨Æ¥ó¼W¥[ ¦pªG®t¶Z¦A©Ô¤j PÈ»P·ÀI¤ñ¤]·|§ó§C 5 ·ÀI¤ñ 0.57 ²©ö¨Ó»¡´N¬O¨â²Õ¤ñ¸û¦bÁ`¦s¬¡´Á¤è±¥i°§C43%¦º¤`·ÀI 6 ³o¥u¬O³æÃĪvÀøªº®ÄªG, ÁÙ¨S¦³Áp¦X¥ÎÃÄ ,³o¤@ÂI«ÜÃöÁä |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/24 ¤U¤È 12:22:55²Ä 2411 ½g¦^À³
|
QQ¤j¡A ¡u¬°¦ó¶¥±èªº°ª«×³£¤£¬Û¦P, ¦³ªº°ª, ¦³ªº§C ? ¨C¤@Ó³æ¤@®ÉÂIªº¶¥±è¬O¥Nªí"¢°"¤£¬O¶Ü ? ¨º¬°¦ó¦³°ª§C©O¡H¡@°ª§Cªº¤£¦P¹ï¢H³y¦¨«Ü¤jªº¼vÅT©O. ¡v ³o¬O³]¸ê®Æªº¼vÅT¡A¦pªG¤@Ó¹êÅç²Õ§¹¥þ¨S¦³³]¸ê®Æ¡A¬J¨S¦³drou out¡A¥B¤@ª½µ¥¨ì©Ò¦³±wªÌ³£µo¥Í¨Æ¥ó¤~²Îp¤ÀªR¡A¨º»ò¨CÓ¶¥±è¤U°ªº°ª«×·|§¹¥þ¤@¼Ë¡AnÓ±wªÌ°Ñ»P¹êÅç¡A¨CÓ¶¥±èªº°ª«×³£¬O1/n¡A¦@¤U°nÓ¡A±q¤@¶}ÀYªº¾÷²v=1¡A¨CÓ¶¥±è¤U°1/n¡A³Ì«á¤@Ó¤U°§¹¤F¡A¾÷²vÈè¦n=0 ¦ý¹ê»Ú¤W¨S¦³¤@ÓÁ{§É®ÉÅ秹¥þ¨S¦³³]¸ê®Æªº¡A³]¸ê®Æµo¥Í®É¡A´N¹º¤@Ó°é°é¡A¾÷²vȤ£¤U°¡A¦]¬°¨S¦³µo¥Í¦º¤`¨Æ¥ó¡A¦ý³]¸ê®Æ¥»¨¤]¬O¤@ӼƾڡA¦û¤F¹Ïªí¤U¤ènumber at risk¤@ӼƾڡAY¦b¬YӮɶ¡°Ï¬q§e²{¤F³\¦hªº³]¸ê®Æ¡A·|Åý¤U¤è¹Ïªíªºnumber at riskªº¼Æ¦r¨³³t¤U°¡AÁöµM·í¤U¾÷²vȨS¦³¤U°¡A¦ý³]¸ê®Æ¬O§âªí¹F¤U°ªºÅv§Q¥æµ¹«á±µo¥Í¨Æ¥óªº±wªÌ¡A¦]¦¹«á¨Óµo¥Í¨Æ¥óªº±wªÌªº¤U°Åv«·|¼W¥[¡C Á|§C¤ÏÀ³²Õ¬O³Ì©úÅ㪺¨Ò¤l¡A¤@¶}©l§C¤ÏÀ³²Õªº²Ä¤@Ó¶¥±è¤]¬O¤U°1/112=0.89%¡A¦ý¦]¬°§C¤ÏÀ³²Õªº³]¸ê®Æ«Ü¦h¡A¥H¤ÎÀHµÛ®É¶¡¶bµo¥Íªº¦º¤`¨Æ¥ó¡A¨ì28Ó¤ë®É¡A§C¤ÏÀ³²Õªºnumber at risk¥u³Ñ¤U24¡A28Ó¤ë®É¡A§C¤ÏÀ³²Õ¹ïÀ³ªº¾÷²vȤj¬ù=66%¡A¦¹®É¥un¤@¦³¶¥±è¤U°¡A¸Ó¶¥±è¤U°ªºÅv«´N¬O66%/24=2.75%¡A©Ò¥H±z¤~·|µo²{¶¥±è¤U°°ª«×¤£¤@¼Ë¡A¨Æ¹ê¤W¬O«á±ªº¶¥±è¤U°°ª«×·|¤ñ«e±¶V¨Ó¶V°ª¡A³o³£¬O³]¸ê®Æªº¼vÅT¡A¦ý¥u¦³³o¼Ë³B²z¤~¬O¤½¥¦X²zªº¡C chen6053¤j¡A ±z´x´¤¦ípºâ¶¥±èªº§Þ¥©¤F¡I ¦b°ª¤ÏÀ³²Õ0~16Ӥ뤤¡A¦@¦³18Ó¼Æ¾Ú ¦b³oӰϬq§Úºâªº¶¥±è¬O13Ó¡A 13»P12ªº®t²§¡A¤p§Ì²qÀ³¸Ó¬O°ª¤ÏÀ³²Õ¦³¤@¤p¬q¶¥±è³Q¹ï·Ó²Õªº°é°éµ¹»\¦í¤F¡A¤£©ö¼Æ²M·¡¡C¦ý¦]¬°°ª¤ÏÀ³²ÕªºÁ`¶¥±è¼Æ=21¡A§Ú«á¨Ó¼Æ¤F16~28Ó¤ë+¤j©ó28Ӥ몺¶¥±è¦@¦³8Ó¡A¦]¦¹¤p§Ì´N²q0~16Ӥ몺°Ï¬q¦³13Ó¡C ©Ò¥H±o¨ì¤F0~16Ó¤ë¡A°ª¤ÏÀ³²Õ¦³13Ó¦º¤`¨Æ¥óµo¥Í¡A5Ó³]µo¥Í ¦]¬°2014/6¦¬®×~2015/10 data lock=16Ó¤ë¡A¦]¦¹°ª¤ÏÀ³²Õ°£¤F2014/7¥i¯à¦¬ªº¨º1¦ì©Î2¦ì±wªÌ¬O¦]¬°Æ[¹î®É¶¡¤Óµu¦Ó³]¥~¡A¹ê»Ú¤W¥i¯à5¦ì©Î4¦ì©Î3¦ì¬O¦]¬°drou out¦Ó²£¥Í³]¡C¦]¬°2014/7³Ì«á¤@Ӥ리®×ªº±wªÌ¼Æ¶q«Ü¤Ö¡A¥L̦b¹Ï«¬¤W´X¥G¥þ³¡³£¬O¥H15~16Ӥ몺³]¸ê®Æ(°é°é)§e²{¡A¦b¹Ï¤Wn¤À¿ë15~16Ӥ몺°é°é¼Æ¥Ø¦³´XÓÃø«×«Ü°ª¡A¦]¦¹±N³o2014/7¦¬®×ªº±wªÌ©¿²¤¤£°µ¤ÀªR·|¤ñ¸û²¤Æ¡C ¦]¦¹¡A±oª¾¡A °ª¤ÏÀ³²Õ¦@112¤H¡A¦b0~16Ó¤ë³oӮɶ¡°Ï¬qªº¦ÒÅç¡A¦³13¦ì¦º¤`¡A5¦ìdrou out¡A¦³112-18=94¦ì¶i¤J16~28Ó¤ë®É¶¡°Ï¬qªº¦ÒÅç¡C 999¤j¡A ¥²¶·¼Æ¥X¤T²Õ¤À§O¦b0~16Ó¤ë¡B16~28Ó¤ë¡B¤j©ó28Ó¤ë¤TӮɶ¡°Ï¬qªº¶¥±è»P°é°é ¤~¯à°µ¤ñ¸û¥¿½Tªº§PÂ_¡A¥Ø«e¹Ï¤WÅã¥Üªº¡A§C¤ÏÀ³²ÕÁÙ¬O²¤¿éµ¹¹ï·Ó²Õ¡A¦ý¹ê»Ú¤W822¦b§C¤ÏÀ³²Õ¤]¦³Àø®Ä¡A¥u¬OÀø®Ä¨S¦³°ª¤ÏÀ³²Õ¨º»ò¤j¡C ¤W±ªº¤º®e±z°Ñ¦Ò¬Ý¬Ý¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/24 ¤U¤È 12:05:25²Ä 2410 ½g¦^À³
|
999¤j ¨ã§K¬Ì¤ÏÀ³¨ü¸ÕªÌ¨äOS´Á¤¤Àò©úÅã§ïµ½ÁÍ¶Õ ±q¨Æ¥óÁ`¼Æ¨Ó¬Ý µL¤ÏÀ³ªÌµo¥Í¨Æ¥óÁ`¼Æ¤ñ²v¤ñ¦w¼¢¾¯(PBS) OPT-822/821 ¤ÏÀ³ªÌ (n = 112) ¨Æ¥óÁ`¼Æ 21 (18.75%) OPT-822/821 µL¤ÏÀ³ªÌ (n = 112) ¨Æ¥óÁ`¼Æ 29(25.89%) ¦w¼¢¾¯(PBS) (n= 124) ¨Æ¥óÁ`¼Æ 35 (28.23%) ¤ÏÀ³ªÌvs. ¦w¼¢¾¯¤§·ÀI¤ñ0.57 |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/24 ¤W¤È 10:55:32²Ä 2409 ½g¦^À³
|
¤p©_¤j«e½ú... ÁÂÁ±zªº´£ÂI... §Ú«·s¨Ì±zªº«ü¾É¬Ý¹Ï»¡¬G¨Æªºµ²ªG... ³o¹ï¤ñ°_¨Ó¡A¹êÅç²Õªº§C¤ÏÀ³...¦ü¥GOS¤]¤ñ¹ï·Ó²Õnªø...¡H ¤£ª¾³oӬݪk¥¿¤£¥¿½T¡H ½Ð«ü±Ð¡C ¦³¤@¸sºë^ªº¯E¤Í«e½ú¡A¤@ª½¦uÅ@µÛ¦p¦P¥Í§Þ¤åª¼ªº¯E¤Í¡A±ß½ú¤@ª½¤ß¦s·P¿E... ±`«Ü·P°Ê...«D±`·PÁ¡C ¥xÁÞ¤j«e½ú¡ACliff¤j«e½ú...½Ñ¦h«e½ú...¨¯W¤]©e©}±z̤F¡I ÁÂÁ¡AÁÂÁ¡I |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/8/24 ¤W¤È 09:12:39²Ä 2408 ½g¦^À³
|
ÁÂÁ¤p©_¤jªº¸Ñ»¡ |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/8/23 ¤U¤È 11:34:44²Ä 2407 ½g¦^À³
|
¤p©_¤j¤j§A¦n °ª¤ÏÀ³ 0~16Ӥ릳112-94=18Ó¼Æ¾Ú ¶¥±è12+°é°é6=18 ³o¼Ë¹ï¶Ü ÁÂÁ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/8/23 ¤U¤È 11:21:53²Ä 2406 ½g¦^À³
|
¤p©_¤j: ÁÂÁ±z@¤ßªº«ü¾É. ³o¤¤¶¡¼Æ¦rªºÅܤÆ, ¤]¬O«ä¯Á«Ü¤[¤~ºCºCÅé·|¥X±zn§Ú¬ÝªºªF¦è. ¼Æ¦r¤ºÁÙ¦³¼Æ¦r, ¯u¦³·N«ä. ¤j·PÁÂ°Õ ! ÁÙ¦³¤@Ó¤p¤pªººÃ°Ý, ½Ð±Ð¬°¦ó¶¥±èªº°ª«×³£¤£¬Û¦P, ¦³ªº°ª, ¦³ªº§C ? ¨C¤@Ó³æ¤@®ÉÂIªº¶¥±è¬O¥Nªí"¢°"¤£¬O¶Ü ? ¨º¬°¦ó¦³°ª§C©O¡H¡@°ª§Cªº¤£¦P¹ï¢H³y¦¨«Ü¤jªº¼vÅT©O. |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/23 ¤U¤È 11:09:57²Ä 2405 ½g¦^À³
|
123¤j¡A 0¡ã4Ӥ룸¼Æ¡A³o¼Ë¼Æ±o¤Ó²Ó¤F 0¡ã16Ӥ룸¼Æ¸û¦³·N¸q¡A¦]爲2014/6¦¬®×¡ã2015/10 data lock¬O16Ó¤ë 16¡ã28Ӥ룸¼Æ¤]¦³·N¸q¡A¦]¬°2013/6¦¦¬®×¡ã2015/10 data lock¬O28Ó¤ë ª½½u£¸±øªí¥Ü¥u¦³³]¡A¨S¦³¦º¤` |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/8/23 ¤U¤È 11:07:09²Ä 2404 ½g¦^À³
|
Doan, Thao ³o¬O¤°»ò®Ñ§r |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/23 ¤U¤È 11:02:52²Ä 2403 ½g¦^À³
|
ÁÂÁ¤p©_¤jªº¸Ñ´b §A»¡ªº¨S¿ù¥u¬ÝOS´N¦æ¡AOS¤~¬O822ªº»ùÈ©Ò¦b(¯à¼µ¦h¤[¤£¬OÀù¯g¯f±w¯u¥¿nªº,¯à¬¡¦h¤[¤~¬O¯u¥¿¤º¤ßnªº) Ó¤H¨ä¥L¸É¥R: ¨ÅÀùOBI822ªº¤»°ª ¥|§C ¤@¼ç¤O ¤»°ª:¦w¥þ©Ê°ª,¥Í¬¡«~½è°ª ,ªø´Á¦s¬¡²v°ª,°ª´¼°]«OÅ@,±M¤@©Ê°ª(Globo H ¨t²ÎÁÞ§Üì),°ª¦X§@±ÂÅvª÷¼ç¤O ¥|§C:¤¤§CÃÄ»ù¤£¨ü¬ü°êÁ`²Î¤j¿ï¶D¨D°§CÃÄ»ù¬F¨£ªº¼vÅT,§C¥´°w®É¶¡,§C¥´°w¦¸¼Æ,§C®aÄÝ·ÓÅUt¾á ¤G¼ç¤O:AdagloxadSimolenin ¦³¼ç¤Oµo®i¬°Blockbuster ÃĪ« ¥»ª©¯E¤Í¹ï³o¨â±i»ùȳs«°ªº¹Ïªín¦h¬Ý´X²´ §ë¼v¤ù13 ´Á¤¤Á`¦s¬¡´Á¡]·N¹ÏªvÀø±Ú¸s¡^ §ë¼v¤ù17 ²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS) ¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160) |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/8/23 ¤U¤È 07:36:15²Ä 2402 ½g¦^À³
|
¬O¤£¬O¶g´Á¤@±ø½uªºnºâ0¶¥±è¡A©Ò¥H°é°é¬O³]¸ê®Æ¡A©Ò¥H¤U³´ªº¼Æ¾Ú¬O¥Î¶¥±è»P°é°éºâ¥X¨Óªº.... |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/8/23 ¤U¤È 07:22:02²Ä 2401 ½g¦^À³
|
¤p©_¤j §ÚÁÙ¬O¤£¤F¸Ñ³o¸Ìªº¶¥±è(¦º¤`)©M°é°é(³])¸ò¤U±ªº¼Æ¾Ú¦³¦óÃö«Y? ¨Ò¦p°ª¤ÏÀ³0-4=112-110=2Ó¼Æ¾Ú ¬Ý¤@¤U°ª¤ÏÀ³0-4Ó¤ë¬O¤@Ó¶¥±è(¦º¤`) 2Ó°é°é(³]) ¨º³o¥NªíÔ£?¤£¦n·N«ä³á |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/23 ¤U¤È 06:32:22²Ä 2400 ½g¦^À³
|
123¤j¡A ±z»¡ªº¨S¿ù¡A6/15ªº^¤åª©¸ÑªR«×¦n¤S¦³¹ï»ô ©Ò¥H¥Î³oÓÀɮײ´·ú¤£¦Y¤O ¥xÁÞ¤j¡A ¡u©Ò¥H18Ó¼Æ¾Ú = 0~16Ó¤ë®É¶¡°Ï¬q¤º ¶¥±è¼Æ(¦º¤`¨Æ¥ó)+°é°é¼Æ(³]¸ê®Æ) 18Ó¼Æ¾Ú ´N¬O number at risk ³o¼Ë¹ï¶Ü¡H¡v ¨S¿ù ¤£¹L¡A°®¯Ü§Ñ±¼¡unumber at risk¡v³oÓµü·J¦n¤F ¥ô¦ó®É¶¡°Ï¬qªº¶¥±è¼Æ(¦º¤`¨Æ¥ó)+°é°é¼Æ(³]¸ê®Æ)=¹Ï¤U¤è¸Ó°Ï¬qªº¼Æ¦r=¸Ó°Ï¬q§e²{¤F¦h¤Ö¼Æ¾Ú ¼Æ¾Úªº§e²{¡A¤£¬O³]´N¬O¦º¤` ¥H°ª¤ÏÀ³²Õ¬°¨Ò¡A0~4Ӥ릳112-110=2Ó¼Æ¾Ú 4~8Ӥ릳110-105=5Ó¼Æ¾Ú 0~16Ӥ릳112-94=18Ó¼Æ¾Ú ¨ä¥¦¨Ì¦¹Ãþ±À¡K¡K. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/23 ¤U¤È 05:42:02²Ä 2399 ½g¦^À³
|
¤p©_¤j: ¬YӮɶ¡°Ï¬qªº¶¥±è¼Æ(¦º¤`¨Æ¥ó)+°é°é¼Æ(³])=¸Ó®É¶¡°Ï¬qªº number at risk ¨Ò¦p¡G°ª¤ÏÀ³²Õ¦b0~16Ó¤ë¦@¦³112-94=18Ó¼Æ¾Ú ©Ò¥H18Ó¼Æ¾Ú = 0~16Ó¤ë®É¶¡°Ï¬q¤º ¶¥±è¼Æ(¦º¤`¨Æ¥ó)+°é°é¼Æ(³]¸ê®Æ) 18Ó¼Æ¾Ú ´N¬O number at risk ³o¼Ë¹ï¶Ü? |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/8/23 ¤U¤È 05:38:05²Ä 2398 ½g¦^À³
|
¹ï¤F ^¤åª©¬O¦³¹ï»ôªº |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/8/23 ¤U¤È 05:21:34²Ä 2397 ½g¦^À³
|
SORRY §Ú·d¯º¤F~¬O¤@¼Ëªº |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/8/23 ¤U¤È 05:16:18²Ä 2396 ½g¦^À³
|
¤p©_¤j mops.twse.com.tw/nas/STR/417420160615M001.pdf ³o¤@¥÷¸Ì±¸ÑªR«×¦n«Ü¦h³á¡A²´·ú¤£·|¦Y¤O |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/23 ¤U¤È 02:12:13²Ä 2395 ½g¦^À³
|
§Ñ¤F´£¿ô¡A 6/5ªºP17¡A¹Ïªº¸ÑªR«×¤Ó®t ©ñ¤jn¥Î6/15ªºP30 ¦ý6/15ªºP30¹Ï¤U¤èªº¼Æ¦r¨S¦³¹ï»ô ©Ò¥H³Ì¦n6/5ªºP17»P6/15ªºP30¨Ö¥Î QQ¤j¡A ¥ý¤£n¥hºÞPFS¤F¡APFS½T¹ê»POS¦³Ãö¡Aµ¥®É¶¡¨ì¤F¤½¥q·|¦³¸Ô²Ó»¡©ú ¥u¬ÝOS´N¦æ¡AOS¤~¬O822ªº»ùÈ©Ò¦b ¼Æ°é°é®e©ö¼Æ¿ù¡A¤×¨ä¬O16~28Ó¤ë³oӰϬq¡A¦]¬°°é°é·|«Å| ¼Æ¶¥±è¤~¤£·|¼Æ¿ù °ª¤ÏÀ³²Õ¦³21Ó¶¥±è¡B§C¤ÏÀ³²Õ¦³29Ó¶¥±è¡B¹ï·Ó²Õ¦³35Ó¶¥±è ¬YӮɶ¡°Ï¬qªº¶¥±è¼Æ(¦º¤`¨Æ¥ó)+°é°é¼Æ(³])=¸Ó®É¶¡°Ï¬qªºnumber at risk ¨Ò¦p¡G°ª¤ÏÀ³²Õ¦b0~16Ó¤ë¦@¦³112-94=18Ó¼Æ¾Ú ¦]¦¹¡AY±z¯à¼Æ¥X°ª¤ÏÀ³²Õ¦b0~16Ӥ릳´XÓ¶¥±è¡A´N¥i¥Hª¾¹D°ª¤ÏÀ³²Õ¦b0~16Ӥ릳´XÓ°é°é¡A16~28Ó¤ë¡B28Ó¤ë¥H¤W¨Ì¦¹Ãþ±À¡A¨ä¥¦²Õ¤]¨Ì¦¹Ãþ±À¡A§â¤TÓ²Õ§Oªº0~16Ó¤ë¡B16~28Ó¤ë¡B28Ó¤ë¥H¤Wªº¤TӮɶ¡°Ï¬qªº³]¼Æ¥Ø©M¦º¤`¨Æ¥ó¼Æ¥Ø¤À§O°O¿ý¤U¨Ó¨Ã°µ¤ñ¸û¡A´N¥i¥Hª¾¹D822¦b¦¹¹êÅ窺¼vÅT¤O¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/23 ¤U¤È 12:52:22²Ä 2394 ½g¦^À³
|
¦U¦ì¤j¤jªººÃ´b»P¤£¦w¥þ³¡¥i¥H¦b6¤ëªÑªF·|¦^µª°ÝÃD¤¤§ä¨ìµª®× ¯S§O¬O¦b±i¸³³Ì«á6¤ÀÄÁ»¡©ú»PÁ`µ² (³Ìºë±mªº¦b³Ì«á60¬í) |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/8/23 ¤U¤È 12:37:24²Ä 2393 ½g¦^À³
|
¤p©_¤j: ¦]¬°¤§«eOSªº¼Æ¾Ú§Ú¤@ª½³£¤£Ãl, ©Ò¥H¦b¥Í§Þ®i²{³õ½Ð±Ð¤½¥qªº¤Hû. ¦^µª¬O³o¼Ëªº: ¯f¤H¶i¤J¹êÅçY¶¶§Q¥´§¹9°w´N¶i¤J PFSªºfollow up. ³oÓbase¬O8©P. Y°lÂÜ´Á¨S´c¤Æ, ¶i¤J OS¼Æ¾Ú., °lÂÜ´Á´c¤Æ«hPD. Y9°w«e´c¤Æ, ´Nª½±µ¶i¤J OS. ¦]¬°data lock¬O¥h¦~11¤ë, ©Ò¥H¨º®ÉÁÙ¦³¤H¦b PFS follow up base ¤¤, ÀH®É¤é¹L¥h, ºI¦Ü¥Í§Þ®i®É©|¥¼¶i¤JOSªº¤H¼Æ¤w¤£¦h¤F. §ÚÁÙ¬OµLªk°Ñ³z³o¤¤¶¡¦p¦ó¥h¬ÝOS, ¤§«e¤]¬O¼Æ°é°é¼Æ¨ìÀY·w, ´£¨Ñ³o¸ê®Æµ¹±z°Ñ¦Ò. ¤£ª¾¹D§ÚªºÆ[©À¬O§_¥¿½T, §Ú»{¬°OSªº³Ì²×¼Æ¾Ú¨ú¨M©ó§ÜÅ骺®É®Ä, ¥Ø«e¤wª¾¬O¥H¦~°O, ¦ý2¦~, 3 ¦~,¡K.´N¦³«Ü¤jªº®t²§. ½Ð±Ð³oÆ[©À¥¿½T¶Ü ? Cliff ¤j: ©µÄò¤W±ªº°ÝÃD½Ð±Ð±z¤£ª¾¬O§_¤F¸Ñ¦³Ãö³o§ÜÅ骺°O¾Ð©Ê ? ¬O§_²z½×¤W¤HÅé²£¥Í§ÜÅé, §ÜÅé«ùÄò·s¥Í¥NÁÂ, ³oºØ·s¥Íªº§ÜÅé¯à§_©µÄò°O¾Ð¬O§_´N¬O¦b°Q½×ªº§ÜÅé°O¾Ð ? ÁÙ¬O¦óºØª¬ªp©O ? ·U²`¤J¬Ý822¬ÛÃöªº¸ê®Æ, ¦³®É¯u¦³·U¬Ý·U©ü¤§·P., ¤Ó¯EÃv¤F. ·P®¦ª©¤W¦U¦ì¤j¤jªº«ùÄò¥I¥X, ¹³¿O¶ð«ü¤Þ¤è¦V¸Ñ´b. ·PÁÂ. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/23 ¤U¤È 12:26:33²Ä 2392 ½g¦^À³
|
·PÁ²q·Q¤j Cliff ¤j ¤p©_¤j ´£¨ÑÄ_¶Q¸ê°T ¬Q¤Ñ¹Ú¨ìºÑºñªº¦Ë¤l ¦¤WÁp·Q¨ì¤ñÈ ¤ñÈ ¦s¹Ú¹Ò²q´ú±À¦ô ¤Å°µ¬°§ë¸ê°Ñ¦Ò ±q2016 ASCO§ë¼v¤ù12 13 14 16 17 ±À¦ô¦UºØÁ`¦s¬¡´Á 1 ±q2016 ASCO§ë¼v¤ù12 13 ±À¦ôÁ`¦s¬¡´ÁMOS»P¯e¯fµL´c¤Æ¦s¬¡´ÁM PFS ¤ñȬù6.34¿ (52Ó¤ë/ 8.2Ó¤ë) 2 ±q2016 ASCO§ë¼v¤ù16 17 ²£¥Í§K¬Ì¤ÏÀ³¦¸±Ú¸s¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160) ±À¦ôÁ`¦s¬¡´ÁMOS = §ë¼v¤ù16²£¥Í§K¬Ì¤ÏÀ³¦¸±Ú¸sM PFS 12.1 Ó¤ë X 6.34= 76.7Ó¤ë (¹ï§ë¼v¤ù17²£¥Í§K¬Ì¤ÏÀ³¦¸±Ú¸s¤§MOS ±À¦ô)( °²³]¹ºª½½u±À¦ôµo²{·|¶W¥X60Ó¤ëÆ[¹î´Á) (·|¥H³æÃĪvÀø ¶W¹Lù¤óPERJETA® +trastuzumab + docetaxel MOS 56.5Ó¤ë) 3 ±q2016 ASCO§ë¼v¤ù14 §¹¦¨¥þµ{¤E¦¸ª`®gªº¦¸±Ú¸sµL´c¤Æ¦s¬¡´Á M PFS 22.5 Ó¤ë X 6.34= 142.65Ó¤ë (±q2016 ASCO §ë¼v¤ùÓ¤H¦X²z²q´ú¿z¿ï¯f±w«á,¦A§¹¦¨¥þµ{¤E¦¸ª`®gªº¦¸±Ú¸s,¥¼¨ÓÃĪ«¤W¥««áÄ~Äò¬I¥´«O«ù¤@©w§ÜÅé¶q,¯f±wÁ`¦s¬¡´ÁMOS ·|¬O³Ì°ª) |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/23 ¤W¤È 11:26:07²Ä 2391 ½g¦^À³
|
·PÁ¤p©_¤j¤j µ¹ªº¥\½Ò ±zÁ`¦³³Ð·sªºµo²{©Mµo·Q Åý¦bµL²áªº½L¶Õ¸Ì,¦³¤F¦³½ìªº¤u§@ ¬Q¤Ñ«Ü´e,¬°¤å¤§»Ú,¬ðµM«Ü¦h¾Ô¤Í¯B¤W¤ßÀY ¤µ¤é±z´N¤W¨Óµ¹¤j¹Ù¥mÀ{ ¯uÁÂÁ±z§r ª©±¤]´e,¤]½Ð±`±`µ¹¤j®a¤@Ó°ò¥»±ªº±Ò¥Ü ÁÂÁ±z! ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/8/23 ¤W¤È 10:58:36²Ä 2390 ½g¦^À³
|
Cliff¤j¡A²q·Q¤j¡A¦U¦ì¤j¡G ·PÁÂCliff¤j¦bÁÞ¬ì¾Çªº¯EÃv»â°ìÁ`¬O´£¨Ñ§Ú̾A®Éªº¸Ñ´b¡I ·PÁ²q·Q¤j¦bªÑ»ù¤W¤W¤U¤U¤§¥~¤Þ¾É§ÚÌ°µ°ò¥»±ªº¡u²q·Q¡v¡I ª¢ª¢®L¤é¡A¥i¯à¬OÀY¼ö©ü¤F¡A§âp17ªº¹Ï¦b¹q¸£¿Ã¹õ«e¤£Â_©ñ¤j ³ºµMµo²{¹Ï¤Wªº°é°é(³]¸ê®Æ)¡B¶¥±è(¦º¤`¨Æ¥ó)³£¥i¥H²M·¡ªº¼Æ¥X¨Ó ¨Ò¦p¡A°ª¤ÏÀ³²Õ¦b0~16Ӥ릳´XÓ³]¡A´XÓ¦º¤`¡H¦b16~28Ӥ릳´XÓ³]¡A´XÓ¦º¤`¡H¤j©ó28Ӥ릳´XÓ³]¡A´XÓ¦º¤`¡H³£¥i¥H²M·¡ªº¼Æ¥X¨Ó ¦P²z¡A§C¤ÏÀ³²Õ¤]¼Æªº¥X¨Ó¡A¹ï·Ó²Õ¤]¼Æªº¥X¨Ó ¼ÆµÛ¼ÆµÛ¡A¹ï¤§«e°Q½×ªº¡u¬ÛÃö¡v»P¡u¦]ªG¡v¡B¡uimmortal time bios¡v¡B822¦b°ª¤ÏÀ³²Õ»P§C¤ÏÀ³²Õ¤W¤À§O§e²{ªºÀø®Ä©¿µM¦³¤F¹y®©¡C ¦³¿³½ìªº¤H¥i¥H¼Æ¼Æ¬Ý¡A¬Ý¬Ý¬O§_¥i¥H²q¨ì¤U¤@±iOS´Á¤¤¤ÀªR¹Ïªºªø¬Û¡C |
|
|
·|û¡Gneilwang10142859 µoªí®É¶¡:2016/8/23 ¤W¤È 10:35:18²Ä 2389 ½g¦^À³
|
Cliff ¤j¡G ¥ýÁÂÁ±zªº»¡©ú¡A ¤p§Ì«e°}¤l¸ÉŪ¤@¨ÇDoan, Thaoªº³Ì·s¹Ï¸Ñ§K¬Ì¾Ç ¦Aµ²¦X ²Î¤@§ëÅU ±i¥ß¸s¬ã¨sû ©ó2015/10/19 ©Òµoªíªº¯E¹©³ø§i¤¤P5-P9 ªº¤º®e ¤p§Ìº¥º¥²z¥X 822 ÁÞ¤À¤l¬Ì]ªº§K¬Ì¾÷¨îªº¬[ºc(Áö»¡©|¥¼Àò±oÁ{§É¼Æ¾Úªº¦õÃÒ)¡A ¤µ¤Ñ¦A«ôŪ ±zªº»¡©ú¡A¦A¦¸Âç²M¤F¤@¨Ç§x´b§Ú¤w¤[ªº°ÝÃD ¦A¦¸ÁÂÁ±zµL¨p¦a¤À¨É |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/23 ¤W¤È 07:00:25²Ä 2388 ½g¦^À³
|
·PÁ Cliff ¤j®¦¼wªº¾É¥¿»P»¡©ú Cliff¤j®¦¼w µS¦p¤@³¡¤j¼Æ¾Úªº¶W¯Å¹q¸£ ¹L¥h ¥¼¨Ó¡F¬G¨Æ l¥Í ¥þ³£¤W®à¡AÀH¤j®a¦Û¥Ñ¿ï¥Î ¤p§Ì¦½ÃC ½Ð¤j®a©Ù¥h¤p§Ì¬Q¤éªºJ¨¥¶Ã»y ÁÂÁ¤j®a ¤]¦A¦¸ÁÂÁ Cliff ¤j®¦¼w ¼ö¤ßªº«ü¾É ·P®¦¡I |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/23 ¤W¤È 02:13:38²Ä 2387 ½g¦^À³
|
²q·Q¤j«e½ú¡G ÁÙ¬O°ò¥»±¥i·R¡K +1 ¥Ñcliff¤j«e½ú¡A¥xÁÞ¤j«e½ú¦bESMOµoªí·|¤§«e¡A«·s»â¾É¤j®a½Æ²ß¯E¹©ªº°ò¥»±¡A¦¹®É¦¹¨è¯uªº¬O³Ì¦nªº®É¾÷¡C ·PÁ½Ѧì±M·~«e½ú¦A¦¸«ü¾É¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/23 ¤W¤È 01:58:08²Ä 2386 ½g¦^À³
|
·PÁÂ¥xÁÞ¤j«e½ú¡ACliff¤j«e½ú¡G ¦p¦¹§Ú§ó²M·¡¨º¤@±in³s±µ¨º¤@¶¨Ó¬Ý¡C ¨ä¹ê§Ú¯uªº¦³ÂI¬Ý©ü¤F¡K¤@ª½§ä¤£¨ìµ²½×¡AÁÂÁ±z̪º¤£§[«ü¾É¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/23 ¤W¤È 12:19:26²Ä 2385 ½g¦^À³
|
999¤j §ë¼v¤ù17»P§ë¼v¤ù«á±ªºsummary¤w¸gµ¹¤©§Anªºµª®×¡A§ÜÅé®Ä»ù>=1:160¤£½×¦bÁ`¦s¬¡´ÁOS©Î¯e¯fµL´c¤Æ¦s¬¡´ÁPFS»P¹ï·Ó²Õ¡AµL¤ÏÀ³²Õ¬Û¤ñ³£¯à¬Ý¨ìÅãµÛÀø®Ä¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/23 ¤W¤È 12:18:22²Ä 2384 ½g¦^À³
|
²q·Q¤j¤j¡G ¨º¦ì¬ü°ê¦Ñ¥~¡]Ronald T. Raines¡^ªº¬ã¨s¦b³oùØ¡G¥»ª©Page.11¡u2015/7/15 ¤U¤È 01:46:25²Ä 331 ½g¦^À³¡v¡C ¥t¥~ ¡uGH§ÜÅé°£¤F¥iµ²¦XGH§Üì¥~¡A¬O§_¤]¥iµ²¦XSSEA-3 ©Î SSEA-4 §Üì?¡v GH§ÜÅé¥u·|µ²¦XGH§Üì¡C ¦ýY§âGH§Ü쥴¤J¦Ñ¹«Å餺¡A·|»¤µo¥X¤TºØ§ÜÅé¡GGH§ÜÅé¡]±N¨Ó·|»PGH§Üìµ²¦X¡^¡BSSEA-3§ÜÅé¡]±N¨Ó·|»PSSEA-3§Üìµ²¦X¡^¡BSSEA-4§ÜÅé¡]±N¨Ó·|»PSSEA-4§Üìµ²¦X¡^¡C ¦]¬°¾ð¬ð²ÓM·|§â¥´¤JªºGH§Üì§Ë¸H¡A³o¨Ç¸H¤ù·|¦U§O»¤µo¥X¤Wz¤TºØ§ÜÅé¡C¤ºÒÁÞªº¸H¤ù´N¥i¯à¦]¦¹»¤µo¥XSSEA-3§ÜÅé¡A·íµM¥|ºÒÁÞªº¸H¤ù¥i¯à¦]¦¹»¤µo¥XGb4§ÜÅé¡A¤TºÒÁÞªº¸H¤ù¥i¯à¦]¦¹»¤µo¥XGb3§ÜÅéµ¥ÂøÂøªº§ÜÅé¥X¨Ó¡K¡A¤£¹L¡A§ÚÌ©Ònªº·íµM´N¬OGH§ÜÅé¡BSSEA-3§ÜÅé»PSSEA-4§ÜÅé³o¤TªÌ¡C ¦b¤HÅ餺¦p¦ó©O¡H±À½×À³¸Ó¤]·|¦p¤Wzªºª¬ªp¬Û¦P¡A¤]§Æ±æ¯u¬O¦p¦¹¡A©Ò¥H·QÂdzo¦¸è¸Ñª¼ªº³ø§i¨Ó¤F¸Ñ»P½T»{¡F¤£¹L¨´¤µ¥¼ª½±µ´¦ÅSSSEA-3§ÜÅé»PSSEA-4§ÜÅ骺®Ä»ù»PÀø®Äªº¤ÀªR¸ê®Æ¡C ¡uSSEA-4§ÜÅé°£¤Fµ²¦XSSEA-4§Üì¥~¡A¬O§_¤]¥iµ²¦X¥t¨âºØ§Üì¡H¡v §âSSEA-4§Ü쥴¤J¦Ñ¹«Å餺¡A¥u·|»¤µo¥X¤@ºØ§ÜÅé¡GSSEA-4§ÜÅé¡A¥¦±N¨Ó¥u·|»PSSEA-4§Üìµ²¦X¡C ¦]¬°B²ÓM¥u·|¾ãÓ§]¾½SSEA-4¡A¤£·|§â¥´¤JªºSSEA-4§Üì§Ë¸H¡A©Ò¥H¥u·|»¤µo¥X³æ³æ¤@ºØSSEA-4§ÜÅé¦Ó¤w¡C §Ú̲ߺD§â¸Ü»¡±o²³æ¨Ç¡A´N·|Åܦ¨¤F¡u¥´¤F822©Ò²£¥Íªº§ÜÅé¡A¥i¥H¹ï§ÜGH¡BSSEA-3¡BSSEA-4¤TºØ§Üì¡K¡v¡A¨ä¹ê©Ò«üªº¬O¡u·|»¤µo¥X¤Wz¤TºØ§ÜÅé¡A¨CºØ§ÜÅé±N¨Ó·|¦U§O±M¤@¦a»P¥¦Ì¬Û¹ïÀ³ªº§Üìµ²¦X¡v¡A¦Ó¤£¬OGH§ÜÅé±N¨Ó·|»PSSEA-3§Üì©ÎSSEA-4§Üìµ²¦X¡A¦]¬°¥²¶·¿í¦u§Üì-§ÜÅé±M¤@©Êªºì«h¡A³o¬O§ÜÅ骺¯S©Ê¡C 999¤j ¡u³o²£¥Í1:160§ÜÅé¸òOSªºªøµu¬O¤£¬O·|¦³ª½±µÃö«Y¡H²£¥Í1:160§ÜÅ骺±wªÌ¬O§_¨äOS·|§óªø¤[...¡H¡v ³oÀ³¸Ó¬O¤j®a³£·Qª¾¹Dªºµª®×¡Aµ²ªG¦p¦ó¡H°O±o±i¸³»¡¹L¡A§ÜÅé®Ä»ù·U°ªªÌ¡AÀø®Ä·U¨Î¡C¦ý¥Ø«eOSªº¼Æ¾Ú©|«Ý¦¨¼ô¡Aµ¥«Ý¤¤¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/22 ¤U¤È 11:54:32²Ä 2383 ½g¦^À³
|
Pfizer to Buy Medivation for $14 Billion ½÷·ç¥H140»õ¨C¤¸¨ÖÁÊMedivation www.wsj.com/articles/pfizer-to-buy-medivation-for-14-billion-1471864168 ¹³¯E¹©³oºØ¥H¦hºØÀù¯g²ÓMªí±¤W§¡¦³ªí²{ªºGlobo¨t¦CÁÞ§Ü쬰¼Ð¹vªº¥D°Ê§K¬ÌÀøªkÃĪ«¬ãµo¤½¥q OBI833 ªÍÀù, ¤j¸zª½¸zÀù, GÀù, ¨ÅÀù¦~©³±N§¹¦¨Á{§É¤@´Á¦¬®× OBI822 ¨ÅÀù§¹¦¨Á{§É¤T´Á, §Z±_Àù§Y±N§¹¦¨Á{§É¤G´Á, ¨ä¥L¦hºØ¾AÀ³¯g¤]±N¦b¤U¥b¯à±À¥XÁ{§É¤G´Á OBI888 ©ú¦~¶i¤JÁ{§É¤@´Á ¦]¬°¬ãµoªº²£«~OBI 822 833 888 858 868 ¼ç¤O±j¤j °ê¥~¤jªº¥Í§Þ¤½¥qªêµøÏàÏà,¥H¤Ñ»ù¨ÖÁʯE¹© ªº¥i¯à©Ê¤£¯à±Æ°£,Ó¤H¬ã§P¯E¹©¦^¥x¥Øªº¬On°l¨D¦¨¬°¥þ²yÀù¯g§K¬ÌÀøªkªº»â¨ì«~µP,¤£·|»´©ö³Q¨ÖÁÊ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/22 ¤U¤È 11:29:45²Ä 2382 ½g¦^À³
|
²q·Q¤j«e½ú¡A¥xÁÞ¤j«e½ú¡G ·PÁ¤£§[«ü¾É...ÁÂÁ±zÌ¡C ¦A½Ð±Ð±zÌ... ³o²£¥Í1:160§ÜÅé¸òOSªºªøµu¬O¤£¬O·|¦³ª½±µÃö«Y¡H ²£¥Í1:160§ÜÅ骺±wªÌ¬O§_¨äOS·|§óªø¤[...¡H ÁÂÁ¡AÁÂÁ«ü¾É¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/22 ¤U¤È 09:19:37²Ä 2381 ½g¦^À³
|
½Ð±Ð ¦³¾Ç¥Í¤Æªº¤j¤j GH§ÜÅé°£¤F¥iµ²¦XGH§Üì¥~¡A¬O§_¤]¥iµ²¦XSSEA-3 ©Î SSEA-4 §Üì? ¦P¼Ëªº¡ASSEA-4§ÜÅé°£¤Fµ²¦XSSEA-4§Üì¥~¡A¬O§_¤]¥iµ²¦X¥t¨âºØ§Üì¡H ©Î³\¬OÄø°ÝÃD¡A¦ý¤p§Ì»{¬°«Ü«n¡A¤£¥i¤£ª¾¡A¬O¥H¦³¦¹°Ý ¥ý¦æÁÂÁ¤F |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/22 ¤U¤È 08:34:52²Ä 2380 ½g¦^À³
|
ÁÙ¬O°ò¥»±¥i·R❤ ·PÁ©Ҧ³±a»â¤p§Ì¹ï°ò¥»±¦³©Ò»{ÃѪº¥ý¶i¤j¤jÌ ´N¦pCliff¤j®¦¼w©Ò¨¥¡A¬ã¨s GH³Ì²`¤Jªº¬O¥xÆW ¤]³\³Ì»â¥ýªº¤]¬O¥xÆW ·í¥«³õn§âÀs½¼¬Ý±o¤SŤ¤S½M®É¡A¬O¥«³õªº¿ï¾Ü¡A³o¬O¤H¤ß©Ò³y¦¨ n¬ã¨s¤H¤ß ¤Ó¦hÅÜ¡A¥u¦³¦Ñ¯ª©v»¡±o¦n¡A¡u¤H¤ßÀI´c¡v GH¬O¤£¬OÄ_¡H¡I±N¨Ó·|¤£·|¦¨爲¤j¼t°l³vªºµJÂI¡A¥BÆ[¨äÅÜ ²{¦b¬ü°ê¾Ç¬É¦³¬ãµoGH§í¨î¾¯¡A¬O§_¥NªíGH¦³¼ç¦bªº»ùÈ ¦ý¬O¤£¬O¤S¦]GHÃø¥H¤j¶q¥Í²£¡A©Ò±Ä¥Îªº´À¥N§@ªk¡H¤£±o¦Óª¾ «e½g½×¤åªº§@ªÌ¤¤¡A¦³¦ìSamuel J. Danishefsky ¡A¦ü¥G¤S´£¨Ñ¬YºØª`¸Ñ¡H GH ±N¨Ó·|¬O¥D¬y¶Ü¡H ¤p§Ì¤£ª¾ ¥H¤W¯ÂÄÝÓ¤H¤Û·Q¡A½Ð§O¦b·N ÁÂÁ¤j®a¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/22 ¤U¤È 06:32:45²Ä 2379 ½g¦^À³
|
999¤j 1¹êÅç²Õ¬O¥þ³¡¤H¦³50%²£¥Í§ÜÅé¹F1:160? A ³o¤@ÃD²q·Q¤j¤w¦^µªªº«Ü§¹¾ã¤F 1:160¥u¬O¬°¤F«K§Q¤À²Õ(¥¿Å¤H¼Æ) ©Ò°µªº¬É©w §â§ÜÅé®Ä»ù´¿¸g°ª¹L1:160ªº¸ÕÅçªÌ¡AºÙ¦³¤ÏÀ³²Õ ,§â§ÜÅé®Ä»ù¥¼´¿°ª¹L1:160ªº¸ÕÅçªÌ¡AºÙ¨S¦³¤ÏÀ³²Õ Ó¤H²q·Q¹êÅç²Õ224¤Hªº§ÜÅé®Ä»ù¥i¥H±q°ª¨ì§C±Æ§Ç,±q°ª¨ì§C§ì¨ì²Ä112¤H®Éè¦n¬O1:160 ±Æ§Ç¶V«e±§ÜÅé®Ä»ù¶V°ª,§ì¨ì²Ä112¤H¤~¬O«ÂI ,1:160¤£¬O«ÂI ¦pªGn°µ¥þ²y¤T´ÁÁ{§É§ä¯f±w¤]¤£¤@©w ¬Onèè¦n§ä§ÜÅé®Ä»ù°ª¹L1:160 ³o»P¼Ë¥»¼Æ¦³Ãö 2 ÁÙ¬O¥´§¹9°wªº¹êÅç²Õ¦³50%ªº±wªÌ²£¥Í§ÜÅé1:160? A:¥´§¹9°wªº¹êÅç²Õ¤H¼Æ104¤H¡A¬Û¹ï©ó¦w¼¢¾¯²Õ¡A¨äµL´c¤Æ¦s¬¡´Á¡]PFS¡^¹F22.5Ó¤ë ¨ã§ïµ½ÁͶաC ¹Ïªí14¨Ã¥¼´£¨ì§ÜÅé®Ä»ù>=1:160 À³¸Ó¬O¥un¥´§¹9°w´N¦³¦p¦¹Àu²§ªºÀø®Ä ªÑªF·|¦³´£¨ì¥¼¨ÓÃĪ«¤W¥««á·|¬ã¨s¨C¹jX¤ë¦A¸É¥´¤@°w ( ¤EӤ르§¹9°w Æ[¹î¨ì2¦~§ÜÅé¨ÌµM¦s¦b) ¦]¬°Á{§É¸ÕÅ禳°w¦¸»P¹êÅç´Á¶¡ªº¨î»P¤W¥««á¨S¦³°w¦¸»P¹êÅç´Á¶¡ªº¨î¦X²z²q´ú¯f±wÁ`¦s¬¡´ÁÀ³·| §óªø,¦pªGFDA¯àºÉ§Ö¦P·NOBI822¸ó¤J¦¤¤´Á¨ÅÀù, ²×µ²¨ÅÀù¤]¤£¬O»»»»µL´Áªº¹Ú 3 ¦pªG§ÜÅé®Ä»ù±q >= 1:40 ¶}©lºâ ¤£¬O±q>=1:160¶}©lºâ À³¸Ó¶W¹L85%ªº¤H³£¯à²£¥Í§ÜÅé |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/22 ¤U¤È 05:04:31²Ä 2378 ½g¦^À³
|
°²¦p¬O³o¼Ë ¨º 888 À³¸Ó¤ñ¥¦±j¤~¬O¡H¡I ³o¼Ë¡A GH·|¦¨爲Åã¾Ç¶Ü¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/22 ¤U¤È 04:55:01²Ä 2377 ½g¦^À³
|
¦Ñªá²´¶V¨Ó¶V«¤F¡H ¤£ª¾¦³¨S¦³¬Ý¿ù¡H ³ºµM¦³¾Ç¬É¦b¬ãµo Globo H §í¨î¾¯¡H http://pubs.acs.org/doi/ipdf/10.1021/acscentsci.5b00164 ³o¬O¬Ý¤¤¨ºªù¤lªº¾÷Âà§r¡H ¤p§Ì½k¶î¤F ¦³¥ý¶i¤j¤j¥i«üÂI¶Ü ÁÂÁ¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/8/22 ¤W¤È 08:56:10²Ä 2376 ½g¦^À³
|
¤j®a¦w¦n! ³Ìªñªº®ðª^¦³ÂI´e °Q½×¨Ç°ò¥»±ªºªF¦è¡A ¦n¹³¤]¬O¤£¿ùªº¸Ñ´e¾¯ 999¤jªº°ÝÃD¡A ¤p§Ì¤]¬O¥~¦æ °O±o±i¸³»¡¹L¡A 1:160¥u¬O¬°¤F«K§Q¤À²Õ(¥¿Å¤H¼Æ) ©Ò°µªº¬É©w §â§ÜÅé®Ä»ù´¿¸g°ª¹L1:160ªº¸ÕÅçªÌ¡AºÙ¦³¤ÏÀ³²Õ ¤S§â§ÜÅé®Ä»ù¥¼´¿°ª¹L1:160ªº¸ÕÅçªÌ¡AºÙ¨S¦³¤ÏÀ³²Õ µM¨Æ¹ê¤W¡A ³o¨Ç¨S¦³¤ÏÀ³²Õ ªº¸ÕÅçªÌªº§ÜÅé®Ä»ù¤À§G¦b 0 ~1:80¡A ¨ä¤¤³¡¥÷¸ÕÅçªÌ ¤´¦³§ÜÅé²£¥Í¡A ©Ò¥H¦³85%ªº¤H²£¥Í§ÜÅ餧»¡ ¦]¦¹¡A ¤p§Ì»{¬°§ÜÅé®Ä»ù´¿¸g°ª¹L1:160ªº¸ÕÅçªÌ¡A©Î¬°¹êÅç²ÕÁ`¤H¼Æªº50% ¤p§Ì¨Ìµ}°O±o Theratope ªº§ÜÅé®Ä»ù¤¤¦ì¼Æ¦b1 ¸U¥H¤W¡A 822ªº®Ä»ùY¦³¦¹ªí²{¡A Àø®Ä©Î±N¶W¤Z¡A ¤£ª¾¦¹¤è±¦³µL¥i¨úªøªÌ? ¥tK-M¹Ï©³¤Uªº n ( at risk ) ¥i¥H±NK-M¹Ïªº¼Æ¾Ú¤Æ¬°¸Õºâªí¨Ó¼ÒÀÀ¡A¦ý ²{¤´¯Ê¤U¤@¶¥¬qªºK-M¹Ï ¨Ó¦LÃÒ ¤p§Ì¤£¤~ ¤´«Ý¥ý¶i«e½ú«ü¥¿ ¤p§Ì¤]¦³°ÝÃD¡A ½Ð¤j®a°Q½×ÄÀºÃ ´N¬O10/10 ¤½¥q¿ìªº¬ã°Q·| ¨ä¤¤ªº Panel Discussion: The Future of Immunotherapy inOncology: Where Does Adagloxad Simolenin Fit in? ³oÓ Where Does Adagloxad Simolenin Fit in? ½Ð°Ý¤j®a¦³¦ó¬Ýªk ÃD¥~¸Ü ³o¨ÇɨéªÌ¡A ¤Ñ¤Ñ·d³o©Û»s³y½æÀ£À~´²¤á¡A Åý¤HµL¨¥ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/8/22 ¤W¤È 01:00:42²Ä 2375 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡ACliff¤j«e½ú¡A½Ñ¦h²Îp¾Ç«e½ú¡G ¤j®a¦n¡I ¤p§Ì¤gªk¬ã²ß¶i«×½wºC...¸g¼Æ¤ë¤ñ¹ïASCO¹Ïªí»P¤½¥q¤½¶}µo¨¥...ÁÙ¬O¨S·dÀ´¹ÏªíªºÅã¥Ü¬O 1¡n¡G¹êÅç²Õ¬O¥þ³¡¤H¦³50%²£¥Í§ÜÅé¹F1:160? 2¡n¡GÁÙ¬O¥´§¹9°wªº¹êÅç²Õ¦³50%ªº±wªÌ²£¥Í§ÜÅé1:160? 3¡n¡G02/23ªºªk»¡·|±i¸³»¡©úªº¶W¹L¯Î°|ªø»¡ªº85%ªº¤H²£¥Í§ÜÅé? ¬Oµ´¤j¦h¼Æ¤H³£·|²£¥Í§ÜÅé¡A¦³¤F§ÜÅé´N·|²£¥ÍÁ{§ÉÀø®Ä... ³o¸òASCO©Òµoªíªº¹Ïªí...§Ú«ç»ò¹ï³£¹ï¤£¥X¨Ó...? ¬O§_½Ð½Ñ¦ì«e½ú«ü¾É¤p§ÌÀ³¸Ó¬O¬Ý¦ó¹Ïªí¯à¹ï·Ó¤½¥qªºµo¨¥¤º®e...? ¤p§Ì¹ïªº«D±`»{¯u¡A¦ýÁÙ¬O®{³ÒµL¥\...®¥½Ð«e½ṳ́£§[«ü¾É... ·PÁÂ...ÁÂÁ¤j®a¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/18 ¤U¤È 03:21:40²Ä 2374 ½g¦^À³
|
Cliff ¤j ÁÂÁ´£¨Ñ¸ê°T¤À¨É |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/18 ¤U¤È 01:36:10²Ä 2373 ½g¦^À³
|
¥xÁÞ¤j 1.¤p§Ìªº¬Ýªk»P«ù¤[ªº¯E§J¤j¬Q¤Ñªº¬Ýªk®t¤£¦h¡A¤]¸ò¥h¦~12¤ë©³®É§ÚÓ¤Hªº¬Ýªk®t¤£¦h¡]¥»ª©page9¡G2015/12/29 ¤U¤È 11:39:45¡F²Ä 763 ½g¦^À³¡^¡C 2.¥t¥~¡A¥I¶Oªº¥Í§Þ²£·~°Ó±¡³ø§i§âOBI Pharma¦C¤J¤ÀªR¡A³o¦Ü¤Ö¦b¥h¦~¤W¥b¦~´N¦³¥L®a¥Xª©Ãþ¦üªº¥Zª«¡A¥u¬O¦P¼Ën¥I¥X°ªÃB»ù®æ«á¤~±o¥H¾\Ū¡A©Ò¥H¨s³ºùØÀY¼g¤F¬Æ»ò¡u¤º®e¡v¡A§Ú·QÀ³¸Ó¤~¬O¤F¸Ñªº«ÂI§a¡C¥ú¬Ý¥Ø¿ýªº¸Ü¡K¡K ¡]³o®a¤½¥q2014¦~3¤ëÁÙ´À°ò¨È¥Í§Þ¥X¹L±M¥Z©O¡G¡uwww.researchandmarkets.com/reports/2789561/medigen_biotechnology_corporation_product#pos-1 ¡v¡A¦Ó¥B¹F30¶¡A¦h©ó2015¦~³o¥÷OBI¥u¦³23¶¡K¡K¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/18 ¤W¤È 10:32:58²Ä 2372 ½g¦^À³
|
Cliff ¤j ³¯¹a¬z°|¤h¹Î¶¤³o½g¬ã¨s»P¨ÅÀùOBI822ªº§ÜÀù¾÷¨î¦³Ãö Ó¤H»{¬°¥i¬°¨ÅÀùOBI822´£¨Ñ³¡¤ÀMOA ªº¬ì¾Ç°ò¦ ¤£ª¾¦³¦ó¬Ýªk? Globo H ceramide acts as immune checkpoint and angiogenic factor in tumor microenvironment |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/18 ¤W¤È 10:18:22²Ä 2371 ½g¦^À³
|
²³¤j¤j: ¨ÅÀù¨«¦b¥þ²yÀù¯g§K¬ÌÀøªk³Ì«eºÝªº¥xÆW¯E¹©¥Í§Þ¤½¥q¤wÀR®¨®¨ªº¶i¤J°ê»Ú»R¥x «i´±±¹ï¥þ²yÄvª§ A¥xÆW¯E¹©¥Í§Þªº¤Ñ®É¦a§Q»P¤H©M ¤Ñ®É: ¬ã¨sªºÀù¯g§K¬ÌÀøªkÃĪ«²Å¦X¥@¬É¬ãµo¼é¬y Àù¯g¤H¤f¼Æ³v¦~¼W¥[ ¦a§Q: ¥H¥xÆW¬°°ò¦a¥H«n´ä¬°¤¤¤ß³W¹º¦¨¥ß¥@¬É¯Å¬ãµo¤¤¤ß,ªF¦è«n¥_ªï¦V¥@¬É ¤H©M: Àò±o¥ø·~®a ªÑªF ¥~¸ê MSCI¤j¤O¤ä«ù °ê¥~±M®aªºªÖ©w»P¤¤¬ã°|ªº±ÂÅv B ¥@¬É½Ã¥Í²Õ´WHO³ø§i«ü¥X¡A¨ì2030¦~¡A¨C¦~¥þ²y¦º©óÀù¯gªº¤H¤f±N·|¨ì¹F1300¸U¡F¿©±wÀù¯g¤H¤f¤W¬Ý2100¸U¡C C ¥þ²y¨ÅÀùµo¥Í¤H¼Æ»P¦º¤`¤H¼Æ Breast CancerEstimated Incidence, Mortality and Prevalence Worldwide in 2012 Estimated numbers (thousands) (WHO) Cases / Deaths / 5-year prev. World 1671 / 522 / 6232 More developed regions 788/ 198 /3201 Less developed regions 883/ 324 /3032 WHO Africa region (AFRO) 100/ 49 /318 WHO Americas region (PAHO) 408/ 92/ 1618 WHO East Mediterranean region (EMRO) 99/ 42/ 348 WHO Europe region (EURO) 494 /143 /1936 WHO South-East Asia region (SEARO) 240 /110 /735 WHO Western Pacific region (WPRO) 330/ 86/ 1276 IARC membership (24 countries) 935/ 257 /3591 United States of America 233/ 44 /971 China 187/ 48/ 697 India 145 /70 /397 European Union (EU-28) 362/ 92/ 1444 D ¥þ²yÀù¯g¥«³õÁÍ¶Õ 1 Oncology cost growth is expected in the 7.5% to 10.5% range annually through 2020, when global oncology costs will exceed $150 billion ( ¹F1629 »õ¬ü¤¸) 2010-2015 ½Æ¦X¦~§¡¼Wªø²v 6.9% 2016- 2020 ½Æ¦X¦~§¡¼Wªø²v 10.5% 2 Yuki ¤j¨â¤Ñ«e¶K¤åÃD¨ì IMS Health ¦bASCO ¶}·|«e¤½¥¬¥þ²y¸~½F¥«³õ³ø§i«ü¥X¡A¥þ²yÀù¯gÃĪ«ªá¶O¨ì2020¦~±N¶W¹L1500»õ¬ü¤¸¡]¬ù¥x¹ô4.9¥ü¡^¡A¥D¦]¬O¥X²{¯à¨ó§U§K¬Ì¨t²Î§ðÀ»¸~½Fªº©ù¶Q·sªvÀø¡C 3 ¥þ²yÀù¯g¥«³õ¤¤j¦a°Ï 2010 / 2015 / 2020 836 »õ¬ü¤¸ / 1065»õ¬ü¤¸ / 1629 »õ¬ü¤¸ ¬ü°ê-- 2010 / 2015 / 2020 340»õ¬ü¤¸/ 485»õ¬ü¤¸/ 791»õ¬ü¤¸ (48.5%) ¼Ú·ù¤°ê-- 2010 / 2015 / 2020 ( ¼wªk·N¦è^) 198»õ¬ü¤¸ / 219»õ¬ü¤¸ / 311»õ¬ü¤¸ ( 19.1%) ¤é¥»-- 2010 / 2015 /2020 94»õ¬ü¤¸ /88»õ¬ü¤¸ / 106»õ¬ü¤¸ ( 6.5%) ·s¿³¥«³õ--2010 /2015 / 2020 87»õ¬ü¤¸ /135»õ¬ü¤¸ / 209»õ¬ü¤¸ (12.8%) ¨ä¥¦¦a°Ï--2010 / 2015 / 2020 117»õ¬ü¤¸ / 138»õ¬ü¤¸ /212»õ¬ü¤¸ (13%) www.imshealth.com/files/web/IMSH%20Institute/Reports/Global_Oncology_Trend_Report_2015_2020/IMSH_Outlook_to_2020_for_Oncology.pdf 4 ¥þ²yÀù¯g¥«³õ2015¦~±q1065»õ¬ü¤¸¨ì2020¦~¹w¦ô1629 »õ¬ü¤¸¦@¼W¥[564»õ¬ü¤¸,¨ä¤¤¤j³¡¥÷³QÀù¯g§K¬ÌÀøªk©Ò¶ñ¸É E ¥þ²y¨ÅÀùªvÀø¥«³õ 1¥þ²y¤KÓ¥Dn¨ÅÀùªvÀø¥«³õ2021¦~±N¹F172»õ¬ü¤¸ (¬ü°ê¡A¥[®³¤j¡A^°ê¡Aªk°ê¡A¼w°ê¡A·N¤j§Q¡A¦è¯Z¤ú©M¤é¥») ¤£¥]¬A ¤¤°ê ·s¥[©Y «nÁú ¥xÆW ªF¼Ú¡B¤¤ªF ©Ô¤B¬ü ¦L«× ªF¨ó¤Q°ê ¦pªG¦³¥]¬A¥«³õ·|¤ñ172»õ¬ü¤¸§ó¤j Breast Cancer Therapeutics in Major Developed Markets to 2021 - Global Breast Cancer Treatment Market Will Reach $17.2 Billion by 2021 (³o¥»¥«³õ¬ã¨s³ø§inªá4995¬ü¤¸ÁʶR ) 2 ³Q´£¨ì¦³¯S¦âªº¤½¥q¥]¬A¥xÆW¯E¹© OBI Pharma Promising Drug Candidates in Pipeline OBI-822/821 - OBI Pharma ¤]¤J¦C ¥H¨ÅÀù¨«¦bÀù¯g§K¬ÌÀøªk³Ì«eºÝªº¥xÆW¯E¹©¥Í§Þ¤½¥q¤wÀR®¨®¨ªº¶i¤J°ê»Ú»R¥x «ö¼s§i¤å²Ä¤G¦æ¤]¯à¬Ý¨ì OBI Pharma »P¤j¼t¦P®É¦W¦C¨ä¤¤ globenewswire.com/news-release/2016/04/26/832645/0/en/Breast-Cancer-Therapeutics-in-Major-Developed-Markets-to-2021-Global-Breast-Cancer-Treatment-Market-Will-Reach-17-2-Billion-by-2021.html 3 ¥t¥~nÁA¸ÑOBI Pharma nªá1500¬ü¤¸ÁʶR¤~¬Ý±o¨ì ¦bsearch Q ¥´OBI Pharma ·|¬Ý¨ìÁʶR»ù®æ www.researchandmarkets.com/reports/3513286/obi-pharma-inc-product-pipeline-review-2015#pos ¥H¤W¸ê°T¶È´£¨Ñ¤À¨É°Ñ¦Ò ¦p¦³¿ù½Ð§ó¥¿ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/8/17 ¤U¤È 09:28:11²Ä 2370 ½g¦^À³
|
·PÁÂCliff¤jªº¤À¨É ¦³Ãö¡uGlobo H ceramide acts as immune checkpoint and angiogenic factor in tumor microenvironment¡v ¡uYu J, Cheng JY, Wang SH, Tsai YC, Wu JC, Hung JT, Lin J, Yeh KT, Yu AL¡v³¯¹a¬z°|¤h¹Î¶¤¡C ¡]cancerres.aacrjournals.org/content/76/15_Supplement/A20 ¡^ ¤p§Ì¤j·§ÂsÄý¤@¤U ı±o¤º®e¸òµ{´º«Û³Õ¤h½×¤å ½²©öªà³Õ¤h½×¤å¤§¤¤¤å½×¤å¤º®e¬Û¦P ¤j®a¥i¥H¥ý¬Ý¬Ý¨â½g³Õ½× |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/17 ¤U¤È 03:56:11²Ä 2369 ½g¦^À³
|
¥H¤Uªº¤º®e»P822¨S¦³ª½±µ¬ÛÃö¡A¨S¿³½ìªÌ¥i³w¦æ¸õ¹L¡C 2016/07/21 Cell Chemical Biology¡G ¡uHigh sensitivity and low toxicity fucose probe for glycan imaging and biomarker discovery¡v¡]www.cell.com/cell-chemical-biology/pdf/S2451-9456(16)30203-3.pdf ¡^ ¤é¥»²z¤Æ¬ã¨s©Ò¡]²z¬ã¡^·s¬ãµoªº°ª±Ó·P«×§C¬r©Êªº©¥Ä¦ÁÞ¡]Fucose¡^±´°w¡A¥i¥Î©ó»EÁÞ³y¼v»P¥Íª«¼Ð°O¡C 2016/07/22¤é´C³ø¾É¡G ¡u¿}Âêの°ª·P«×検¥Xに¦¨¥\¡Ðバイオマーカー¶}発への応¥Îが¥Ø«eに¡Ð¡v¡]www.riken.jp/pr/press/2016/20160722_2/ ¡^¡F¡]¨â¬Û¹ï·Ó¡Aì¨ÓÁÞÂê´N¬O»EÁÞ¡A¡K¤é¤å§Ú¤@¬¤£³q¡K¡^ ¥H¤Wªº¤º®e¦³½Ð°ª¤â«üÂI¡A¥H¤U¯Â¬°Ó¤H¬Ýªk¡C I.°|ªø»P¤é¥»²z¬ã¦³¤@¬q³¯¦~©¹¨Æ¡A¦Ñ¯E¤ÍÀ³¸Ó³£ª¾¹D¡]µù1¡^¡A³y´N¤F2003¦~³Q§õ»·õ«e°|ªøÁܽЦ^¥x¥ô¤¤¬ã°|¤Æ¾Ç©Ò¯S¸u¬ã¨sû¡A¦A±µ¥ô°ò¦]Å餤¤ß¡AµM«á¤~¤S±µ¥ô°|ªø¾¡C·í¦~¤é¤è²z¬ã¬O¦p¦ó¹ï«Ý³o¦ìÁÙ¦b¬ü°êScripp¡¦s¥ô¾ªº©ú¤é°ê»Ú¤§¬P¡A¡u¡KRIKEN¯S§O§¹J¯Î±Ò´f¡A¥i¥H¤£¥Î¨ì¤é¥»¬ã¨s°|¾á¥ô±M¾¡A¦Ü©ó«Ý¹J¡A°£¤F¬ã¨s¸g¶O¤Î¬ã¨s¤Hû«Ý¹J¤§¥~¡A¥un¨ì¤é¥»¤u§@¡A¥H¤éÁ~2000¬ü¤¸p¡A¥~¥[¤@¼l¦³ªá¶éªº¬v©Ð¥i¨ÑÀH®É©~¦í¡C¡K¡v¡A¹ï·Ó¤µ¦~°|ªø¦b¥xÆW¨ü¨ìªº¤£¥«Ý¹J¡AÁÙ¤@«×³Q¥H³g¦¾¦W¸q²¾°e°»¿ì¡A¯u¬O²ö¤jªº«V°d¡A¨´¤µ¤´¥¼µ¹¥L¸Ó¦³ªº¥¤Ï¡A¥O¤H®ð¼«ÃøÃ`¡C II. Globo H¤§©Ò¥H¨ã¦³¨º»ò¯S®íªºPÀù¨¤¦â¡A¨Ó¦Û©ó¨äµ²ºc¤¤©Ò§tªº©¥Ä¦ÁÞ¡F¥¦»PSSEA-4ªºµ²ºc®t²§³B¤]¦b³oÓ³¡¥÷¡AGlobo H§t©¥Ä¦ÁÞ¡A¦ÓSSEA-4§t³è²G»Ä¡A³oÓ®t²§³y¦¨¤F³o¨âÓ¤»ºÒÁÞ©Ò»¤µo¥X¨Óªº§ÜÅéµ²ªG¤j¤£¬Û¦P¡A¤]¦]¦¹³y¦¨¤£¤@¼Ëªº¥«³õ»ùÈ¡C III. ¬YºØ¯S©w«~ºØÆFªÛ¥i¥Î¨Ó§ÜÀù¡A¥¦ªº¾÷Âà¤]¦P¼Ë¦b2013¦~³Q¤¤¬ã°|µo²{¡A³o¤w¬O»D¡]µù2¡^¡Aì¨Ó¤]¬O¸òGlobo H¡B©¥Ä¦ÁÞ¦³Ãö¡A³o´N¤£¦A´£¡AˬO±qµù2³ø¾É¤¤´£¨ìªº³\¥ý·~°|¤hªºÓ¤H¬ã¨s¦A©µ¦ù¥X¥h¡AÓ¤Hµo²{³\°|¤hªº¬ã¨s´À¥t¤@®a¥¼¤W¥«¤½¥q¡u¤¤µØ®ü¬v¥Í§Þ¡vªº½ÅĦ°·±d¹«~§ä¨ì¤F¥i¯àªº§@¥Î¾÷Âà¡A¤]¦P¼Ë¬O¸ò©¥Ä¦ÁÞ¦³Ãö¡A¦³ÂI¸U¹DÂk©vªº·Pı¡]µù3¡^¡C Àù¯g¤j¼Ä--©¥Ä¦ÁÞ ½ÅĦ¡]©ø¥¬¬O¨ä¤¤¤@ºØ¡^¤¤ªº½ÅĦÁÞ½¦¡]Fucoidan¡^´I§t©¥Ä¦ÁÞ¡]Fucose¡^¡A¤w¦³«Ü¦h¤¤¥~ªº°Êª«¹êÅç¬ã¨sµo²{³oÓ¦¨¥÷¨ã¦³§Üµoª¢¡B§Ü¦åºÞ¼W¥Í¡B§Ü®ñ¤Æ¥\¯àµ¥¡A¤×¨ä¤é¥»¦b³oÓ»â°ìµÛ¾¥»á²`¡]µù4¡^¡C³o®a¤½¥qªº¨â¦ì¥D«ù¤H¬O®ü¬v¾Ç°|ªºn¦n¦P¾Ç¡A¨ä¤¤³½Ã¨Á²M½÷20¦~¨Óªº¬G¨Æ¡A¥H¤Î¯Î°|ªø¹ï©óÁޤƾǪº°õµÛ§ë¤J¡A¦b»ñ°Äªá¶}ªº²¦·~®É¸`¡A¹ïªÀ·|·sÂA¤H¨Ó»¡¡A»áȱoª±¨ý¡Fª¢ª¢®L¤é¡AªÑ»ù¤£º¦¡A¦U¦ì¬Ý¬Ý§O¤H¦¨¥\ªº¬G¨Æ¡Aפ߾i©Ê¡A¥i¥HÁקK¤ßÅ]¶Ã»R¡A¶Ã¤F¤è¤o¡C ¡]½ÅĦ¹«~ÄÝ°·±d¹«~¡A822¬O¬ãµo¤¤ÃÄ«~¡FÄݩʤ£¦P¡A¯Â´N¾Ç²z±´°Q¡A¤£¬°«P¾P¡A½Ð¤Å»~·|¡C¡^ µù¡G 1. 2014/6¤ë¸¹-¬ì¾Ç¤HÂø»x¡G¡u§Nªù»â°ì¹J¤W¦n©_¤ßÆF¡v¡]²Ä5¶ sa.ylib.com/MagCont.aspx?PageIdx=5&Unit=featurearticles&Cate=&id=2439&year= ¡^ 2. 2013/08/30¡G¡u¸Ñ¶}ÆFªÛ¦hÁÞ¹ï§K¬Ì¤Î§ÜÀù¬¡©Êªº¯«¯µ±¯½¡v¡]www.sinica.edu.tw/manage/gatenews/showsingle.php?_op=?rid:6042 ¡^¡F ¡uÆFªÛ¦hÁÞ§ÜÀù ¤¤¬ã°|¸ÑÁ¼¡v¡]tw.news.yahoo.com/%E9%9D%88%E8%8A%9D%E5%A4%9A%E9%86%A3%E6%8A%97%E7%99%8C-%E4%B8%AD%E7%A0%94%E9%99%A2%E8%A7%A3%E8%AC%8E-044930316.html ¡^ 3. 2012/12/28¡G³\¥ý·~±Ð±Â¡G¡uFucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGF£] receptor degradation in breast cancer¡v¡]carcin.oxfordjournals.org/content/34/4/874.long ¡^ 2014/08/06¡G³\¥ý·~±Ð±Â¡G¡uFucoidan inhibition of lung cancer in vivo and in vitro: role of the Smurf2-dependent ubiquitin proteasome pathway in TGF£] receptor degradation¡v¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC4202167/ ¡^ 4. 2011¤é¥»¡G¡uFucoidan Extract Induces Apoptosis in MCF-7 Cells via a Mechanism Involving the ROS-Dependent JNK Activation and Mitochondria-Mediated Pathways¡v¡]journals.plos.org/plosone/article?id=10.1371/journal.pone.0027441¡^ 2011¦~¤é¥»¹ï©ó¤p¤À¤l½ÅĦÁÞ½¦ªº¬ã¨sµ²ªG¡A©ú½T«ü¥X500Da¤p¤À¤l½ÅĦÁÞ½¦¡A§í¨îÀù¯gªº®ÄªG¸û¤j¤À¤l¨Î¡C 5. ¡u·R³½¦¨Ã¨¡I®ü°|¦n¥S§Ì±ó¤d¸U¦~Á~ ¾i¥X¤d¸U¨»ùªF¬P´³/¥xÆW«G°_¨Ó/¤T¥ß·s»D¥x¡v¡]www.youtube.com/watch?v=If4my2Nm2go ¡^ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/17 ¤U¤È 01:54:19²Ä 2368 ½g¦^À³
|
2016/07/28 AACR¥Xª©¡G ¡uGlobo H ceramide acts as immune checkpoint and angiogenic factor in tumor microenvironment¡v ¡uYu J, Cheng JY, Wang SH, Tsai YC, Wu JC, Hung JT, Lin J, Yeh KT, Yu AL¡v³¯¹a¬z°|¤h¹Î¶¤¡C ¡]cancerres.aacrjournals.org/content/76/15_Supplement/A20 ¡^ ¡uAACR Special Conference: The Function of Tumor Microenvironment in Cancer Progression; January 7-10, 2016; San Diego, CA¡v ºKn¥Z¥X¤F¡C ³o¤@½g¬O2016/1¤ëAACR¾À³ø®i°Ïªº¤å³¹¡A½s¸¹A20¡A·í®É©|¥¼¸Ñª¼¡A¥h¦~¦~©³¥ý³Q¥Xª©¤j§ä¨ì¥Ø¿ý¡A¶K¦b¥»ª©page.9 ¡u°e³øªº10135990 µoªí®É¶¡:2015/12/29 ¤U¤È 05:03:19¡F²Ä 752 ½g¦^À³¡v¡A²{¦b¥Z¥XºKn¡C¦³¤ß¤H¤£§«Åª¤@Ū¡A¬Ý¬Ý¦³¨S¦³·s«GÂI¡H ¥Xª©¤j¡A¼ç¤ô¹L¤[¡A¦³®`°·±d¡A¦Ü¤Ö¤W¨Ó´«¤@¤f®ð§a¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/13 ¤W¤È 11:25:41²Ä 2367 ½g¦^À³
|
ÁÙ¦³¨Ó¦Û^°êªº¦¨¥\¦ò ¤ý«a¥[°Ã Stephen Johnston, MA, PhD, FRCP Steven ¥v«Ò¤å ©Ô¤B¡A§Æþ ¤ý«a¡Aªá«a¡C www.hitutor.com.tw/english-name-g.php www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-stephen-johnston |
|
|
·|û¡Gming10140949 µoªí®É¶¡:2016/8/13 ¤W¤È 10:39:12²Ä 2366 ½g¦^À³
|
³¯³Õ¤hªºÂà¥ô¤@¨Æ,Ó¤H¤]ı±o¬OÅý¥X¦ì¤lµ¹§ó°ê»Ú§óºë^ªº¤H¨Ó¨ó§U¶}µo, ¦pªG¯uªº¤£¦n,³¯³Õ¤hÀ³¸ÓÂ÷¶}´N¦n,¤£¥²Âà¥ô©eû,©Ò¥HÀ³¸Ó«Ü§Ö¥i¥H¬Ý¨ì·s¤H¨Æªº«Å¥¬ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/13 ¤W¤È 09:49:42²Ä 2365 ½g¦^À³
|
Á|¥@¡uµ}¡vÃÄ822¡A§ä¡u§Æ¡v¦r½úªº¨Ó¸ó¤M¡]¬Jµ}¥B½å¡K¡^¡C ¡uµ}§Æ¡v¬Û±¤¡H ¥_¬ü¡GDr. Hope S. Rugo¡]§Æ±æ¦ò¡^¡F ¼Ú¬w¡GDr. Heather L. McArthur¡]§Æõ¡D³Á§Jªü·æ¡^¡C ª¯»L¤@¤U¡A§Æ±æ¦o̯ର822¦h¥[¤@ÂI¤O¡C ¡]www.mskcc.org/cancer-care/doctors/heather-mcarthur ¡^¡B¡]www.lbbc.org/about/about-us/reviewer/heather-l-mcarthur-md-mph ¡^¡C |
|
|
·|û¡G¦Ñ¶À10142116 µoªí®É¶¡:2016/8/13 ¤W¤È 01:54:08²Ä 2364 ½g¦^À³
|
èè¤~ºô¸ô¤W¬Ý¨ìOBI pharmaAgenda OBI ±N©ó2016/10/10 18:30-20:00Á|¦æ¼t°Ó¬ã°Q·| ¡]ESMO industry satellite symposium) ³sµ²: www.esmo.org/content/download/86212/1595326/file/Novel-Approaches-to-Active-Immunotherapy-in-Oncology-Targeting-Globo-Series-with-Adagloxad-Simolenin.pdf 18.00 ¡V 18.30 Registration and Dinner 18.30 ¡V 18.35 Welcome and Introduction Moderator: Stephen Johnston, MA, PhD, FRCP 18.35 ¡V 18.55 The Globo Series: Carbohydrate Tumor-Specific Antigens ¡GChi-Huey Wong, PhD 18.55 ¡V 19.15 Rationale and Development of the Active Immunotherapy Adagloxad Simolenin ¡GHeather L. McArthur, MD, MPH 19.15 ¡V 19.35 Adagloxad Simolenin in Metastatic Breast Cancer:¡GResults from the OBI-822-001 trial Chiun-Sheng Huang, MD 19.35 ¡V 19.55 Panel Discussion: The Future of Immunotherapy inOncology: Where Does Adagloxad Simolenin Fit in? Moderator: Stephen Johnston, MA, PhD, FRCP Heather L. McArthur, MD, MPH Chiun-Sheng Huang, MD Chi-Huey Wong, PhD ¥xÆW³¡¤À¥Ñ¯Î°|ªø»P¶À«T¤É¥D¥ô»âx, ´Á«Ý¦³§ó¦h·sªº¬ã¨s¼Æ¾Úµoªí |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/12 ¤U¤È 07:37:05²Ä 2363 ½g¦^À³
|
§R°£11 ¥H¤U¦C°ê¥~¸ê°T¨ú¥N The World¡¦s Top Medical Journals www.healthwriterhub.com/top-medical-journals/ Top 10 Journals in Biology and Medicine dbiosla.org/publications/resources/topten.html Âå¾Çªº»â°ì¤Ó¼s ¯E¹©³Ì·Qµoªíªº´Á¥Z«ÜÃø²q ¦pªG¤S²Ó§óÃø²q´ú ¥unª¾¹D The World¡¦s Top Medical Journals »P Top 10 Journals in Biology and Medicine ´N°÷¤F |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/12 ¤U¤È 02:00:22²Ä 2362 ½g¦^À³
|
8 ·sÀù¯g§K¬ÌªvÀø OBI-833/834 Epithelial cancer ªÑªF·|¤½¥q´£¨ì§Y±N¥Ó½ÐIND OBI-833/834 ¬Ý°_¨Ó¬O¥u§ï¦õ¾¯ 9 ¤£n¥Î»ø¤Æªº«äºû¥h±À´ú«äºûÆF¬¡ªº¯E¹©,¦b¬ü°ê¹«~ÃĪ«ºÞ²z§½ U.S. Food and Drug Administration ªº¼u©Ê»PÆF¬¡¤Î¥H¯f±w¥Í©Rªº¦s¬¡¤ÎÃĪ«¦w¥þ©Ê¦Ò¶q¤U,¤£n¤@ª½»{¬°¥þ²y¤T´Á¤@©w¥H¥½´Á¨ÅÀù¬°¥l¶Ò¹ï¶H 10 ¤½¥q¦b2016¦~6¤ëªÑªF·|¦A«×»¡©ú½Ð¦U¦ì¤j¤j¤£¥Î¾á¤ßCMC 11 2016¦~6¤ëªÑªF·|¤½¥q¦³´£¨ìn¦b¦³¦Wªº´Á¥Zµoªí Ó¤H¬d¥X¥|¤j³»¯ÅÂå¾Ç´Á¥Z¬O«ü 1 ·s^®æÄõÂå¾ÇÂø»x¡]New England Journal of Medicine¡ANEJM¡^2015 Journl Impact Facter 59.558 2 ¬h¸¤M(Lancet) 2015 Journl Impact Facter 44.002 3 ¬ü°êÂå¾Ç·|Âø»x(Journal of the american medical association,JAMA) 2015 Journl Impact Facter 37.684 4 ^°êÂå¾Ç´Á¥Z(British Medical Journal,BMJ) 2015 Journl Impact Facter 19.697 kknews.cc/news/nmkyr3.html ¥H¤W¦@11«h¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¶³²H·»´10142966 µoªí®É¶¡:2016/8/12 ¤U¤È 12:35:42²Ä 2361 ½g¦^À³
|
¤£¦n·N«ä ¤p§Ìµo¤å¿ùªO À³·íµo¤å¦Ü¯E¹©²á¤Ñ«Ç sorry |
|
|
·|û¡G¶³²H·»´10142966 µoªí®É¶¡:2016/8/12 ¤U¤È 12:30:58²Ä 2360 ½g¦^À³
|
¤p§Ìè¨ì¦¹ª© ½Ð¦U¦ì¤j¤j«ü±Ð ¤p§Ì±oª¾¯E¹©³Q½Õ°ªÅv« ¥Nªí¥~¸ê¬Ý¤¤¥xÆW·sÃĪѤ]ªí¥Ü¥L̪¾¹D¥xÆWªº¥¼¨Ó©ú¬P²£·~¦bþ ¥L̲´¥ú¬Ýªº¤ñ¤@¯ë§ë¸ê¤j²³ÁÙ»· |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/12 ¤U¤È 12:29:34²Ä 2359 ½g¦^À³
|
1¦³«í¤j»¡ªº¹ï ¥»¦¸¸³¨Æ¿ïÁ|¬O³\¤Í®¥³Õ¤h°û©Ú,¥Ø«e¤´¾á¥ô¤½¥q¬Y©eû·|ªº©eû,«ùÄò«ü¾É¤½¥q,¬O¤½¥qªº¤j®aªø, ¤£·|Â÷¶}¤½¥q 2¥xÆW¯E¹©¥Í§Þ¡]4174¡^11¤é«Å¥¬¡AìÂå°Èªø³¯¯Â¸Û³Õ¤h¦]Ó¤H¦]¯À½ÐÃã¡A¦Û8¤ë10¤é¥Í®Ä¡A¤µ°_±N¥[¤JÂå¾Ç¿Ô¸ß©eû ·|¡AÄ~Äò¬°¯E¹©®Ä¤O¡C 3 ¤@Ó¦¨ªø©Êªº¤½¥q¾°ÈÅܰʬO«Ü¥¿±`ªº ,ªÑªF·|¤¤¶ÀÁ`¦³´£¨ìn©µÅó°ê¤º¥~Àu¨q³»¦y¤H¤~,¦b¾¦ì©T©w¦³±¡ªp¤U ¥² »Ýn®¿¥X¾¯Ê©µÀÁ°ê¤º¥~Àu¨q³»¦y¤H¤~ 4 6¤ë26¤éªÑªF·|¤½¥q´£¨Ñ¬Û¦h¤j®aºÃ¼{°ÝÃDªº¦^µª , 2¤ë22¤éªk»¡·|»P6¤ë26¤éªÑªF·|¨â¦¸±µÄòÅ¥¤~¯à¤ß»â¯«·| www.youtube.com/watch?v=0dbJhccA8GU 5 Âಾ©Ê¨ÅÀù¦³¯f±wNED, °ª´_µo©Êªº¤T³±©Ê¨ÅÀù¤]¦³¯f±wNED,¤@©w·|¥Ó½ÐBTD, ¤½§iªº¸ê°T¶V«á±¶V¦n,¥un±ø¥ó°÷¦n ¯E¹©¨S¦³²z¥Ñ©Úµ´822¨t¦C±ÂÅv,³o¦¸Á{§É¸ÕÅç¬O¦¨¥\ªº¥O¤H¿³¾Äªº ( Hope Rugo, M.D. ¤]¥Îexciting ¦r²´¨Ó¦æ ®e¥»¦¸Á{§É¸ÕÅç) ³¯Âå°Èªø´£¨ì: ¦]¬°¹ï·Ó²Õ¨S¦³¦A¤À¦³²£¥Í¨¬°÷§K¬Ì¤ÏÀ³»P¨S¦³²£¥Í¨¬°÷§K¬Ì¤ÏÀ³¨â²Õ, Ó¤H»{¬° ¦]¬°¹êÅç²Õ¦³¤À,¦b³oºØ±¡ªp¤U·|»~»{¹êÅç²Õ¨S¦³²£¥Í¨¬°÷§K¬Ì¤ÏÀ³ªº±Ú¸s¤ñ¹ï·Ó²Õ®t, ³o¬O¦]¬°¤@Ó¦³¤À诅,¤@Ó¨S ¤À²Õ, ¦p¦P®³¦³¤À²Õªº¹êÅç²Õ¦Ò30¤À40¤À50¤À»P¨S¤À²Õªº¹ï·Ó²Õ¦Ò60¤À70¤À80¤À¨Ó¤ñ¸û·íµM¬O¤£¤½¥ªº¤ñ¸û 6 ¥Ó½ÐBTD ¬ü°ê¼f®Ö®É¶¡¥u»Ý2Ó¤ë (60¤Ñ¤º )Ó¤H²q´ú¤w°e¥X¥Ó½Ð,¤E¤ëÀ³·|¦³®ø®§ 7 833¦¬®×¬Û·í¶¶§Q ¹w¦ô¦~©³§¹¦¨¦¬®×, ÁÞ´¹¤ù¥Î¦b·f°tÀù¯g¥ÎÃĨӴú¶q§ÜÅé¶q¥«³õ¤ñ¸û¤j,¤½¥q³oÓ½×z¤w±j¯Pªí¹F ¨ÅÀùOBI822 ²×±N¦¨¥\¤W¥« ¥H¤W´£¨Ñ°Ñ¦Ò |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/8/12 ¤U¤È 12:17:41²Ä 2358 ½g¦^À³
|
¹xµ£¤j,5619¤j ±z̤ӫȮð¤F!¥u¬O°w¹ï¦Û¤w¤F¸Ñ¨ìªº¸ê°T°µ»¡©ú! ¥tÂå°ÈªøÂ÷¾ì¦]¡A¤p§Ì¤£ª¾,§PÂ_¥i¯à¤]°Ý¤£¥X©Ò¥HµM¨Ó! ¤£¹L¤p§Ì±q¤½¶}Æ[´ú¯¸¬d¸ß¸g²z¤H¥Ó³ø¸ê®Æ¡AÂå°Èªø¥i¯à¬O104¦~1¤ë´N¥ô¥B¦W¤U¨ÃµL¯E¹©«ùªÑ¡A¼vÅT©ÊÀ³¸Ó¤£¤j¡A ¥B¥ý«e¯E¹©®×ªº½T¥i¯à¹ï¤½¥q³¡¤Àû¤u©Î¸g²z¤H¤ß²z±³y¦¨¥´À»¡AÂå°Èªø¦n¹³¬O¥HÃÒ¤H¨¤À³Q¶Ç°T¡A²{Â÷¾¡A ¥[¤W³\°Æ¸³¦^°ê¦ü¥G¤]¨S¦³¦A³Q¬ù½Í¡A¤£ª¾¬O§_ªí¥Ü¯E¹©®×°»¬d§Y±N¦³¦nªºµ²ªG¡A´Á«Ý¤¤¡A¥H¤W¬O¤p§Ì¦Û¤vªº·Qªk¡A¨Ñ°Ñ! |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/8/12 ¤W¤È 11:41:12²Ä 2357 ½g¦^À³
|
¦³«í¤j: ÁÂÁ±zÁ`¬O²Ó¤ß¥B¼ö¤ßªº¬d¸ß¤Î¤À¨É ¹³É¨é¸ê°T¤Î³\³Õ¤hªº°Ê¦Vµ¥µ¥. ½Ð°Ý±zª¾¹DÂå°Èªø´«¤Hªºì¦]¶Ü? |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/12 ¤W¤È 11:40:00²Ä 2356 ½g¦^À³
|
ÁÂÁ¦³«í¤jªº¸ÑÄÀ¡C ¸g²z¤Hªº«ùªÑ¨C¤ë¥Ó³ø¡C¡§©eû·|¡¨¦¨û¤£¦bªk³Wªº¥Ó³ø½d³ò¡C³o¦ü¥G¬Oªk³Wªºº|¬}¡C¦³¨Ç¡§©eû·|¡¨©Ò±µÄ²ªº¾÷±K¶W¹L¸g²z¤H¡A§Æ±æ¯E¹©«µø¤½¥qªv²z¡AÁקK¸¨¤H¤f¹ê¡C½Ð¦b¦¹¼ç¤ôªº¤½¥qû¤u¶Ç¹F¤pªÑªF·N¨£¡C |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/8/12 ¤W¤È 11:24:54²Ä 2355 ½g¦^À³
|
5619¤j ³oÓ°ÝÃD,¤p§Ì¦³½Ð±Ð¹L¤½¥q,¥»¦¸¸³¨Æ¿ïÁ|¬O³\¤Í®¥³Õ¤h°û©Ú,¥Ø«e¤´¾á¥ô¤½¥q¬Y©eû·|ªº©eû,«ùÄò«ü¾É¤½¥q,¬O¤½¥qªº¤j®aªø,¤£·|Â÷¶}¤½¥qªº,¥H¤W¨Ñ°Ñ |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/12 ¤W¤È 10:51:33²Ä 2354 ½g¦^À³
|
³\¤Í®¥³Õ¤hÂ÷¶}¯E¹©¤F¶Ü¡H¤£¦A¬O¸³¨Æ¡A¤]¤£¬O¸g²z¤H¡]¤£¬Oû¤u¡^¡C³\³Õ¤h¬O¤½¥qªº¦@¦P³Ð¿ì¤H¡A·sÃĶ}µo»PÁ{§É¸ÕÅ窺«n°Ñ»PªÌ¡A¥Lªº°Ê¦V¡A¤½¥qÀ³¸Ó¦³Ó»¡©ú¡A¦Ó¤£¬OªÑªF·|«á¤½§G·s¤@©¡¸³¨Æ¿ïÁ|µ²ªG´Nºâ¤F¡CºÃ´b¡C |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/8/12 ¤W¤È 09:42:21²Ä 2353 ½g¦^À³
|
§Z±_Àù¯e¯f´c©Ê«×°ª¡A¥B´_µo¾÷²v«D±`°ª¡A´c¤Æµ{«×¤ñ¨ä¥LÀù¯gªº¨Ó±oÄY«¡C²Ä¤@´Á¡B²Ä¤G´ÁÁÙ¦³¾÷·|²¬Â¡¡A¦ý¦pªG¨ì¤F²Ä¤T´Á¥H«á¡AªvÀø´Æ¤â¡A¦s¬¡²v¤£¼ÖÆ[¡C ¼B´_¿³ªí¥Ü¡A§Z±_¦ì©ó¦b°©¬ÖµÄ¤¤¶¡¡A¤j¤p´N¹³¤@Ó3¦Ü5¤½¤Àªº®Ö®ç¡Aªì´Á§Z±_Àù¨ÃµL¯gª¬¡Aª½¨ì¸¡µÈ´eµh¡A´NÂå±µ¨ü¶WµªiÀˬd¡Aµo²{¸¡µÄ¤º³£¬O¸¡¤ô¡A³o®É¦Ü¤Ö¤w¸g¨ì¤F²Ä¤T´Á¡C 6¦¨¤ÆÀø¥b¦~«á´_µo ¶Ç²ÎªvÀø¤W¡A§Z±_Àù±wªÌ¥u¯à«ùÄò¨Ï¥Î¤Æ¾ÇªvÀø¡A¦ý¤»¦¨¯f±w¦b¤ÆÀøÀøµ{µ²§ô«á¥b¦~¤º´_µoÂಾ¡CÁ{§ÉÅã¥Ü¡A±ß´Á§Z±_Àùªº¥§¡¤¦~¦s¬¡²v¶È¦³20%¡A²Ä¥|´Áªº¤¦~¦s¬¡²v§ó¬O¤p©ó5%¡C §Z±_Àù´_µo²v°ª¡BP¦º²v°ª¡A±wªÌ©ó¤ÆÀø«á´X¥GµL¥Í¬¡«~½è¥i¨¥~~~~ ¥H¤W¬O§Ú¦bºô¸ô¤Wgoogle¨ìªº¸ê®Æ ¥Ñ¦¹¬Ý¨Ó§Z±_Àù¬Û·í¥û²r ±wªÌ¦³«Ü¤jªº¥i¯àÁÙ¨S¨Ó±o¤Î²£¥Í§ÜÅé´N¤S´_µo¤F §ÚÓ¤H¹ïobi822¥Î©óªvÀø±ß´Á§Z±_Àù¤£©ê¤Ó¤jªº«H¤ß ¤£ª¾¹D¦U¦ìªº¬Ýªk¦p¦ó¡H |
|
|
·|û¡GFaFaFa10140966 µoªí®É¶¡:2016/8/12 ¤W¤È 04:54:54²Ä 2352 ½g¦^À³
|
¤j¤j: ½Ð°Ý °¨°ºªºOBI-822§Z±_ÀùÁ{§É¸ÕÅç«ç¼ËªºOS¤~ºâº}«G? ¦ôp¨ìþ¤@¦~þ¤@©u«e°¨°º³£ÁÙ¨S¤½§GÁ{§É¼Æ¾Ú³£ºâ¬O¨S®ø®§´N¬O¦n®ø®§? ÁÂÁÂ! |
|
|
·|û¡Gªü©v10140551 µoªí®É¶¡:2016/8/8 ¤U¤È 07:56:39²Ä 2351 ½g¦^À³
|
BMYªº©ú¬PÃÄOpdivoªºCheckmate-026©P¤¤½¥¬NSCLCªºÁ{§Éµ²ªG¡A¥¢±Ñ Á{§É¿z¿ï¤FPD-L1>5%ªº¯f±w541¤H¡A¤À¨â²ÕNivolumab ¨C¤½¤çÅé«3mg¡A¨â©P¬I¥´¤@¦¸¡C¥t¤@²Õ«h¬O²{¦³ÃĪ«ªº¤ÆÀø¡Aµû¦ôªº¥Dn¥Ø¼Ð¬OPFS¡A¤S¬OPFS¡Aµ²ªG¤]¥¢±Ñ¡A§Ú¬ÝÁÙ¬O¤£n¥ÎPFS¤ñ¸û¦n¡C³oÓÁ{§Éªº¼Æ¾Ú¸òPȳ£¨S¤½¥¬¡C ©P¤¡ABMY«®À16%¡A¾Ö¦³KeytrudaªºMRK¡A¬Ý¨ì¹ï¤â¥¢±Ñ¡A«Ü¶}¤ßªº¤Wº¦10%¡C Checkmate-026ªº¦¸n¥Ø¼ÐªºORR¡BOS¼Æ¾ÚÂ÷¦¨¼ô³£ÁÙ¦¡A©Ò¥H¡A§ÚÌÄ~Äò¬Ý¤U¥h¡C ÃD¥~¸Ü¡AMerckªºkeytruda¬D¿ïPD-L1ªºªí¹F²v³£n50%¥H¤W¡ABMY³o¦¸¥un¨D5%¡A¬O¤£¬O½ä¤Ó¤j?? ¥t¥~¡A822ªº¤T´Á¡A·|¿z¿ï¯f¤H¶Ü?? |
|
|
·|û¡G²´10000155 µoªí®É¶¡:2016/8/5 ¤W¤È 08:39:15²Ä 2350 ½g¦^À³
|
www.medscape.com/viewarticle/865148 ³oºô§}¦³Dr. Hope Rugo¦b6/22±µ¨ü³X°Ýªº¬ÛÃö¸ê°T À³¸Ó»Ýn¥[¤J·|û¤~¯à¬Ý§a? Ãö©ó822½Ð±q10:48¶}©lªY½à ¤£¹LnÅ¥^¤å¬Ý^¤å´N¬O...*_* °µ¥\½Ò§a ¥[ªo |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/5 ¤W¤È 08:29:42²Ä 2349 ½g¦^À³
|
°Ñ»P2016¦~ESMO¹ï¥xÆW¯E¹©¨Ó»¡¬ÛÃö«n¡A¦]¬°¼Ú¬wÄÝ©ó¯E¹©³W¹ºªº¦X§@±ÂÅv¦a°Ï¡A³oÓ¦b¼Ú¬w·Ó¶}ªº¥þ²y²±·|¦p¦PÄv§Þ³õ¤@¯ë¦U¦Û®i²{¹ê¤O¡A®Ú¾Ú2014¦~ESMO²ÎpÁ`¦@¦³¨Ó¦Û134Ó°ê®a19809¦ì°Ñ»PªÌ¡A460¦ì¨üÁܽР¾á¥ôspeaker,¦³21Ó®i¥Ü³q¹D¡A180Ó¬ã°Q·|¡AÁ`¦@´£¥æ2754½g½×¤åºKn 2016¦~±¡ªp·|¬O¦p¦ó?¤j®a«ø¥Ø¥H«Ý¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/4 ¤U¤È 11:18:49²Ä 2348 ½g¦^À³
|
Ó¤H¹ï822 ASCO slide No.11»PNo.18ªº¬Ýªk¡G No.11¸ü©úÀH¾÷¤À°t«á¹êÅç²Õ»P¹ï·Ó²ÕªºBaseline Characteristics¡A³o±iªíªºì©l¥Î·N¤£¬O¥Î¨Ó¬Ý822¦bþÓ±Ú¸s·|¦³®Ä¡C¦Ó¬O³z¹L³o±iªíªº¦U¶µ¤ÀªR¤ñ¸û¡A§i¶D§ÚÌ©Ò¦Cªº¨C¤@ÓÅܶµ¡A¤w³Q³]p±±¨î¤U¨Ó¡A©Ò¥H¦b¸ÕÅ窺³]p¤U¡A¹êÅç²Õ»P¹ï·Ó²Õªº³o¨ÇÅܼƤw¸gµL²Îp®t²§¡A¤]´N¬O¤£³Q³o¨ÇÅܼƼvÅT¡C©Ò¥H¨C¤@¶µªºpȤ@©wn¬O>0.05¤~¬O¹ïªº¡CY¦³¥ô¤@¶µp<0.05, ¨º¸ÓÅܶµ´N¥i¯à·|¤zÂZ³Ì«á¨â²ÕªºÀø®Ä¤ñ¸û¡A¨º¨Ã«D¼Ö¨£¡C ³o±iªíªº»ùÈ»Pºë¯«¦b©ó¨C¤@¶µÅܼƦb¨â²Õ¤§¶¡³£¬Op>0.05¡C ¥Øªº¬O·Qn¨Æ¥ý§â·Q±o¨ì¡B§ì±o¨ìªºÅܼƦb³oùØ¥ý±±¨î¤U¨Ó¡Aµ¥¨ì³Ì«á¸Ñª¼µ²ªG¥X¨Ó®É¡A¦pªG¸ÕÅç²Õªº½T¥X²{Àø®Ä¡A«h¥i¥H§â¨ºÓÀø®Ä¥þ³¡Âk¥\©ó¸ÕÅç²Õ¥´¤F822ªºÃö«Y¡C No.18«hÀ°§U§Ú̧ä¥X¦³Àø®Äªº¦¸¸s¡AÀ°§U¤ÀªR¥H§Q¤U¶¥¬q²Ä¤T´ÁÁ{§É¸ÕÅ窺³]p¡C Ó¤H»{¬°¸Ñª¼«á³¡¤À´CÅé»~§âNo.11¸ÑŪ¬°¡uªvÀø¤ÏÀ³»P±wªÌÅ餺Globo Hªºªí²{µLÃö¡C¡v¡F¥BÓ¤H»{¬°¤½¥qÀ³¬O±qNo.18±oª¾¡u¥HOBI-822ªvÀø«á²£¥Í§ÜÅé»P§_¡A»P¬O§_±a¦³Globo-H¨S¦³ÅãµÛ¬ÛÃö©Ê¡F¥ç§Y¨S¦³Globo-H§ÜìªÌ¡A¸gOBI-822ªvÀø«á¥ç¯à²£¥Í§ÜÅé¡A¡K¡v ¹x¥Û¤j¡G ¡uHerceptin¸g¹L¦h¦~¹ê»Ú¨Ï¥Î¤§«áÁÙ¯à³vº¥ÂX¤j¨Ï¥Î½d³ò¡A©Î³\¤£³æ¯Â¬O«ü¼Ð§PŪªº°ÝÃD¡C¡v¤p§Ì»P±z¬Ýªk¨ÃµL¤£¦P¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/4 ¤U¤È 12:03:46²Ä 2347 ½g¦^À³
|
5619¤j 1ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{¶qµL¬ÛÃö¡]©Ê¡^Ó¤H»{¬°³o¤w¬O«Ü¦nªº¬ì¾Ç¨Æ¹ê§e²{»P»¡©ú «ÂI¬O¯à¤£¯à²£¥Í¨¬°÷§ÜÅé, ¤£¬O¬Ý¨ÅÀù¨È«¬©ÎGlobo H ªí²{ ,§Ú¤£ª¾¹D¤½¥q¬O§_·|¤½§GSSEA3 SSEA4 ¬ÛÃö¼Æ¾Ú ©Ò¥H§Ú¤~¥Î¥i¯à¨âÓ¦r,Ó¤H»{¬°«nªº¬On¬Ý¯à¤£¯à¦b¦w¥þ¦³«~½èªºªvÀø¤U¯àªø´Á¦s¬¡,³o¬O¯f±wnªº, ¤]¬O¬ü°êFDAnªº,¯E¹©nªº¬OÃĪ«¯àºÉ§Ö¤W¥«»P¨ÅÀù¾A¥Î¤H¤fµo´§¨ì·¥¤j¤Æ´ÀªÑªFª§¨ú³Ì¤j§Q¯q,§Únªº»P¤½¥qnªº¨S¦³¤£¦P 2¤K¤ë¦³¤@¦ì°ê»Ú¯Å¨ÅÀù±M®an¨Ó¥x ©¡®Én¯S§Oª`·N°T®§¤½§i |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/8/4 ¤W¤È 11:09:46²Ä 2346 ½g¦^À³
|
¥xÁÞ¤j¡AÁÂÁ±z¸Ô²Óªº»¡©ú¡C ¦³§ÜÅé´N¦³Àø®Ä, ¬Oªº¡C ªvÀø¤ÏÀ³Åã¥Ü»PGlobo Hªí²{¶qµL¬ÛÃö¡]©Ê¡^, ¬Oªº¡A¤½¥q§ë¼v¤ù¬O³o»òªí¥Üªº¡C ¬°¦ó·|¦³¦p¦¹µ²ªG¡H±z»¡¡§¥i¯à»PSSEA3 SSEA4 ¦³Ãö¡¨¡A ¡§¥i¯à¡¨¤@µüªí¥Ü¤£½T©w¡A¤½¥qµo¥¬ªº°T®§¦ü¥G±q¥¼¦³ªÖ©w¤§·N¡C ¡§¤£¬O¡¨©Î¡§«Ý¼á²M¡¨¡H ³o¤´¬O¤p§Ì¤ß¤¤ªººÃ°Ý¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/4 ¤W¤È 09:48:35²Ä 2345 ½g¦^À³
|
5 ¨ÅÀùOBI822³oÁûÃÄ ¹ïHer2¶§©Ê¨ÅÀù ,¤T³±©Ê¨ÅÀù, ¶Pº¸»X¶§©Ê¨ÅÀù³£¦³ªvÀø¤ÏÀ³ ©Ò¥H¤~·|²£¥ÍµL¬ÛÃö¡]©Ê¡^ ´NºâÂX¤j¼Ë¥»¼Æ¤]¥i¯à·|¦³¦P¼Ëµ²ªG 6 2016 ASCO §ë¼v¤ù18 PFS: ¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{ ¦³§K¬Ì¤ÏÀ³ªÌ vs. ¦w¼¢¾¯ ¦³§K¬Ì¤ÏÀ³ªÌ vs. µL¤ÏÀ³ªÌ ³o¨â²Õªº·ÀI¤ñÈ hazard ratio Áö¦³¤@¨Ç®t¶Z,¦ý¥þ³¡¦V¥ª¬Ý,¨S¦³¦V¥k¬Ýªº ( ªí¥Ü¤£½×¸~½F¥Íª«¼Ð°O¨È«¬¬°¦ó¤ÎGloboH ªí²{ ³£¦³Àø®Ä) 7 ¦³§ÜÅé´N¦³Àø®Ä, «ÂI¬O¬Ý¯à¤£¯à²£¥Í¨¬°÷§ÜÅé, ¤£¬O¬Ý¨ÅÀù¨È«¬©ÎGloboH ªí²{ ,888¦]¬°²£¥Í§ÜÅé ¤½¥q·íµM·|¥þ¤Oµo®i |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/4 ¤W¤È 09:00:35²Ä 2344 ½g¦^À³
|
¯E§J¤j ¤½¥q 6/5 ASCO ¤½¥¬§ë¼v¤ù¡@«á¨Ó¦³µo¤½§i¡@×¥¿ 2016 ASCO §ë¼v¤ù: ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{¶qµL¬ÛÃö, µL¬ÛÃö¡]©Ê¡^¡@Ó¤H»{¬°³o¬O¨Æ¹êªº§e²{»P»¡©ú ¥H¤U¬OÓ¤H¸ÑŪ: 1 ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬n¦³¬ÛÃö¡]©Ê¡^ ¨Ò¦p¥²»Ý¹ïA¨È«¬¦³ªvÀø¤ÏÀ³, ¦ý¹ïB¨È«¬»PC¨È«¬µLªvÀø¤ÏÀ³, ¦³²Îp®t²§¤~·|¦³¬ÛÃö¡]©Ê¡^°¾°¾¨ÅÀùOBI822³oÁûÃÄ ¹ïHer2¶§©Ê¨ÅÀù ,¤T³±©Ê¨ÅÀù, ¶Pº¸»X¶§©Ê¨ÅÀù³£¦³ªvÀø¤ÏÀ³ ©Ò¥H¤~·|²£¥ÍµL¬ÛÃö¡]©Ê¡^ 2¤ëªk»¡YK´£¨ì·í¥X¦¬®×®É¨Ã¨S¦³¯S§O¥h¿z¿ï¨ÅÀù¨È«¬ ¥¼¨Ó¤W¥««á¨Ï¥Îªº¤H¤f¼Æ·|«D ±`¤j¤£·|¨ü ( µL¬ÛÃö©Ê¤£¬OµL®Ä ¤£n³Q»~¾É) 2 ªvÀø¤ÏÀ³Åã¥Ü»PGlobo Hªí²{¶qµL¬ÛÃö¡]©Ê¡^, (µL¬ÛÃö©Ê¨Ã¤£¬OµLÀø®Ä¤£n³Q»~¾É),Globo Hªí²{¶q¦³ 0 +1 +2 +3 ¬ã¨sµ²ªGµo²{ : Globo H +3 ¦³ªvÀø¤ÏÀ³ ,Globo H +2 ¤]¦³ªvÀø¤ÏÀ³, Globo H +1 ¤]¦³ªvÀø¤ÏÀ³ , Globo H 0 ¤]¦³ªvÀø¤ÏÀ³, ¦]¬°³£¦³ªvÀø¤ÏÀ³·íµM·|²£¥Í»P Globo Hªí²{¶qµL¬ÛÃö©Êªºµ²ªG,¥¼¨ÓÃĪ«¤W¥««á¨Ï¥Î ªº¤H¤f¼Æ¤]¤£·|¨ü 3 ¬°¦ó·|¦³¦pµ²ªG ¥i¯à»PSSEA3 SSEA4 ¦³Ãö (¬ü°êªk»¡Â²³ø 12¶¹Ïªí:¯f¤H²Õ´¤Á¤ù&Àù²ÓM®è SSEA-3 60% ªí²{, SSEA-4 90% ªí²{ , Globo H 60-80% ªí²{) 4 2¤ëªk»¡YK´£¨ì: ¨S¦³¿z¿ï Globo H ¬O¥¿½T¨M©w |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/8/4 ¤W¤È 08:26:42²Ä 2343 ½g¦^À³
|
Cliff¤j¡A ¤p§Ì¥H¬°¡AHerceptin¸g¹L¦h¦~¹ê»Ú¨Ï¥Î¤§«áÁÙ¯à³vº¥ÂX¤j¨Ï¥Î½d³ò¡A©Î³\¤£³æ¯Â¬O«ü¼Ð§PŪªº°ÝÃD¡C HerceptinÁÙ¬O¦³¬Û·íªº°Æ§@¥Î¡A¥ÎÃįA¤Î¦w¥þ©ÊÅU¼{¡C©Ò¥H¹ï©ó¤ñ¸ûmarginalªº¯f¤H¡AY¤£²Ó¥[§P§O´N§ëÃÄ¡A«Ü¥i¯à¹ú¤j©ó§Q¡A¤Ï¦Ó®`¤F¯f¤H¦h¨ü¸o¡C©Ò¥H¤W¥«¤Q¾l¦~«á¡A²Öp¼Æ¤Q¸U¯f¨Ò¡A¤~§ä¥X³o¨Çmarginal (HER2++)¯f¤H¤¤ªº¤@³¡¥÷¤´¬O¾A¦X¨Ï¥Î¸ÓÃĪ«ªº¡C 822¹ï¤£¦P¨È«¬ªº¯f±wÀø®Ä¬Û®t¦h¤Ö¤´¤£²M·¡¡A¦ý¬O¥un¦w¥þ©Ê³£«Ü°ª¡A°ò¥»¤WÂå¥Í§ëÃÄ«KµL»ÝÅU§Ò¡AÁ{§É®Öã¥é³æ¼e¯¶¬O½Ö¥I¿úªº°ÝÃD¡C¦pªG®Öã±o¯¶¡A«D¥é³æ½d³òªÌ¥²¶·¦Û¶O¡A©TµM¼vÅT¥«³õ¦¨ªø¡A¦ý¬O²Ö¿n¤@©wªº¨Ï¥Î¯f¨Ò¼Æ¡A¦A³v¨B¥Ó½ÐÂX¥R¨Ï¥Î¹ï¶H¡A¦b822À³¸Ó¬O¥i¦æªº¡C²¦³º¡AµL¦w¥þÅU¼{¬O¨äµ´¹ïÀu¶Õ¡C ¦³¿ù»~³B½Ð«ü¥¿¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/8/4 ¤W¤È 08:10:21²Ä 2342 ½g¦^À³
|
¥t¥~¸É¥R ¤½¥q 6/5 ASCO ¤½¥¬§ë¼v¤ù¡@«á¨Ó¦³µo¤½§i¡@×¥¿ 2016 ASCO §ë¼v¤ù: ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{¶q¡@¡@µL¬ÛÃö µL¬ÛÃö¡]©Ê¡^¡@¤£µ¥©óµLÃö¡]³o¥]§tµL¦]ªG©Ê¤ÎµLÃö³s©Êªº·N«ä¡^ «eªÌ¬O¬ÛÃö©Ê¦ÒÅ祼¹FÅãµÛ¡@¬O²Îp¤Wªº¦ÒÅçµ²ªG¡@¤£¥Nªí¨S¦³¹ê»Ú¤WªºÃö³s©Î¦]ªGÃö«Y¡@ ¬ÛÃö¬ã¨s¤§²Îp¦ÒÅ禳®Ä©Ê»P§_¡@±`¥Î²Îp¦ÒÅç¤O»P«¬¤@©Î«¬¤G¿ù»~¨Ó»¡©ú¡@²o¯A¼Ë¥»¤j¤p¡@´ú¶q¤èªk ¡@´ú¶qÅܶµ ¤wª¾¤G´Á¬ã¨sªº¸~½F¨È«¬»P¥Íª«¯S¼x¤ÀÃþ¼Ë¥»¼Æ¤Ó¤Ö¡@¡@©Ò¥H¤£¯à¦³®Ä±À½×¬O§_ÅãµÛ¡@À³¬OµL±eÃhºÃ Ó¤H¢¤Á´Á«Ý¡@¦³¹êÅç¬ã¨s¨ÓÅçÃÒ¦]ªG©Ê¡@¥Íª«¯S¼x¨È«¬»PÀø®Äªº¦]ªGÃö«Y¡@¦Ó«D¬ÛÃö¬ã¨s¡]³o¥u¬OÅçÃÒÃö³s©Ê¡^ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/8/4 ¤W¤È 07:33:02²Ä 2341 ½g¦^À³
|
¥xÁÞ¤j Ó¤H¥H¬ì¾Ç¹êÅ窺¨¤«×¨Ó»¡ ¤G´Á¹êÅç¸~½F¨È«¬»P¥Íª«¯S¼x¤ÀÃþ¤§¼Ë¥»¼Æ ¹L¤Ö ¾ÉP¬ÛÃö©Ê¤£ºÞÅãµÛ»P§_ ³£¦]¬°²Îp¦ÒÅç¤O§C ¦Ó¤£¾A¦X°µ¥X¦³®Ä©ÎµL®Äªºµ²½×. ·|¥Ç¤@«¬¿ù»~©Î¤G«¬¿ù»~ ¦ý¬O´N¬ì¾ÇªvÀø¾÷Âàì²z §ä¥X¥Íª«¯S¼x¤ÀÃþ »PÀø®ÄªºÃö«Y ¬O³Ì¥i¥H¤ä«ùªvÀø¾÷Â઺ÅçÃÒ¤èªk¤§¤@ ¦pªG°²¦p ¥Íª«¯S¼x¤ÀÃþ»PÀø®ÄµLÃö ¨º»ò888ÁÙÄ~Äò°µ¶Ü 888¹wp¬OGH³æ§Ü ¬O°w¹ï³æ¤@§ÜìGH ¦¹§ÜÅé§Üì³æ¤@©Ê ¤£®e²V²c ¦AªÌ868ÁÞ´¹¤ù´Nºâ¦³®Ä´ú¥X¥Íª«¯S¼xGH ¤S¦³¦ó¥Î¡H YÀø®Ä»PGHµLÃö¡A¨º¤£¥Î¿z¿ï´ú¸ÕGH¤F 868´N¤£¥Îµo®i¤F ¦^¨ì¸~½F¨È«¬ ´N¸~½F¨È«¬»PÀø®ÄªºÃö«Y §ÚÓ¤H¤ñ¸û¤£¦b·N ³o¬OÀ³¥Î¥«³õªº¤j¤p°ÝÃD Y822¹ïA¨È«¬¦³®Ä ¦ÛµMFDA¨üÃÒ¾A¥ÎA¨È«¬ ¦ý¬OÁ{§É¤W ¤H¤§±N¦º ÂX¤j¨Ï¥Î©ó¨ä¥L¨È«¬ ±`¦³ªº¨Æ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/8/3 ¤U¤È 11:10:04²Ä 2340 ½g¦^À³
|
¯E§J¤j 1 2016¦~2¤ëªk»¡°w¹ï¥¼¨ÓGHªº¤ÀÃþ©Ò¹ïÀ³ªºªvÀø±Ú¸s¶ÀÁ`¤w¦³»¡©«, ¥i¦AÅ¥¤@¦¸«á¦A»P¯E¤Í¤À¨É§AÅ¥¨ì¤°»ò 2 2016 ASCO §ë¼v¤ù21 : ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{¶qµLÃö §A·Q¨ì¤°»ò? §A»{¬°¬ã¨sµ²ªG¦³Ãö¤ñ¸û¦n ÁÙ¬OµLÃö¤ñ¸û¦n? ±ø¤j: ¦A¥X¨Ó´«´«®ð ¦nªÅ«~ªº¤é¤l¤£¦h¤F ( ¨C¦~5¤ë¤ë¦Ü10¤ë¥xÆWªÅ«~³Ì¦nªº®ÉÔ ¤@¤ùºñªoªo) ¦pªGªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo H ªí²{¶q¦³Ãö §ÚÓ¤H»{¬°¥N»x´N¤j±ø¤F ¥H«e´¿¶K¤å¤À¨ÉªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬µLÃö¬O¦n¨Æ, ©¯¹Bªº¬OªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo H ªí²{¶qµLÃö ( ¥i²Ó¤À¦¨¨â³¡¥÷) A ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬µLÃö B ªvÀø¤ÏÀ³Åã¥Ü»PGlobo H ªí²{¶qµLÃö ¤£ª¾±ø¤j¦³¦ó°ª¨£? ¬ã¨sµ²ªG¦³Ãö¤ñ¸û¦n ÁÙ¬O¬ã¨sµ²ªGµLÃö¤ñ¸û¦n? |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/8/3 ¤U¤È 10:12:06²Ä 2339 ½g¦^À³
|
cliff¤j ì¨Ó¦p¦¹¡A¨º»ò§Ú´N¤£¥Î¦h·Q¤F¡C ¦ý¬OÁÙ¬On·PÁ±zªº¤À¨É ¦]¬°Åý§Ú·Q¨ì ¥¼¨ÓGHªº¤ÀÃþ ©Ò¹ïÀ³ªºªvÀø±Ú¸s¡A«Ü¥i¯àÃþ¦üHERªº¨Ò¤l¦Ó©ñ¤j¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/3 ¤U¤È 08:36:07²Ä 2338 ½g¦^À³
|
«ù¤[ªº¯E§J¤j¡G ©êºpÅý±z¶O¯«¤F¡C ³æ¯Â¬O«üHER2 testing§PŪ¼Ð·Ç¤£¦P©Òl¦ù¥X¨ÓªºÀø®ÄªºÅU¼{¡A¤£¬O¸òGH 0 1+ 2+ 3+¦³Ãö¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/8/3 ¤U¤È 12:40:43²Ä 2337 ½g¦^À³
|
Cliff¤j ±z´£¨ìHER2(+)ÀËÅ窺¤èªk ¤p§Ì·Q¤F¤@±ß ¨S¦³·Q¨ì¸òGH 0 1+ 2+ 3+¦³¦óÃö³s ¥i§_©ú¥Ü¤@¤U¡H ·P®¦ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/8/2 ¤U¤È 09:33:45²Ä 2336 ½g¦^À³
|
¤@¶g«e°Q½×¤FHER2(+)ÀËÅ窺¤èªk»P§PŪªººØºØ¡]¥»ª©²Ä2358½g¦^À³¡^¡A¬Q¤Ñ¡]8/1¡^ªº¤@«h¥~¹q³ø¾É¡A¥¿¦n¤]¸ò³oÓ¥DÃD¦³ÂIÃö³s¡A´£¨ì¥Zµn¦b2016/7/25ªºÁ{§É¸~½F¾Ç´Á¥Z¡]JCO¡FJournal of Clinical Oncology¡^ªº¤@½g¤å³¹¡A¤ÀªR¤F2013¦~HER2ÀËÅç§PŪ¼Ð·Çªº×q¡AÅý²Å¦XHerceptin©ÎTykerb©ÎPerjetaªvÀøªº±Ú¸s¦h¥X¬ù10+ ¢H¡C I´º»¡©ú¡G ¨ÅÀù±wªÌY¸gÀËÅ笰HER2(+)ªÌ¡A¥i¥H¾A¥ÎHerceptin©ÎTykerb©ÎPerjetaªvÀø¡F©Ò¿×¶§©Ê«üªº¬OHER2¡]+++¡^¤~ºâHER2-positive¡AY¥u¦³¡]++¡^«h¥²¶·¦A°µFISH½T»{¡CÀËÅç©Ò¨Ì´`ªº§PŪ¼Ð·Ç¸g¹L¾ú¦~¨Óªº×q¨´¤µ¤w¨ì¤F²Ä¤TÓª©¥»¡A±q³Ì¦ªº1998¦~Herceptin¨ú±oÃÄÃҮɪºFDA¼Ð·Ç¡A¨ì2007¦~ASCO×q¬°AC2007¡A¦A¨ì2013¦~ASCO¦A×q¦¨¬°²{¦bªºAC2013ªº¼Ð·Ç¡C ³o«h¥~¹q³ø¾É¡G¡ubreastcancer-news.com/Number+of+HER2-positive+Breast+Cancers+Double+Under+New+Guidelines¡v 2016/07/25 JCO¬ã¨s½×¤å¡G¡ujco.ascopubs.org/content/early/2016/07/19/JCO.2015.61.8983.full¡v ¬ã¨sµo²{¡A쥻¥HAS2007¬°§PŪ¼Ð·Ç®É¡A¤@¨Ç³B©ó¦Ç¦â¦a±a¡]equivocal¡^¡A¤]´N¬OHER2(++)ªº±wªÌ¡A±µ¨ü¶i¤@¨BªºFISHÀËÅç®É¡AY¥H1998¦~FDA¼Ð·Ç¨Ó§PŪ·|¦³11.8%¦]¦¹³Q§PŪ¬°HER2 positive¡FY¥HAC2007¦~¼Ð·Ç§PŪ·|¦³9.4%³Q§PŪ¬°HER2 positive¡FY¥HAC2013¦~¼Ð·Ç¨Ó§PŪ·|¦³24.1%³Q§PŪ¬°HER2 positive¡F¦h¥Xªº10+¢H±wªÌ¥i¥HÀòã¥ÎHerceptin¨t¦CªºÃĪ«ªvÀø¡C¡]§Ú±Ä¬ã¨s½×¤å¤Wªº¼Æ¾Ú¡^ ¬ã¨s¤¤´£¨ì³o¨Ç¦h¥X¨Óªº±Ú¸s¡A¦b·í¦~Herceptin¨ú±oÃÄÃÒªºpivotal study¤¤¬O¤£·|³Q¦C¤J¦¬®×ªº¡]¥H¦¬IHC HER2(+++)±wªÌ¬°¥D¡^¡A©Ò¥HHerceptin¹ï³oÓ¸sÅ骺Àø®Ä¬O¥¼¸g»{ÃÒªº¡A§@ªÌ»{¬°À³¸Ón¥[¥HÂç²M¡C Herceptin¨t¦CªºÃĪ«¦³¨S¦³¦]¦¹³Ð³y§ó¦hªº¦~¾P°â¶q¡H¥i¥H°Ñ¦Ò¤@¤U³oùتºHerceptin »PPerjetaªº³v¦~¾P°â¶q²Îp¡G¡updl.com/royalty-revenue/historical-product-revenue/¡v |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/7/29 ¤W¤È 01:07:03²Ä 2335 ½g¦^À³
|
§ó¥¿ 5 6 888Á{§É³]pÁÙ¨S¦³´£¥X¨Ó¡A¦pªG¤£»Ýn¦A¥[´£¤É§K¬Ì¤Oªºcyclophosphamide «h§R°£ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/7/29 ¤W¤È 12:07:46²Ä 2334 ½g¦^À³
|
To¥xÆW¯E¹©¥Í§Þ¤½¥q ´å¬ãµoªø ¬ãµo³B³Bªø¿à³Õ¤h, ÂàĶÂå¾Ç°ÆÁ` §E³Õ¤h 1¬ü°êÁ{§É¸~½FÂå¾Ç·|¤ë25¤é¥X¥Zªº¡uASCO POST¡vÂå¾Ç³q°T¡A¯S§O¤¶²Ð¨ã®i±æ©Êªº¨ÅÀù·sÀøªk¡F¥xÆW¯E¹©©Ò´£¥XªºOPT-822/OPT-821²Ä¤G/¤T´ÁÁ{§É¸ÕÅ禨ªG¡A¤]¦b¸Ó¥Z³ø¾Éªº¤TºØ¨ÅÀù·sÀøªk¤§¦C,ªÑªF¤Ñ¨ì³oÓ®ø®§¬Û·íªY¼¢,³o³£¬O¥xÆW¯E¹©¥Í§Þ¤½¥q¬ãµo¤Hû§V¤Oªº¦¨ªG 2¥¼¨ÓOBI 822 833 888 Á{§É¸ÕÅ禳¨Ç¦ÑÃÄ·s¥Î¤]ȱo¹Á¸Õ°µ¬°Áp¦X¥ÎÃÄ,¯S§O¬O¨º¨Ç³Qµo²{¯à®ø°£Àù¯g·F²ÓMªº¦ÑÃÄ ÅýOBI 822 833 888 ªºÃĮĵo´§¨ì³Ì°ª ,¨Ã¾Ö¦³Àù¯g§K¬ÌÀøªkªº¥þ²y³Ì¨ÎÄvª§¤O 3¬ü°êÀù¯g±M¥Z Oncotarget ¥h¦~¥Zµn¤F¤@½g¤£¦P©ó¶Ç²ÎÀù¯gÃĪ«ªvÀøªº¬ã¨s¢w¢wÂǥѧܥͯÀ®ø°£Àù¯g·F²ÓM¡C³o½×ÂI¬O¥Ñ^°ê°Ò¹ý´µ¯S¤j¾Ç¬ð¯}¨ÅÀù¬ã¨s³æ¦ì¡]Breakthrough Breast Cancer Research Unit¡^ªº¥D¥ô Michael Lisanti ´£¥X¡A¦Ó¥LªºÆF·PÂÕ«ä¡A¨Ó¦Û©ó 8 ·³¤k¨à Camilla ªº§®¨¥§®»y¡Cªº½T±þ¦º·F²ÓM¤~¯à§í¤î¸~½F¼W¥Í, ³o¨Ç§Ü¥Í¯À¤w¸g¨Ï¥Î¼Æ¤Q¦~¡A¬O¦¤w³Q FDA ©Ò»{¥iªº¥ÎÃÄ¡A¨ã¦³¤j¶qÃĪ«¾÷Âà¤Î¤HÅé¬ã¨s¦¨ªG¸ê®Æ¡A¦]¦¹¡AYÀ³¥Î¦bÀù¯g¤è±¡A³o¶µ·sµo®i·|§ó¬Ù®É¡B´î¤Ö¦¨¥»¡A¤]¯à©MOBI 822 833 888Áp¦X¥ÎÃĨӴ£°ªÀø®Ä, Åý§ÜÀù¾÷¨î§ó¦h¤¸¤Á¤J (OBI 822 833 888 Globo H series µo²{¯à¹v¦VÀù²ÓM»PÀù·F²ÓM) (§ó¦h¾÷¨î¹v¦VÀù·F²ÓM) technews.tw/2015/02/11/antibiotics-beats-cancer/ Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose www.ncbi.nlm.nih.gov/pmc/articles/PMC4580062/ 4 ¥t¥~¤é¥»¦³¦b¬ãµo³oÁû§Üµoª¢¦ÑÃÄ Sulfasalazine (SSZ) Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). CONCLUSIONS: This is the first study of SSZ as an xCT inhibitor for targeting CSCs. Reduction of the levels of CD44v-positive cells and GSH was observed in some patients, consistent with the mode of action of SSZ in CSCs. www.ncbi.nlm.nih.gov/pubmed/27055559 5 ¦ÑÃÄ·s¥Î¤]ȱo¹Á¸Õ©ó¥¼¨Ó822 833 888 Á{§É¸ÕÅç°µ¬°Áp¦X¥ÎÃĤñ¸û 822+cyclophosphamide+SSZ »P 822+cyclophosphamide ¤ñ¸û 888+cyclophosphamide+SSZ »P 888+cyclophosphamide ¤ñ¸û 833+cyclophosphamide+SSZ »P 833+cyclophosphamide ¤ñ¸û 822+cyclophosphamide+ Doxycycline »P 822+cyclophosphamide ¤ñ¸û 888+cyclophosphamide+Doxycycline »P 888+cyclophosphamide ¤ñ¸û 833+cyclophosphamide+ Doxycycline »P 833+cyclophosphamide ¤ñ¸û Doxycycline ±j¤OÅð¯À Sulfasalazine (SSZ) ´µ¼Ö¸z·»¿õ 6 ¤û¬z¤j¾ÇÁ{§É¯«¸g¾Ç±Ð±Âù´µ«Âµ¥¤H°w¹ï¨â¸U¤¤d¦h¦W¯f±w¡A¶i¦æ¤F¤K¶µ¸ÕÅç¡A®É¶¡ªø¹F¥|¨ì¤K¦~¡C¥L̵o²{¡A¤ñ°_¥u ¦Y¦w¼¢¾¯ªº¯f±w¡A¨C¤ÑªA¥Îªü´µ¤ÇÆFªº¯f±w«á¨Ó¦º©óÀù¯gªº¾÷²v¡A¤j´T°§C¤F¤G¤@¢H¡C 822+cyclophosphamide+ Aspirin »P 822+cyclophosphamide ¤ñ¸û 888+cyclophosphamide+Aspirin »P 888+cyclophosphamide ¤ñ¸û 833+cyclophosphamide+ Aspirin »P 833+cyclophosphamide ¤ñ¸û (ªA¥Î5¦~Aspirin¥H¤W¤~¯àµo´§°§CÀù¯g¦º¤`·ÀI(¹¹DÀù¡B¯ØŦÀù¡B¸£Àù»PªÍÀù) (GÀù©M¤j¸zÀù±o¦Y¤Q¦~ ) (¦¬®×®É¥i¬ã¨s¤@²Õ¤wªA¥Î5¦~Aspirin ªº¹¹DÀù¡B¯ØŦÀù¡B¸£Àù»PªÍÀù¨ü¸Õ¶i¦æ¤ñ¸û) www.cw.com.tw/article/article.action?id=5012032 7 ¬ì¾Ç¬ã¨sªA¥Îªü´µ¤ÇÆFÁöµM¯à°§C¦º©óÀù¯gªº¾÷²v,¦ý¦]¦³¥X¦å·ÀI,»Ý¸g¥DªvÂå®vµû¦ô¤~¯àªA¥Î,¤£¥i¦Û¦æÁʶRªA¥Î 8 ¥H¤W¬ðµo©_·Q ¥i¯à¤£¤Á¹ê¦b ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/7/28 ¤U¤È 12:29:32²Ä 2333 ½g¦^À³
|
©Ó¤Ñ¤j ÁÂÁ±zªº¤ÀªR»P»¡©ú Cliff¤j ·PÁ±z¹ï±iª©»PASCOª©ªº¾÷¨î¹Ï ¦³²`¤Jªº¤ñ¸û ±zªº¸Ñ»¡ ´N¤ñ¸û¥i¥H¼á²M¤@¨Ç²Ó¸`ªººÃ´b ½T¹êASCOª©¤ñ¸û²¤Æ ¦Ü©óGH-KLH¥´¤JÅ餺¬O§_·|«P¨ÏÅ餺§Î¦¨GHCer ¥u¬OÓ¤HºÃ´b ¬Û«HÀHµÛÁÞ¬ì¾Çªºµo®i §Ú̱N¥i¥H¶V¨Ó¶V²M·¡ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/7/28 ¤W¤È 11:31:16²Ä 2332 ½g¦^À³
|
«ù¤[ªº¯E§J¤j¡G ±z»¡822§@¥Î¾÷Âà¦b¨âÓª©ª©¤Wªº»¡ªk²¤¦³¤£¦P¡H ¤é²±±i¸g²z2015/04/27ªº¡u600»õ¡A6000»õ¡HÁÞ¤À¤l¬Ì]»P¯E¹©ªº¼ç¤O¡v²Ä10¶ªº¡uOBI-822®ø·ÀÀù²ÓM»P¤Ï«b¨®¾÷¨îªº¹Ï¸Ñ¡v¡A¼È¥BºÙ¬°±iª©¡F ¥t¥~ASCO Slide No.5ªº§@¥Î¾÷Âà¥Ü·N¹Ï¡A¼È¥BºÙ¬°ASCOª©¡C §Úı±o¨âª©®t¤£¦h¡AASCOª©¤ñ¸û²³æ¡A±iª©ªº¸ô®|¤Æªº¤ñ¸û²Ó¡A¦ý±iª©¥¼¼Ð¥Ü¥X¸ÉÅé¡]complement¡^»P¦ÛµM±þ¤â²ÓMNK cellªº¸ô®|¡F§â±iª©ªºIgM¥[¤W§l¤Þ¸ÉÅé¡]§YCDC¸ô®|¡^¡A¦A¥h§ðÀ»GH Ceramide¡FIgG¥[¤W§l¤ÞNK cell¡]§YADCC¸ô®|¡^¡A¦A¥h§ðÀ»GH Ceramide´N¸òASCOª©®t¤£¦h¤F¡C¦A¨ÓASCOª©¤WªºAPC¡]§Üì§e²{²ÓM¡^¬O¤@Ӳκ١A¦b±iª©ùا⥦²Óµe¥X¨Ó¡A´N¬O¤TºØ¡GDendritic cell¡BMacrophage¤ÎB cell¡C³o¤TºØAPC§â822³oÓ§Üì§]¾½¤§«á¡A§e²{µ¹T cell¡FT cell¦]¦¹³Q¬¡¤Æ¡A¶i¤@¨B¦A¥h¬¡¤ÆB cell»PT cell¡C®t§O¦b©ó³Ì«á³Q¬¡¤ÆªºT cell¡A¦b±iª©µù©ú¬OCytotoxic T cell¡F¦bASCOª©µù©ú¬OCTLs¡]Cytotoxic T lymphocyte¡×Cytotoxic T cell¡F¼gªk¤£¦P¦Ó¤w¡^¡C ¥t¥~§Ú¤£ª¾¹D´åÂ÷ªºGH·|¤£·|»PCeramideµ²¦X¦Ó³y¦¨²ÓMÀù¤Æ¡H¥uª¾¹D¬ü°ê¦³¾ÇªÌ©ó2014¦~µoªí¬ã¨sµ²ªG¡A¸ÕµÛ¥h¤F¸Ñ³æ®è§ÜÅé¹ï©T©wªºGHªº¿Ë©M¤O»P´åÂ÷ºAªºGHªº¿Ë©M¤O¦³¦ó®t§O¡Hªí¥Ü´åÂ÷ºAªºGHªº½T´¿³QÃöª`¹L¡A¬O§_¤]¬O°ò©ó¸ò±z¤@¼ËªºÅU¼{¡H µ²ªGÅã¥Ü°Êª«¹êÅ礤¡A³æ®è§ÜÅé¤ñ¸û³ßÅw¸ò¡u©T©wªºGH¡vµ²¦X¡A¦Ó¤£³ßÅw¸ò¡u´åÂ÷ºAªºGH¡vµ²¦X¡F¨âªÌªº¿Ë©M«×¬Û®t20¿¤§¦h¡I¦Ó¥B§ó³ßÅw¸ò¡u©T©wªºSSEA-4¡vµ²¦X¡C¤£¹L³o¦ü¥G¸ò888¤ñ¸û¦³Ãö¡I¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC4237592/ ¡^ |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/7/28 ¤W¤È 10:15:22²Ä 2331 ½g¦^À³
|
¤£¹L¦^¨ì¥¿ÃD ½Ð±Ð¨â¦ì ©Î¬O¨ä¥L¯E¤Í ¤wª¾822¬OGH-KLH¡Ï821 ªº²Õ¦X YGH-KLH¥´¤JÅ餺¡A³y¦¨GH§e²{´åÂ÷ºA¤À¤l ©Î¬O822»s³y®É¡A¤º¦³GH´åÂ÷ºA¤À¤l ½Ð°ÝGH´åÂ÷ºA¤À¤l¬O§_·|»P¯«¸gñQÓi(ceramide)µ²¦X§Î¦¨ÁÞà½è¤è¦¡¡A¸¨¦b¥¿±`²ÓM¤W¡A«P¦¨²ÓMÀù¤Æ¡H©Î¬O¸¨¦bÀù²ÓM®û¼í²Õ´¤¤¡A«P¦¨Àù²ÓMÂX´²©ÎÂಾ¡H ¤£·| ²Ä¤@ conjugate¦nªºªF¦è ¥Lªº¤À¤l¶q«Ü¤j¡A©Ò¥H¨S¦³conjugate¦nªºÁÞ¤À¤l¦]¬°¤À¤l¶q¤p¡A©Ò¥H¥i³Q¾÷¾¹¦^¦¬ ¥i¯à·|¦³¤@ÂI´Ý¯d¡A¦ý³oÓ¶qÀ³¸Ó«D±`§C ²Ä¤G GHCer¬O¤º¥Í©Êªº¡A©Ò¿×¤º¥Í©Êªº´N¬O²ÓM¥Î¥L¸Ì±ªº»Ã¯À¦X¦¨³oÓ¡A¬OÄÝ©óM¤ºªº¥Í¦X¦¨¡A±z´£¨ìªº´åÂ÷ª«¬OM¥~ªº ªF¦è ²Ä¤T ¤Æ¾Ç(§t¥Í¤Æ)¤ÏÀ³¡A³£»Ýn¦Ò¼{¨Ò¦p·Å«×¡B»ÄÆP¡B¯S²§©Ê¡B¿@«×µ¥µ¥¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/7/28 ¤W¤È 09:00:31²Ä 2330 ½g¦^À³
|
¦A¤@¦¸ÁÂÁ»P·P¿E Cliff ¤j®¦¼w ´£ºõ®²»âªº´£ÂI¥Ü³¯¹a¬z¦Ñ®v«ü¾Éªº½×¤å ¦ý¤]´n¼Û ¬ì¾Ç¿v°_ªºÃ¿ÆX ¬O¦p¦¹¦aÃø¥HëƶV ¤p§ÌŪ¤F¤SŪ ·Q¤F¤S·Q ¬Ý¤F¤S¬Ý ¨ÌµMÃú¸Ì¬Ýªá ²@µLÀYºü ±i«a§õ«a ±i¤T¤ý¤... ¨Ì¬O¬P¬Pº¡¤Ñ ·wÀYÂà¦V ¸Õ¹Ï±NCliff ¤j®¦¼w »P±Û«a¤j¤jªº¤j¤å³sµ² «¢! ¯º¦Û¤v¦Û¤£¶q¤O§r! ÁÂÁ¤j®a! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/7/28 ¤W¤È 08:15:18²Ä 2329 ½g¦^À³
|
ÁÂÁÂCliff¤j»P±Û«a¤jªº¸ÑªR ¤wª¾¸Ó¬ã¨s«ü¥X GHCer¥i¥H§í¨îB»PT²ÓM¬¡©Ê ¼W¥Í¸~½F¦åºÞ «P¶iÀù²ÓMÂಾ À³¸Ó´N¬OGHªº¾÷Âà ¦ý¬O822¯u¥¿¾÷Âର¦ó ÁÙ»Ýn¶i¤@¨B¼á²M ¦]¬°ASCO§ë¼v¤ù¤º®e ¹ï©ó¾÷Âधø¹Ï ¦ü¥G¦³¨Ç©_©Ç »P¸s¯q±i¬ã¨sûªº³ø§i²¤¦³¤£¦P ¤£¹L¦^¨ì¥¿ÃD ½Ð±Ð¨â¦ì ©Î¬O¨ä¥L¯E¤Í ¤wª¾822¬OGH-KLH¡Ï821 ªº²Õ¦X YGH-KLH¥´¤JÅ餺¡A³y¦¨GH§e²{´åÂ÷ºA¤À¤l ©Î¬O822»s³y®É¡A¤º¦³GH´åÂ÷ºA¤À¤l ½Ð°ÝGH´åÂ÷ºA¤À¤l¬O§_·|»P¯«¸gñQÓi(ceramide)µ²¦X§Î¦¨ÁÞà½è¤è¦¡¡A¸¨¦b¥¿±`²ÓM¤W¡A«P¦¨²ÓMÀù¤Æ¡H©Î¬O¸¨¦bÀù²ÓM®û¼í²Õ´¤¤¡A«P¦¨Àù²ÓMÂX´²©ÎÂಾ¡H |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/7/27 ¤U¤È 11:34:50²Ä 2328 ½g¦^À³
|
GHªºPÀù¾÷Âॻ¨¬J·s¤S½ÆÂø¡A¤£¬O±`®û¦b³oÓ»â°ìªº¾ÇªÌ¬O«ÜÃø§ËÀ´ªº¡C§ÚÌ¥unª¾¹D¤j·§´N¥i¥H¡AGH·|»P¯«¸gñQÓi(ceramide)µ²¦X§Î¦¨ÁÞà½è¤è¦¡¦s¦b²ÓMªí±¤W¡A©Ò»¤µoªº§K¬Ì§í¨î²{¶H¨Ã«D¥Ñ¼W¥[½Õ¸`©ÊT²ÓM¼Æ¶q©M¬¡©Ê©Î¬O¤Þ°_²ÓMä¤`©Ò¾ÉPªº¡CGHCer¦bT¡BB²ÓM¬¡¤Æ¹Lµ{¤¤§¡·|§í¨îNotch1³J¥Õ¼W¥[¡A¦Ó¼vÅT¨ä«áÄò°ò¦]½Õ±±¡CµM«á°O±o½×¤åµoªí©ó2013¦~¡A³o¼Ë´N«Ü±j¤F¡A¨ä¥Lªº²Ó¸`À³¬°¨ä¦¸¡C¡]¦ýCyclophosphamideªºÃĮīh¬O§í¨î½Õ¸`©ÊT²ÓM¼Æ¶q¡A¦Ó¶¡±µP¬¡T²ÓM»P¦ÛµM±þ¤â²ÓMNK cell¨Ó¹F¨ìªvÀù®ÄªG¡^ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/7/27 ¤U¤È 10:06:47²Ä 2327 ½g¦^À³
|
«D±`«D±`·PÁ ±Û«a¤j¤j ©M Cliff ¤j®¦¼w ªºÄÀºÃ ¹ï¤p§Ì¨Ó»¡¡A²z½×²Ó¸`µÛ¹ê¤ÓÃø¡A©|«ÝºCºC®ø¤Æ ¤£¹L¡A´N·§©À¦Ó¨¥ ©Îµy¯àÅé·|¤½¥q©Ò掲¥Üªº---§ÜÅé¶q¶V°ª¡AÀø®Ä¶V¦n ªº¹D²z ¬O§_´N¬OGH§ÜÅé¶q¶V¦h¡A¶V¯à²M°£GH§Üì¡A¾ÉPÀù²ÓM¶V·|³Q§K¬Ì¨t²Îª®±þ¡A¦Ó¨ÏÀø®Ä¶V¦n ¡H °ª§ÜÅé²ÕªºOS K-M¹Ï¬O§_´N¬O¨ÒÃÒ¤§¤@©O¡H «¢¡A³o¬O¤p§Ì¹ï822ªº»{Ãѧó²`¡AÁÙ¬O¤@ºØ»~¸Ñ¡H ¦A¦¸·PÁ ±Û«a¤j¤j ©M Cliff ¤j®¦¼w ªº«ü¾É ¦³¤½¥qªº§V¤O¥H¤Î¤j®aªº²³§Ó¦¨«° ¿@¿@ªº·ÅÄÉ©¯ºÖ·P¡Aº¡º¡¦a¦b±z§Ú¤ß¤¤ ÁÂÁ¤j®a¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/7/27 ¤U¤È 06:48:23²Ä 2326 ½g¦^À³
|
²q·Q¤j¤j¡A¦b³o¸Ì¡G ¡u¯E¹©°Q½×°Ï--¤é²±µû¦ô³ø§ipage 1-- 2014/9/27 ¤W¤È 01:13:39²Ä 1518 ½g¦^À³¡v¤Î¡u²Ä 1519 ½g¦^À³¡v °ò¥»¤W¥Ø«e¥@¬É¤W¹ïGlobo H¬ã¨s³Ì²`ªºÁÙ¬On¬Ý«¥Ìªº¤¤¬ã°|¡A¤£¬O»\ªº¡C ¡uÀù¯g¬ÛÃöÁÞ§ÜìGlobo H¹ï©ó§K¬Ì²ÓM¬¡¤Æ»P¤ÏÀ³¼vÅT¤§¬ã¨s¡v ¡u½²©öË¡¡F°ê¨¾Âå¾Ç°|¥Í©R¬ì¾Ç¬ã¨s©Ò¡v ¡u³¯¹a¬z¡FªL¤fªø©°¬ö©ÀÂå°|¡F¤¤¬ã°|°ò¦]Å餤¤ß¡v ¤¤¤åºKn¡G¡]ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/login?o=dnclcdr&s=id=%22101NDMC0105039%22.&searchmode=basic#XXX¡^ ¡uGlobo H ¬°¤@Ó´¶¹Mªí²{¦bÀù¯g²ÓM¤Wªº6ºÒÁÞµ²ºc¡A¦Ó¥B¤w¸g³QÃÒ©ú¥Dn¬O¥H©M¯«¸gñQÓi(ceramide)µ²¦X§Î¦¨ªºÁÞà½è¤è¦¡¦s¦b²ÓMªí±¤W¡A¦ý¬O¥Lªº¥\¯à«h©|¥¼³QÃÒ¹ê¡C¦b¥»¬ã¨s¤¤¡A§ÚÌÃÒ©ú¤F·í±N¤HÃþ¶gÃä¦å³æ®Ö²y²ÓM(PBMC)»P¨ÅÀù²ÓMMCF-7¤@°_°ö¾i®É¡A¥i¥Hµo²{¨ÅÀù²ÓM¤Wªºglobo H¥i¥H³Q¤HÃþ¶gÃä¦å³æ®Ö²y²ÓM©Ò§l¦¬¦Óªí²{¦b¨ä²ÓM½¤¤W¡C¦P®É¦b¦³ªí²{globo H¨ÅÀù¯f¤HªºÁ{§ÉÀËÅ餤¡A§Ṳ́]µo²{¦³61¢Hªº²Õ´¤Á¤ùÅã¥Ü¥X¡A¦bÀù²Õ´©P³ò®û¼íªº²O¤Ú²y²ÓM½¤¤W¤]µo²{¨ì¦³globo Hªºªí²{¡C·í±N¦X¦¨ªºglobo H-ceramide(GHCer) ¥H¥~¥[¤è¦¡¤À§O©MPBMC¡B¦Ñ¹«µÊŦ²ÓM©M¯Â¤Æ«áªº¦Ñ¹«T²ÓM¦@¦P°ö¾i¤§«á¡A¦A¥Hanti-CD3/CD28ªº§ÜÅ鬡¤Æ²ÓM«á¡Aµo²{¥~¥[GHCer·|¤À§O´î¤Ö²ÓM¼W¥Í¤ÏÀ³¦Ü³Ñ¤U60¡Ó1%, 50¡Ó7% ©M 62¡Ó5%¡C¦P®É¡A¤]·|´î¤Ö²ÓMªºIL-2¡BIFN-£^©MIL-4ªº¤Àªc¡C§Ṳ́]ÃÒ©ú¤FGHCer¥i¥H§í¨îLPS©Î¬OLPS+IL-4+CD40 ligand¹ï©ó¬¡¤Æ¦Ñ¹«µÊŦ²ÓM©Î¬O¯Â¤Æ«áªºCD19+ B²ÓMªº¼W¥Í§@¥Î¡A©MIgM¥H¤ÎIgG§ÜÅ骺¤Àªc¡A¦P®É¤]§í¨î¤F¼ß²ÓMªº²£¥Í¡C¯«¸gñQÓi(ceramide)¥»¨¦b¤Wzªº¹êÅ礤¨ÃµL¥ô¦ó¼vÅT²£¥Í¡C¥t¤@¤è±¡A§Ṳ́]ÃÒ©ú¤F¥ÑGHCer©Ò»¤µoªº§K¬Ì§í¨î²{¶H¨Ã«D¥Ñ¼W¥[½Õ¸`©ÊT²ÓM¼Æ¶q©M¬¡©Ê©Î¬O¤Þ°_²ÓMä¤`©Ò¾ÉPªº¡CGHCer¤£½×¬O¦b¤HÃþPBMC©ÎªÌ¦Ñ¹«ªºT¡BB²ÓM¬¡¤Æ¹Lµ{¤¤§¡·|§í¨îNotch1³J¥Õ¼W¥[¡A¦Ó¼vÅT¨ä«áÄò°ò¦]½Õ±±¡C§Ú̧ó¶i¤@¨BÃÒ©ú¤FGHCer©Ò¤Þ°_ªºNotch1³J¥Õªº´î¤ÖÀ³¬OÂǥѼW¥[ID3ªºªí²{¨Ó§í¨îNotch1°ò¦]ªí²{©MÂǥѼW¥[Itchªºªí²{¨Ó¹ïNotch1³J¥Õ¶i¦æÃþªx¯À¤¶¾Éªº³J¥Õ½è°¸Ñ¡C¥»¬ã¨sº¦¸ÃÒ©úÀù¯g²ÓM¥i¥HÂÇ¥ÑGHCerªºÀ°§U¨Ó§í¨î§K¬Ì²ÓM¼W¥Í»P¬¡¤Æ¡A¦¹§@¥Î¥i¥HÀ°§U¨ä°kÂ÷§K¬Ì¨t²ÎªººÊ±±¡C¡v ^¤åª©ªº¡G ¡uTsai et al., J Cancer Sci Ther 2013, 5.7 ¡]dx.doi.org/10.4172/1948-5956.1000215¡^ ¡uA Prevalent Cancer Associated Glycan, Globo H Ceramide, Induces Immunosuppression by Reducing Notch1 Signaling ¡v ¡uYi-Chien Tsai½²©öË¡, Jing-Rong Huang, Jing-Yan Cheng, Jin-Jin Lin, Jung-Tung Hung, Yih-Yiing Wu, Kun-Tu Yeh* and Alice L. Yu³¯¹a¬z ¡v ·Q¬Ý¥þ¤å¡G§â¡u10.4172/1948-5956.1000215¡v©ñ¶i¡usci-hub.cc/¡vªº·j´MÄæ¦ì¡A¦A«öopenµ¥«Ý¼Æ¬í§Y¥i±o¡C |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/7/27 ¤U¤È 06:31:39²Ä 2325 ½g¦^À³
|
²q·Q¤j¡A±z´£ªº822©Ò²£¥Íªº§ÜÅé¯à¾ÉPGlobo H´î¤Ö¡A¥i¥H¼W¥[Notch1ªº°¸Ñ¦ÓªýÂ_§K¬Ì§í¨î§@¥Î¡A¶i¦Ó³y¦¨¸~½F®ø°h¡C¥Ñ©óNotch¦b¨Å¸¢Àùªºªí²{¤W¬O¤@Ó«PÀù°ò¦]¡A822ÃÒ¹ê¥i¥H¼W¥[Notch1ªº°¸Ñ¡A§ÚªºªZÂ_¬O822ªºMOA¤wÀò±oªì¨BÅçÃÒ¤F¡C Ras¡]¤j¹«¦×½F¡^©MNotch³o¨âºØÀù²ÓM³J¥Õ½è¡A¬OÅýÀù¯g²ÓM¦¨ªø¦a§ó§Ö³t¥B´c©Ê§ó±jªº¥Dn®Ú·½¡C ¨ä¤¤¡ANotch°ò¦]³Ì¦µo²{©óªGÃÇ¡A¦]¸Ó°ò¦]ªº³¡¤À¥\¯à¯Ê¥¢·|¦bªGÃǯÍÃä½t³y¦¨¯Ê¨è(Notch)¦Ó©R¦W¡ANotch«H¸¹ªº¥\¯à¬O¨Ï¦hºØ¤£¦¨¼ô²ÓM¼È®Éºû«ù¦b¥¼¤À¤Æª¬ºA¡A¥H½Õ¸`²ÓM¹ï¤À¤Æ»¤¾É¦]¤lªº¤ÏÀ³¡A¨Ã¨Ï¥¼¤À¤Æ²ÓM«O«ù¤@©wªº¼Æ¶q¡A·íNotch«H¸¹²§±`¦a«ùÄò¦s¦b®É¡A²ÓM¤£¯à¥¿±`¤À¤Æ¦Ó¹L«×¼W´Þ¡A«Ü¥i¯à´N§Î¦¨¸~½F¡C ¦b÷¨Å°Êª«¤¤¡ANotch«H¸¹Âà¾É³~®|»¤¾É4Ó¨üÅé¡]Notch 1-4)©M5Ó°tÅé¡A¦ÓNotch1°ò¦]«h¬OÅý²ÓM¶i¦æ¤À¤Æ¡A50%¥H¤Wªº¨ÅÀù¤¤¤]¥i¥H¬Ý¨ìNotch signalling¹L«×ªí²{ªº±¡ªp¡C ¦ýNotch»P¸~½FªºÃö¨t¬O½ÆÂøªº¡A¤£¦PªºNotch¨üÅé¦b¤£¦Pªº¸~½F©M¸~½Fµo®iªº¤£¦P¶¥¬q©Ò°_ªº§@¥Î¬O¤£¦Pªº¡C¦bT²ÓM¥Õ¦å¯f¡B¨Å¸¢Àù¡B½¦½è²ÓM½F¡ANotch¬O¤@Ó«PÀù°ò¦]¡C 822¯à¼W¥[«PÀù°ò¦]Notch1ªº°¸Ñ¡A50%¥H¤Wªº¨ÅÀù¤¤¤]¥i¥H¬Ý¨ìNotch signalling¹L«×ªí²{ªº±¡ªp¡A822ªºMOA¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/7/27 ¤U¤È 03:05:17²Ä 2324 ½g¦^À³
|
¦b¦¹½Ð±Ð¯E¤Í¥ý¶i¤j¤jÌ ®É³ø¨tªº³o½g³ø¾É¸Ì ¡u¯E¹©¨ÅÀù·sÃÄÀòµn¬üÁ{§É¸~½FÂå¾Ç·|´Á¥Z¡v http://www.chinatimes.com/realtimenews/20160727003897-260410 ´£¤Î ¡u...³ø§i«ü¥X¡A¦¹¤@Àù¯g¬Ì]OPT-822/OPT-821©Ò²£¥Íªº§ÜÅé¯à¾ÉPGlobo H´î¤Ö¡A¥i¥H¼W¥[Notch1ªº°¸Ñ¦ÓªýÂ_§K¬Ì§í¨î§@¥Î¡A¶i¦Ó³y¦¨¸~½F®ø°h¡C¡v ½Ð°Ý³o¥i¥H¬Ý¦¨¬O 822 ªº MOA ¶Ü¡H¡I ¨£¯º¤F¡A¤p§Ì¤£©À®Ñ¤[¨o ¦³½Ð¤j®a¸ÑºÃ ÁÂÁ¤j®a¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/7/27 ¤U¤È 02:07:24²Ä 2323 ½g¦^À³
|
µæ¤@¹D¤@¹DºÝ¥X¨Ó : ¦W¦C¤TºØ¨ÅÀù·sÀøªk¤§¤¤ ¼ÐÃD¦r¨Ï¥Î promising ¦³§Æ±æªº¡A¦³«e³~ªº¡A¤j¦³¥i¬°ªº ¥Ñ¬ü°êÁ{§É¸~½FÂå¾Ç·|©ó¬ü°êªÛ¥[ô®É¶¡7¤ë25¤é¥X¥Zªº¡uASCO POST¡vÂå¾Ç³q°T¡A¯S§O¤¶²Ð¤»¤ëªìASCO¦~·|©Òµoªí¨ã®i±æ©Êªº¨ÅÀù·sÀøªk¡F¥xÆW¯E¹©(4174)©Ò´£¥XªºOPT-822/ OPT-821²Ä¤G/¤T´ÁÁ{§É¸ÕÅ禨ªG¡A¥ç¦b¸Ó¥Z³ø¾Éªº¤TºØ¨ÅÀù·sÀøªk¤§¦C¡C ( ·PÁ¤p¤p¤j´£¨Ñ©x¤èª©¸ê°T) www.ascopost.com/issues/july-25-2016/quick-takes-on-promising-new-approaches-to-treating-breast-cancer/ ¸É¥R: Steven J. Isakoff ´£¨ì: ¥DnÀø®Ä«ü¼Ð¥¼¹F¼Ð, ¦ý§Ú̦b²£¥ÍIgG/IgM§ÜÅé¤ÏÀ³¯f±w¬Ý¨ì¤@Ó«D±`¥O¤H¿³¾Äªºµ²ªG §ó¶i¤@¨Bªºµo®i¥i²M·¡½T»{ (¥»¦¸Á{§Éµ²ªGªºµo²{) Discussing the study was Steven J. Isakoff, MD, PhD, of Massachusetts General Hospital, Boston, who noted: ¡§The primary endpoint was not met, but we saw a very provocative result in IgG/IgM responders¡K. Further development is clearly warranted.¡¨ The primary...... but we saw a very provocative «e±¤£²z·Q but «á±¨ºÓ¦rprovocative ´Nºâ¤£ª¾¨ì·N«ä²q¤]²q¥X¨Ó¬O¥¿±ªº ¯E¹©°Ñ¥[2016 ASCO ½×¤åµoªí(3¤ë15¤é¬OFinal Late-breaking abstracts ´£¥æ) ¯E¹©°Ñ¥[2016 10¤ë¥Xªì ESMO (European Society for Medical Oncology), ¼Ú¬w¸~½FÂå¾Ç·|¦~·|µoªí½×¤å (10¤ë7¤é-11¤é ¤¦³Á ô¥»«¢®Ú ) Abstracts Intent to submit LBA Trial in Progress: 11 May 2016, 21:00 CEST (Central European Summer Time) Final Late-breaking abstracts (LBA) Final submission deadline 23 August 2016, 21:00 CEST (Central European Summer Time) 2¤ë19 ¸Ñª¼,¤ÀªR¼Æ¾Ú¬ù6Ó¤ë , è¦n¬O¤K¤ë¤¤ ¥ª¥k¼Æ¾Ún¥X¨Ó·Ç³Æ§e³ø ESMO ¦~·| |
|
|
·|û¡Gneilwang10142859 µoªí®É¶¡:2016/7/27 ¤U¤È 01:57:55²Ä 2322 ½g¦^À³
|
¤£ª¾þ¦ì¯«³q¼s¤jªº ¤j¤j¥i¥H§ä¨ì¡A¸Ó½g¤å³¹¡A·Ð½Ð¤À¨É¡A·P®¦ www.appledaily.com.tw/realtimenews/article/new/20160727/916469/ ASCO³Ì·s¥Zª«¤¶²Ð¨ÅÀù·sÀøªk¡@¯E¹©¤J¦C ¯E¹©¡]4174¡^¤µªí¥Ü¡A¬ü°êÁ{§É¸~½FÂå¾Ç·|³Ì·s¥X¥Z¡uASCO POST¡vÂå¾Ç³q°T¡A¯S§O¤¶²Ð¨ÅÀù·sÀøªk®i±æ¡A¨ä¤¤¡A¯E¹©©Ò´£¥X¤§OPT-822/ OPT-821²Ä¤G/¤T´ÁÁ{§É¸ÕÅ禨ªG¡A¥ç¦b¸Ó¥Z³ø¾Éªº3ºØ¨ÅÀù·sÀøªk¤§¦C¡C®Ú¾Ú¯E¹©«ü¥X¡A²Ä¤G/¤T´ÁÀH¾÷Âùª¼ªº¸ó°ê©ÊÁ{§É¸ÕÅç¡A¦@¦¬®×349¦WÂಾ©Ê¨ÅÀùÂಾ©Ê¨ÅÀù¯f¤H¡A³o¨Ç¯f¤H¦Ü¤Ö¦b¤@½u¤Æ¾ÇÀøªk©Î/¤Î²üº¸»XÀøªk«á§e²{¯f±¡Ã©w¡C¹êÅç²Õ¤Î¹ï·Ó²Õ¥H2:1¤ñ¨ÒÀH¾÷¤À°t¡A¹êÅç²Õª`®gOPT822/OPT821¬Ì]¡A¹ï·Ó²Õ¨Ï¥Î¦w¼¢¾¯PBS¡F¥t¥~¡A¨â²Õ¯f¤H§¡±µ¨ü§C¾¯¶q(300 mg/m2)ÀôÁCñQÓiªvÀø¡A²üº¸»XªvÀø¥ç³Q¤¹³\¡Cµ²ªG¡A349¦W±wªÌ¤¤¡A48¢H§¹¦¨9°wª`®g¡A¨Ã¥HµL´c¤Æ¦s¬¡´Á¬°¥DnÀø®Ä«ü¼Ð¡C(¦¿«\®x¡þ¥x¥_³ø¾É) |
|
|
·|û¡G§Þ³N¤ÀªR¬£10139654 µoªí®É¶¡:2016/7/27 ¤U¤È 01:12:15²Ä 2321 ½g¦^À³
|
¦³Ãö¯Eô°ò¥»±ªº¤ÀªR ¤p§Ì³»¦h¬O¶È¤@ª¾¥b¸Ñ ¦ý¦³¦U¦ì¯«¤H¯Åªº¤ÀªR»P¤À¨É Åý¤p§Ì¦b§Þ³N±ªº¾Þ§@¤W½ñ¹ê³\¦h ¦b¦¹¥Ñ°J·PÁª©¤Wªº¦U¦ì¤j¤j¡I |
|
|
|